Study Using CABENUVA™ for the Treatment of Human Immunodeficiency Virus (HIV)-1, Administered in Infusion Centers (IC) or Alternate Sites of Administration (ASA) in the United States (U.S.)

A Phase 4, Open-label, Single Arm Study to Optimize Implementation of CABENUVA for the Treatment of HIV-1, for Administration in U.S. Community-based Infusion Centers or Other Alternate Sites of Administration

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04982445

Acronym

GLACIER

Enrollment

Registered

2021-07-29

Start date

2021-11-18

Completion date

2024-01-31

Last updated

2025-04-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV Infections

Keywords

HIV, CABENUVA, Intramuscular, Cabotegravir, Rilpivirine

Brief summary

GLACIER (Giving Long Acting CABENUVA in an Infusion center/ASA) is an interventional study examining the administration of CABENUVA (Cabotegravir long acting \[LA\] plus Rilpivirine LA) intramuscular (IM) in infusion centers/ASAs in United States. In this study, the intervention is the process of using an infusion center/ASA as the location to receive the CABENUVA IM injections. The acceptability and feasibility of the IC/ASA to deliver CABENUVA IM injections will be assessed from the perspectives of the participants, HIV care providers and IC/ASA staff. In this study, Month 1 is the Baseline visit. CABENUVA is a registered trademark of ViiV Healthcare.

Interventions

DRUGCABENUVA

CABENUVA will be administered IM at infusion centers/ASAs

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Adults (greater than or equal to \[\>=\]18 years old) at the time of signing the informed consent. * HIV-1 infected and have been prescribed CABNEUVA per the United States Prescribing information (USPI). * Participants can be enrolled * If they have been taking oral VOCABRIA + EDURANT or other ART for approximately 1 month (at least 28 days) prior to Baseline/Month 1, or * Already taking CABENUVA prior to Baseline/Month 1 and the last injections were within a 1 month +/- 7-day window or for every 2-month injections, the timing will vary if they are receiving the initiation injections (1 month +/- 7-day) or the continuation injections (2 months +/- 7 days) per the USPI, or * Prescribed direct to inject and receive their 1st injection without an oral lead in at the Infusion Center/ASA on the last day of any other antiretroviral therapy * Agreement to receive CABENUVA IM injections at participating infusion center/ASA.

Exclusion criteria

* Participants are excluded from the study as dictated in the Prescribing Information (CABENUVA \[USPI\]) in consultation with the HIV care provider. * Contraindications, as per the current Prescribing Information \[CABENUVA USPI\] * New health condition / prohibited medication reported - Other Reason at the discretion of the HIV care provider or IC/ ASA staff

Design outcomes

Primary

Measure	Time frame	Description
Number of Participants Who Agree or Completely Agree (a Score of 4 or Higher) Across All Items on the Feasibility of Intervention Measure (FIM)	At Month 8	Feasibility of Intervention Measure (FIM) were employed to evaluate the feasibility of CABENUVA administration at Infusion Centers (IC)/ alternate sites of administration (ASA). Higher scores on FIM indicate greater feasibility, where each item can be scored from 1 to 5: Completely disagree (score=1), disagree (score=2), neither agree or disagree (score=3), agree (score=4), completely agree (score=5). This scoring looked at the number responding '4' or '5' to each question divided by the number completing all 4-items where items refer to the individual questions or statements that participants respond to in order to assess their perceptions of an intervention. Each item is designed to measure a specific aspect of either acceptability or feasibility.

Secondary

Measure	Time frame	Description
Number of Participants Who Agree or Completely Agree (a Score of 4 or Higher) Across All Items on the FIM at Month 1 and 3	At Months 1 and 3	—
Number of HIV Care Providers Who Agree or Completely Agree (a Score of 4 or Higher) Across All Items on the FIM at Month 1, 4 and 8	At Months 1, 4, and 8	—
Number of IC/ ASA Staff Who Agree or Completely Agree (a Score of 4 or Higher) Across All Items on the FIM Prior to Month 1 and at Months 3 and 8	Prior to Month 1 (Baseline) and at Months 3 and 8	—
Change in FIM Score Over Time in Participants at Month 3 and 8	From Month 1 (Baseline) to Months 3 and 8	The mean score for feasibility of the intervention administration was calculated by averaging the responses from the 4 items. The responses were scored based on a scale of 1 to 5 where 1=completely disagree, 2=disagree, 3=neither agree nor disagree, 4=agree, and 5=completely agree.
Change in FIM Score Over Time in HIV Care Providers at Month 4 and 8	From Month 1 (Baseline) to Months 4 and 8	—
Change in FIM Score Over Time in IC/ ASA Staff at Month 3 and 8	From Month 1 (Baseline) to Months 3 and 8	—
Number of Participants Assessed for Feasibility of CABENUVA Administration by Other Quantitative Questionnaires at Month 1	At Month 1	The tailored questionnaire for participants receiving CABENUVA was developed specifically for this study and contains items regarding the reasons for switching to CABENUVA, adherence to their previous oral HIV medication, preferences and attitudes regarding their medication regimen, and perceived advantages and disadvantages of receiving injections at the IC/ASA. In this outcome measure, participants were asked about their views on the IC/ASA administration model (any/biggest concerns about receiving CABENUVA at an infusion center).
Number of Participants Assessed for Feasibility of CABENUVA Administration (Concern About Continuing to Receive CABENUVA) by Other Quantitative Questionnaires at Month 3 and 8	At Month 3 and 8	The tailored questionnaire for participants receiving CABENUVA was developed specifically for this study and contains items regarding the reasons for switching to CABENUVA, adherence to their previous oral HIV medication, preferences and attitudes regarding their medication regimen, and perceived advantages and disadvantages of receiving injections at the IC/ASA. In this outcome measure, participants were asked about their views on the IC/ASA administration model (any concerns about continuing to receive CABENUVA at an infusion center) at Months 3 and 8.
Number of Participants Assessed for Feasibility of CABENUVA Administration by Other Quantitative Questionnaires at Month 3 and 8	At Month 3 and 8	Participants were asked about their views on the IC/ASA administration model (biggest concerns about continuing to receive CABENUVA at an infusion center).
Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 1	At Month 1	The tailored HIV care provider/clinical staff questionnaire was developed specifically for this study and contains items regarding the provider's practice and experience, as well as their attitudes, expectations, and concerns regarding the use of CABENUVA/long-acting injectable administered by ICs/ASAs.
Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 4	At Month 4	—
Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8	At Month 8	—
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1	Prior to Month 1 (Baseline)	The tailored IC staff questionnaire was developed specifically for this study and contains items regarding the staff member's role at the IC, as well as their attitudes, concerns, and anticipated/implemented procedures regarding the use of CABENUVA/long-acting injectable administered by ICs. The IC/ASA staff members were asked to indicate their level of concern across 16 areas of potential concern, on a five-point scale from not at all concerned to extremely concerned.
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3	At Month 3	The IC/ASA staff members were asked to indicate their level of concern across 16 areas of potential concern, on a five-point scale from not at all concerned to extremely concerned.
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8	At Month 8	The IC/ASA staff members were asked to indicate their level of concern across 16 areas of potential concern, on a five-point scale from not at all concerned to extremely concerned.
Number of Participants Assessed for Feasibility of CABENUVA Administration by Qualitative Interviews at Month 8	At Month 8	Qualitative interviews were conducted at Month 8 to evaluate the opinions of participants on the feasibility of CABENUVA administration at IC/ASA.
Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Qualitative Interviews at Month 8	At Month 8	Qualitative interviews were conducted at Month 8 to evaluate the general opinion of HIV care providers on the feasibility of referring participants to receive CABENUVA at the IC/ASA.
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Qualitative Interviews at Month 8	At Month 8	Qualitative interviews were conducted at Month 8 to evaluate the general opinion of IC/ ASA staff on feasibility of CABENUVA administration at the IC/ASA.
Composite Score of Feasibility Process Indications	Up to and including Month 8	Composite score of feasibility process was calculated as the mean of the following four scores: FIM Score, Consent Rate, Show Rate, and Return Rate at Visit, on a 0 to 100 scale, where higher numbers correspond to better feasibility.
Change in Composite Score and Each Item of Composite Score Over Time	Baseline (Month 1) and at Month 8	This outcome measure was planned to evaluate change in composite score from baseline to month 8 according to the protocol. The composite score was however not evaluated as a change over time but as a point in time at month 8 as the components of each of the feasibility composite score (FIM score, consent rate, show rate and return rate) were captured at different time intervals.
Number of HIV Care Providers Who Agree or Completely Agree (a Score of 4 or Higher) Across All Items on the Acceptability of Intervention Measure (AIM)	Months 1 (Baseline), 4, and 8	AIM was employed to evaluate the acceptability of CABENUVA administration at Infusion Centers/ ASAs. Higher scores for AIM indicate greater acceptability, where each item was scored from 1 to 5: Completely disagree (score=1), disagree (score=2), neither agree or disagree (score=3), agree (score=4), completely agree (score=5).
Number of Participants Who Agree or Completely Agree (a Score of 4 or Higher) Across All Items on the AIM	Month 1 (Baseline), 3 and 8	AIM were employed to evaluate the acceptability of CABENUVA administration at Infusion Centers/ ASAs. Higher scores for AIM indicate greater acceptability, where each item was scored from 1 to 5: Completely disagree (score=1), disagree (score=2), neither agree or disagree (score=3), agree (score=4), completely agree (score=5).
Number of IC/ ASA Staff Who Agree or Completely Agree (a Score of 4 or Higher) Across All Items on the AIM	Prior to Month 1 (Baseline), and at Month 3 and 8	AIM were employed to evaluate the acceptability of CABENUVA administration at Infusion Centers/ ASAs. Higher scores for AIM indicate greater acceptability, where each item was scored from 1 to 5: Completely disagree (score=1), disagree (score=2), neither agree or disagree (score=3), agree (score=4), completely agree (score=5).
Change in AIM Score Over Time in HIV Care Providers at Month 4 and 8	Month 1 (Baseline), at Months 4 and 8	The mean score for acceptability of the intervention is calculated by averaging the responses from 4 items. The responses were scored based on a scale of 1 to 5 where 1=completely disagree, 2=disagree, 3=neither agree nor disagree, 4=agree, and 5=completely agree.
Change in AIM Score Over Time in Participants at Month 3 and 8	Month 1 (Baseline), at Months 3 and 8	The mean score for acceptability of the intervention is calculated by averaging the responses from 4 items. The responses were scored based on a scale of 1 to 5 where 1=completely disagree, 2=disagree, 3=neither agree nor disagree, 4=agree, and 5=completely agree.
Change in AIM Score Over Time in IC/ ASA Staff at Month 3 and 8	Month 1 (Baseline), at Months 3 and 8	The mean score for acceptability of the intervention is calculated by averaging the responses from 4 items. The responses were scored based on a scale of 1 to 5 where 1=completely disagree, 2=disagree, 3=neither agree nor disagree, 4=agree, and 5=completely agree.
Number of HIV Care Providers Assessed for Acceptability of CABENUVA Administration in Participants at IC/ ASA by Other Quantitative Questionnaire at Months 1, 4 and 8	At Months 1, 4 and 8	—
Number of Participants Assessed for Acceptability of CABENUVA Administration at IC/ ASA by Other Quantitative Questionnaire in at Months 1, 3 and 8	At Months 1, 3 and 8	The participants were asked how acceptable it was to come to the IC/ASA for CABENUVA using a 7-point scale from very acceptable to very unacceptable where 1= very acceptable, 2= somewhat acceptable, 3= a little acceptable, 4= neutral, 5= a little unacceptable, 6= somewhat unacceptable and 7= very unacceptable.
Number of IC/ ASA Staff Assessed for Acceptability of CABENUVA Administration in Participants at IC/ ASA by Other Quantitative Questionnaire Prior to Month 1	Prior to Month 1 (Baseline)	—
Number of IC/ ASA Staff Assessed for Acceptability of CABENUVA Administration in Participants at IC/ ASA by Other Quantitative Questionnaire at Months 3 and 8	At Months 3 and 8	—
Number of Participants Assessed for Acceptability of CABENUVA Administration at IC/ASA by Qualitative Interviews at Month 8	At Month 8	Participants were asked about their opinion on acceptability of CABENUVA administration at the IC/ASA.
Number of HIV Care Providers Assessed for Acceptability of CABENUVA Administration in Participants at IC/ASA by Qualitative Interviews at Month 8	At Month 8	HIV care providers were asked about their opinion on the acceptability of participants receiving CABENUVA at the IC/ASA.
Number of IC/ASA Staff Assessed for Acceptability of CABENUVA Administration in Participants at IC/ASA by Qualitative Interviews at Month 8	At Month 8	IC/ASA staff were asked about their opinion on the acceptability of administering CABENUVA at an IC/ASA.
Number of Expert Panel That Agree or Completely Agree (a Score of 4 or Higher) Across All Items on the FIM Scale	Prior to Month 1 (Baseline), and at Month 3 and 6	—
Number of Expert Panel That Agree or Completely Agree (a Score of 4 or Higher) Across All Items on the AIM Scale	Prior to Month 1 (Baseline), and at Month 3 and 6	—
Change in FIM Score of Expert Panel Over Time Through Month 6	Prior to Month 1 (Baseline) and Up to Month 6	—
Change in AIM Score of Expert Panel Over Time Through Month 6	Prior to Month 1 (Baseline) and Up to Month 6	—
Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Insurance Coverage for CABENUVA Administration in Participants by Quantitative Questionnaires Prior to Month 1	Prior to Month 1 (Baseline)	—
Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Communication for CABENUVA Administration in Participants by Quantitative Questionnaires Prior to Month 1	Prior to Month 1 (Baseline)	—
Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of CABENUVA Administration (Interval of Time) in Participants by Quantitative Questionnaires Prior to Month 1	Prior to Month 1 (Baseline)	In this outcome measure, Expert Panel members were asked about their views on the IC/ASA administration model (for patients receiving CABENUVA injections at the infusion center, what is the preferred interval of time for patients to be seen by their HIV provider).
Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Referring Participants for CABENUVA Administration by Quantitative Questionnaires Prior to Month 1	Prior to Month 1 (Baseline)	—
Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Insurance and Communication for CABENUVA Administration in Participants by Quantitative Questionnaires at Month 3	At Month 3	—
Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Insurance and Communication for CABENUVA Administration in Participants by Quantitative Questionnaires at Month 6	At Month 6	—
Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of CABENUVA Administration in Participants by Qualitative Interviews Prior to Month 1	Prior to Month 1 (Baseline)	The Expert Panel were asked about the key steps focused on the process of CABENUVA administration at IC/ASAs in order to inform the development of the blueprint.
Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of CABENUVA Administration in Participants by Qualitative Interviews at Month 6	At Month 6	The Expert Panel were asked about the key steps focused on the process of CABENUVA administration at IC/ASAs in order to inform the development of the blueprint.
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires at Month 1	At Month 1	—
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 1) at Month 3 and 8	At Month 3 and 8	—
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 2) at Months 3 and 8	At Months 3 and 8	—
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 3) at Months 3 and 8	At Months 3 and 8	—
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 4) at Months 3 and 8	At Months 3 and 8	—
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 5) at Months 3 and 8	At Months 3 and 8	—
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 6) at Months 3 and 8	At Months 3 and 8	—
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 7) at Months 3 and 8	At Months 3 and 8	—
Number of Participants Assessed for Advantages of Receiving CABENUVA at IC/ ASA by Qualitative Interviews at Month 8	At Month 8	—
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 8) at Months 3 and 8	At Months 3 and 8	—
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 9) at Months 3 and 8	At Months 3 and 8	—
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 10) at Months 3 and 8	At Months 3 and 8	Participants were asked their opinion on who did they reach out to obtain answers to their questions.
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 11) at Months 3 and 8	At Months 3 and 8	—
Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires Prior to Month 1	Prior to Month 1 (Baseline)	Since CABENUVA must be administered within a two-week treatment window every month, IC/ASA staff were asked their opinion about the ease or difficulty in appointment re-scheduling and implementation of CABENUVA administration in their work-flow.
Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires at Month 3	At Month 3	Since CABENUVA must be administered within a two-week treatment window (+/-)7 days relative to the target treatment date), the IC/ASA staff was asked their opinion about the ease or difficulty in appointment scheduling and re-scheduling and implementation of CABENUVA administration in their workflow.
Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires at Month 8	At Month 8	Since CABENUVA must be administered within a two-week treatment window (+/-)7 days relative to the target treatment date), the IC/ASA staff was asked their opinion about the ease or difficulty in appointment scheduling and re-scheduling and implementation of CABENUVA administration in their workflow.
Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 1	At Month 1	—
Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 4	At Month 4	—
Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 8	At Month 8	—
Number of Participants Assessed for Facilitators of CABENUVA Administration by Qualitative Interviews at Month 8	At Month 8	Participants were asked about facilitators that made the process of receiving CABENUVA at IC/ASAs easier.
Number of IC/ASA Staff Assessed for Barriers/Concerns of CABENUVA Administration in Participants by Qualitative Interviews at Month 8	At Month 8	IC/ASA staff were asked their opinion on the infrastructure impact of administering CABENUVA.
Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants by Qualitative Interviews at Month 8	At Month 8	HIV care providers were asked about the facilitators and challenges related to referring participants to IC/ASAs.
Number of Participants Assessed for Preference on the Location to Receive CABENUVA With Other Quantitative Questionnaires at Months 1, 3 and 8	At Month 1, 3 and 8	—
Number of Participants Assessed for Preference on the Location to Receive CABENUVA by Qualitative Interviews at Month 8	At Month 8	—
Number of Participants Assessed for Advantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Month 1	At Month 1	In this outcome measure, participants were asked about their views on the IC/ASA administration model (advantages of going to the infusion center to receive CABENUVA).
Number of Participants Assessed for Advantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Months 3 and 8	At Months 3 and 8	In this outcome measure, participants were asked about their views on the IC/ASA administration model (advantages of going to the infusion center to receive CABENUVA).
Number of HIV Care Providers Assessed for Advantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Month 1, 4 and 8	At Months 1, 4 and 8	In this outcome measure, HIV care providers were asked about their views on the IC/ASA administration model (advantages of referring patients to an infusion center for CABENUVA).
Number of Participants Assessed for Disadvantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Month 1	At Month 1	In this outcome measure, participants were asked about their views on the IC/ASA administration model (disadvantages of going to the infusion center to receive CABENUVA).
Number of Participants Assessed for Disadvantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Months 3 and 8	At Months 3 and 8	In this outcome measure, participants were asked about their views on the IC/ASA administration model (disadvantages of going to the infusion center to receive CABENUVA).
Number of HIV Care Providers Assessed for Disadvantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Month 1	At Month 1	In this outcome measure, HIV care providers were asked about their views on the IC/ASA administration model (potential disadvantages of referring patients to an IC for CABENUVA).
Number of HIV Care Providers Assessed for Disadvantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Months 4 and 8	At Months 4 and 8	In this outcome measure, HIV care providers were asked about their views on the IC/ASA administration model (disadvantages of referring patients to an IC for CABENUVA).
Number of Participants Assessed for Disadvantages of Receiving CABENUVA at IC/ ASA by Qualitative Interviews at Month 8	At Month 8	—
Number of HIV Care Providers Assessed for Disadvantages for Participants Receiving CABENUVA at IC/ ASA by Qualitative Interviews at Month 8	At Month 8	In this outcome measure, HIV care providers were asked about their views on the IC/ASA administration model (disadvantages for participants receiving CABENUVA at IC/ASAs).
Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 1	At Month 1	—
Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 3	At Month 3	—
Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 8	At Month 8	—
Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs (Time Spent at IC) by Other Quantitative Questionnaires at Months 3 and 8	At Months 3 and 8	—
Number of HIV Care Providers Assessed for Acceptability of the Process of Referring Participants to the IC/ ASA for CABENUVA by Other Quantitative Questionnaires at Months 1, 4 and 8	At Months 1, 4 and 8	HIV care providers were asked about the type of patients they found acceptable to refer to an IC to receive CABENUVA.
Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Qualitative Interviews at Month 8	At Month 8	Participants were asked about their opinion on the acceptability of CABENUVA administration at the IC.
Number of HIV Care Providers Assessed for Acceptability of the Process of Participants Receiving Injections at ICs/ ASAs by Qualitative Interviews at Month 8	At Month 8	—
Number of IC/ASA Staff Assessed for Usefulness of the Blueprint Intervention With Other Quantitative Questionnaires Prior to Month 1	Prior to Month 1 (Baseline)	The blueprint guides IC/ASA staff on what to do with referrals to receive CABENUVA at the IC/ASA.
Number of IC/ASA Staff Assessed for Usefulness of the Blueprint Intervention With Other Quantitative Questionnaires at Month 3 and 8	At Months 3 and 8	The blueprint guides IC/ASA staff on what to do with referrals to receive CABENUVA at the IC/ASA.
Number of HIV Care Providers Assessed for Usefulness of Plan of Treatment (POT) by Other Quantitative Questionnaires at Months 4 and 8	At Months 4 and 8	—
Number of HIV Care Providers Assessed for Advantages of Participants Receiving CABENUVA at IC/ ASA by Qualitative Interviews at Month 8	At Month 8	—
Number of HIV Care Providers Assessed for Usefulness of the Blueprint Intervention and POT by Qualitative Interviews at Month 8	Month 8	The blueprint guides HIV care providers on what to do with referrals to receive CABENUVA at the IC/ASA.
Number of IC/ASA Staff Assessed for Overall Opinion of Administering the Injection at an IC/ ASA by Other Quantitative Questionnaires Prior to Month 1 and at Months 3 and 8	Prior to Month 1 (Baseline) and Months 3 and 8	—
Number of Participants Assessed for Overall Opinion of Receiving the Injection at an IC/ ASA by Other Quantitative Questionnaires at Months 1, 3 and 8	At Months 1, 3 and 8	—
Number of HIV Care Providers Assessed for Overall Opinion of Referring the Participant to an IC/ ASA by Other Quantitative Questionnaires at Month 1	At Month 1	—
Number of HIV Care Providers Assessed for Overall Opinion of Referring the Participant to an IC/ ASA by Other Quantitative Questionnaires at Month 4	At Month 4	—
Number of HIV Care Providers Assessed for Overall Opinion of Referring the Participant to an IC/ ASA by Other Quantitative Questionnaires at Month 8	At Month 8	—
Number of HIV Care Providers Assessed for Overall Opinion of Continuing to Refer Participants to an IC/ ASA by Other Quantitative Questionnaires at Month 8	At Month 8	—
Number of Participants Assessed for Overall Opinion of Receiving the Injection at an IC/ ASA by Qualitative Interview at Month 8	At Month 8	Participants were asked about their overall favorable and non-favorable opinion of receiving CABENUVA at the IC/ASA.
Number of HIV Care Providers Assessed for Overall Opinion of Referring Patients to an IC/ ASA by Qualitative Interview at Month 8	At Month 8	HIV care providers were asked about their overall favoring and non-favoring opinions on referring participants to IC/ASA for CABENUVA administration.
Number of IC/ASA Staff Assessed for Overall Opinion of Administering the Injection at an IC/ ASA by Qualitative Interview at Month 8	At Month 8	IC/ASA staff was asked about their overall opinion on the participants referral process.
Number of Injections Occurring Within Target Window From Target Date	Up to and including Month 8	This outcome measure evaluates the fidelity to treatment and dosing window. Fidelity to treatment and dosing window was defined based on a ±7-day window from target treatment date based on the calendar date of baseline injection.
Number of IC/ASA Staff Assessed for Usefulness of the Blueprint Intervention and POT Assessed by Qualitative Interviews at Month 8	Month 8	—

Countries

United States

Participant flow

Recruitment details

A total of 44 patients living with HIV (PLWHIV) were enrolled in the study and all of them received study treatment and were included in the safety population. Staff such as HIV care providers and IC/ ASA staff were not counted as enrolled.

Participants by arm

Arm	Count
Participants Receiving CABENUVA Eligible participants received CABENUVA injections intramuscularly at infusion centers/ASAs monthly or every-2-months.	44
Total	44

Withdrawals & dropouts

Period	Reason	FG000
Overall Study	Lost to Follow-up	1
Overall Study	Protocol Violation	1
Overall Study	Withdrawal by Subject	4

Baseline characteristics

Characteristic	Participants Receiving CABENUVA
Age, Continuous	46.8 Years STANDARD_DEVIATION 12.64
Ethnicity (NIH/OMB) Hispanic or Latino	3 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	41 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	0 Participants
Sex/Gender, Customized Female	9 Participants
Sex/Gender, Customized Male	35 Participants

Adverse events

Event type	EG000 affected / at risk
deaths Total, all-cause mortality	0 / 44
other Total, other adverse events	13 / 44
serious Total, serious adverse events	0 / 44

Outcome results

Primary

Number of Participants Who Agree or Completely Agree (a Score of 4 or Higher) Across All Items on the Feasibility of Intervention Measure (FIM)

Feasibility of Intervention Measure (FIM) were employed to evaluate the feasibility of CABENUVA administration at Infusion Centers (IC)/ alternate sites of administration (ASA). Higher scores on FIM indicate greater feasibility, where each item can be scored from 1 to 5: Completely disagree (score=1), disagree (score=2), neither agree or disagree (score=3), agree (score=4), completely agree (score=5). This scoring looked at the number responding '4' or '5' to each question divided by the number completing all 4-items where items refer to the individual questions or statements that participants respond to in order to assess their perceptions of an intervention. Each item is designed to measure a specific aspect of either acceptability or feasibility.

Time frame: At Month 8

Population: Analysis was performed on the Safety set which includes any participant who completed any portion of any questionnaire at the specified timepoint.

Arm	Measure	Value (COUNT_OF_PARTICIPANTS)
Participants Receiving CABENUVA	Number of Participants Who Agree or Completely Agree (a Score of 4 or Higher) Across All Items on the Feasibility of Intervention Measure (FIM)	31 Participants

Secondary

Change in AIM Score of Expert Panel Over Time Through Month 6

Time frame: Prior to Month 1 (Baseline) and Up to Month 6

Population: Analysis was performed on the Expert Panel which includes any Expert Panel member who completed any portion of any questionnaire at the specified timepoint.

Arm	Measure	Group	Value (MEAN)	Dispersion
Participants Receiving CABENUVA	Change in AIM Score of Expert Panel Over Time Through Month 6	Prior to Month 1 (Baseline)	4.22 Scores on a scale	Standard Deviation 0.619
Participants Receiving CABENUVA	Change in AIM Score of Expert Panel Over Time Through Month 6	Month 6	4.46 Scores on a scale	Standard Deviation 0.51

Secondary

Change in AIM Score Over Time in HIV Care Providers at Month 4 and 8

The mean score for acceptability of the intervention is calculated by averaging the responses from 4 items. The responses were scored based on a scale of 1 to 5 where 1=completely disagree, 2=disagree, 3=neither agree nor disagree, 4=agree, and 5=completely agree.

Time frame: Month 1 (Baseline), at Months 4 and 8

Population: Analysis was performed on the HIV care providers which includes any HIV care provider who completed any portion of any questionnaire at the specified timepoint.

Arm	Measure	Group	Value (MEAN)	Dispersion
Participants Receiving CABENUVA	Change in AIM Score Over Time in HIV Care Providers at Month 4 and 8	From baseline to month 4	0.33 Scores on a scale	Standard Deviation 0.382
Participants Receiving CABENUVA	Change in AIM Score Over Time in HIV Care Providers at Month 4 and 8	From baseline to month 8	0.25 Scores on a scale	Standard Deviation 1.414

Secondary

Change in AIM Score Over Time in IC/ ASA Staff at Month 3 and 8

Time frame: Month 1 (Baseline), at Months 3 and 8

Population: Analysis was performed on the IC/ASA staff which includes any IC/ASA staff who completed any portion of any questionnaire at the specified timepoint.

Arm	Measure	Group	Value (MEAN)	Dispersion
Participants Receiving CABENUVA	Change in AIM Score Over Time in IC/ ASA Staff at Month 3 and 8	From baseline to month 3	-0.24 Scores on a scale	Standard Deviation 0.809
Participants Receiving CABENUVA	Change in AIM Score Over Time in IC/ ASA Staff at Month 3 and 8	From baseline to month 8	-0.03 Scores on a scale	Standard Deviation 0.778

Secondary

Change in AIM Score Over Time in Participants at Month 3 and 8

Time frame: Month 1 (Baseline), at Months 3 and 8

Population: Analysis was performed on the Safety set which includes any participant who completed any portion of any questionnaire at the specified timepoint.

Arm	Measure	Group	Value (MEAN)	Dispersion
Participants Receiving CABENUVA	Change in AIM Score Over Time in Participants at Month 3 and 8	From baseline to month 3	0.03 Scores on a scale	Standard Deviation 0.558
Participants Receiving CABENUVA	Change in AIM Score Over Time in Participants at Month 3 and 8	From baseline to month 8	0.00 Scores on a scale	Standard Deviation 0.604

Secondary

Change in Composite Score and Each Item of Composite Score Over Time

This outcome measure was planned to evaluate change in composite score from baseline to month 8 according to the protocol. The composite score was however not evaluated as a change over time but as a point in time at month 8 as the components of each of the feasibility composite score (FIM score, consent rate, show rate and return rate) were captured at different time intervals.

Time frame: Baseline (Month 1) and at Month 8

Population: Data was collected at the clinic level and analysis was performed on the Clinics that consented one or more participants for administration of intervention.

Arm	Measure	Group	Value (MEAN)	Dispersion
Participants Receiving CABENUVA	Change in Composite Score and Each Item of Composite Score Over Time	Show rate	93.6 Scores on a scale	Standard Deviation 10.49
Participants Receiving CABENUVA	Change in Composite Score and Each Item of Composite Score Over Time	Return rate	92.7 Scores on a scale	Standard Deviation 13.92
Participants Receiving CABENUVA	Change in Composite Score and Each Item of Composite Score Over Time	FIM score	84.7 Scores on a scale	Standard Deviation 17.96
Participants Receiving CABENUVA	Change in Composite Score and Each Item of Composite Score Over Time	Consent rate	52.3 Scores on a scale	Standard Deviation 25.73

Secondary

Change in FIM Score of Expert Panel Over Time Through Month 6

Time frame: Prior to Month 1 (Baseline) and Up to Month 6

Population: Analysis was performed on the Expert Panel which includes any Expert Panel member who completed any portion of any questionnaire at the specified timepoint.

Arm	Measure	Group	Value (MEAN)	Dispersion
Participants Receiving CABENUVA	Change in FIM Score of Expert Panel Over Time Through Month 6	Prior to Month 1 (Baseline)	4.00 Scores on a scale	Standard Deviation 0.991
Participants Receiving CABENUVA	Change in FIM Score of Expert Panel Over Time Through Month 6	Month 6	4.46 Scores on a scale	Standard Deviation 0.534

Secondary

Change in FIM Score Over Time in HIV Care Providers at Month 4 and 8

Time frame: From Month 1 (Baseline) to Months 4 and 8

Population: Analysis was performed on the HIV care providers which includes any HIV care provider who completed any portion of any questionnaire at the specified timepoint.

Arm	Measure	Group	Value (MEAN)	Dispersion
Participants Receiving CABENUVA	Change in FIM Score Over Time in HIV Care Providers at Month 4 and 8	From Baseline to Month 4	0.33 Scores on a scale	Standard Deviation 0.764
Participants Receiving CABENUVA	Change in FIM Score Over Time in HIV Care Providers at Month 4 and 8	From Baseline to Month 8	0.38 Scores on a scale	Standard Deviation 0.177

Secondary

Change in FIM Score Over Time in IC/ ASA Staff at Month 3 and 8

Time frame: From Month 1 (Baseline) to Months 3 and 8

Population: Analysis was performed on the IC/ASA staff which includes any IC/ASA staff who completed any portion of any questionnaire at the specified timepoint.

Arm	Measure	Group	Value (MEAN)	Dispersion
Participants Receiving CABENUVA	Change in FIM Score Over Time in IC/ ASA Staff at Month 3 and 8	From Baseline to Month 3	-0.04 Scores on a scale	Standard Deviation 0.729
Participants Receiving CABENUVA	Change in FIM Score Over Time in IC/ ASA Staff at Month 3 and 8	From Baseline to Month 8	-0.20 Scores on a scale	Standard Deviation 0.7

Secondary

Change in FIM Score Over Time in Participants at Month 3 and 8

The mean score for feasibility of the intervention administration was calculated by averaging the responses from the 4 items. The responses were scored based on a scale of 1 to 5 where 1=completely disagree, 2=disagree, 3=neither agree nor disagree, 4=agree, and 5=completely agree.

Time frame: From Month 1 (Baseline) to Months 3 and 8

Population: Analysis was performed on the Safety set which includes any participant who completed any portion of any questionnaire at the specified timepoint.

Arm	Measure	Group	Value (MEAN)	Dispersion
Participants Receiving CABENUVA	Change in FIM Score Over Time in Participants at Month 3 and 8	From Baseline to Month 3	0.06 Scores on a scale	Standard Deviation 0.667
Participants Receiving CABENUVA	Change in FIM Score Over Time in Participants at Month 3 and 8	From Baseline to Month 8	-0.03 Scores on a scale	Standard Deviation 0.677

Secondary

Composite Score of Feasibility Process Indications

Composite score of feasibility process was calculated as the mean of the following four scores: FIM Score, Consent Rate, Show Rate, and Return Rate at Visit, on a 0 to 100 scale, where higher numbers correspond to better feasibility.

Time frame: Up to and including Month 8

Population: Data was collected at the clinic level and analysis was performed on the Clinics that consented one or more participants for administration of intervention.

Arm	Measure	Value (MEAN)	Dispersion
Participants Receiving CABENUVA	Composite Score of Feasibility Process Indications	80.8 Scores on a scale	Standard Deviation 5.46

Secondary

Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of CABENUVA Administration in Participants by Qualitative Interviews at Month 6

The Expert Panel were asked about the key steps focused on the process of CABENUVA administration at IC/ASAs in order to inform the development of the blueprint.

Time frame: At Month 6

Population: Analysis was performed on the Expert Panel which includes any Expert Panel member who completed any portion of any questionnaire at the specified timepoint study.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Participants Receiving CABENUVA	Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of CABENUVA Administration in Participants by Qualitative Interviews at Month 6	Patient attends first injection appointment	4 Participants
Participants Receiving CABENUVA	Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of CABENUVA Administration in Participants by Qualitative Interviews at Month 6	Staff Identify patients for CABENUVA and discuss with patient	2 Participants
Participants Receiving CABENUVA	Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of CABENUVA Administration in Participants by Qualitative Interviews at Month 6	Staff formally refer patients to verify insurance	3 Participants
Participants Receiving CABENUVA	Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of CABENUVA Administration in Participants by Qualitative Interviews at Month 6	Staff initiates patient on oral lead-in	2 Participants
Participants Receiving CABENUVA	Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of CABENUVA Administration in Participants by Qualitative Interviews at Month 6	Staff schedules first patient visit and conducts pre-visit steps	1 Participants
Participants Receiving CABENUVA	Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of CABENUVA Administration in Participants by Qualitative Interviews at Month 6	Post injection reporting and future appointment scheduling	5 Participants

Secondary

Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of CABENUVA Administration in Participants by Qualitative Interviews Prior to Month 1

The Expert Panel were asked about the key steps focused on the process of CABENUVA administration at IC/ASAs in order to inform the development of the blueprint.

Time frame: Prior to Month 1 (Baseline)

Population: Analysis was performed on the Expert Panel which includes any Expert Panel member who completed any portion of any questionnaire at the specified timepoint study.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Participants Receiving CABENUVA	Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of CABENUVA Administration in Participants by Qualitative Interviews Prior to Month 1	Staff Identify patients for CABENUVA and discuss with patient	2 Participants
Participants Receiving CABENUVA	Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of CABENUVA Administration in Participants by Qualitative Interviews Prior to Month 1	Staff formally refer patients to verify insurance	4 Participants
Participants Receiving CABENUVA	Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of CABENUVA Administration in Participants by Qualitative Interviews Prior to Month 1	Staff initiates patient on oral lead-in	3 Participants
Participants Receiving CABENUVA	Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of CABENUVA Administration in Participants by Qualitative Interviews Prior to Month 1	Staff schedules first patient visit and conducts pre-visit steps	2 Participants
Participants Receiving CABENUVA	Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of CABENUVA Administration in Participants by Qualitative Interviews Prior to Month 1	Patient attends first injection appointment	1 Participants
Participants Receiving CABENUVA	Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of CABENUVA Administration in Participants by Qualitative Interviews Prior to Month 1	Post injection reporting and future appointment scheduling	2 Participants

Secondary

Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of CABENUVA Administration (Interval of Time) in Participants by Quantitative Questionnaires Prior to Month 1

In this outcome measure, Expert Panel members were asked about their views on the IC/ASA administration model (for patients receiving CABENUVA injections at the infusion center, what is the preferred interval of time for patients to be seen by their HIV provider).

Time frame: Prior to Month 1 (Baseline)

Population: Analysis was performed on the Expert Panel which includes any Expert Panel member who completed any portion of any questionnaire at the specified timepoint.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Participants Receiving CABENUVA	Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of CABENUVA Administration (Interval of Time) in Participants by Quantitative Questionnaires Prior to Month 1	Never/ not needed	0 Participants
Participants Receiving CABENUVA	Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of CABENUVA Administration (Interval of Time) in Participants by Quantitative Questionnaires Prior to Month 1	Every month	0 Participants
Participants Receiving CABENUVA	Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of CABENUVA Administration (Interval of Time) in Participants by Quantitative Questionnaires Prior to Month 1	Every 2 months	0 Participants
Participants Receiving CABENUVA	Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of CABENUVA Administration (Interval of Time) in Participants by Quantitative Questionnaires Prior to Month 1	Every 3 months	1 Participants
Participants Receiving CABENUVA	Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of CABENUVA Administration (Interval of Time) in Participants by Quantitative Questionnaires Prior to Month 1	Every 4 months	1 Participants
Participants Receiving CABENUVA	Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of CABENUVA Administration (Interval of Time) in Participants by Quantitative Questionnaires Prior to Month 1	Every 6 months	2 Participants
Participants Receiving CABENUVA	Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of CABENUVA Administration (Interval of Time) in Participants by Quantitative Questionnaires Prior to Month 1	Yearly	2 Participants
Participants Receiving CABENUVA	Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of CABENUVA Administration (Interval of Time) in Participants by Quantitative Questionnaires Prior to Month 1	As needed (i.e., when an adverse event occurs)	1 Participants
Participants Receiving CABENUVA	Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of CABENUVA Administration (Interval of Time) in Participants by Quantitative Questionnaires Prior to Month 1	Unsure/ Not applicable to role	2 Participants
Participants Receiving CABENUVA	Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of CABENUVA Administration (Interval of Time) in Participants by Quantitative Questionnaires Prior to Month 1	Missing	0 Participants

Secondary

Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Communication for CABENUVA Administration in Participants by Quantitative Questionnaires Prior to Month 1

Time frame: Prior to Month 1 (Baseline)

Population: Analysis was performed on the Expert Panel which includes any Expert Panel member who completed any portion of any questionnaire at the specified timepoint.

Arm	Measure	Group	Category	Value (COUNT_OF_PARTICIPANTS)
Participants Receiving CABENUVA	Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Communication for CABENUVA Administration in Participants by Quantitative Questionnaires Prior to Month 1	Preferred mode of communication between HIV provider and IC when a patient discontinues CABENUVA	Fax	5 Participants
Participants Receiving CABENUVA	Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Communication for CABENUVA Administration in Participants by Quantitative Questionnaires Prior to Month 1	Preferred mode of communication between HIV provider and IC when a patient discontinues CABENUVA	Phone call	2 Participants
Participants Receiving CABENUVA	Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Communication for CABENUVA Administration in Participants by Quantitative Questionnaires Prior to Month 1	Preferred mode of communication between HIV provider and IC when a patient discontinues CABENUVA	Secure Electronic Medical Record message	1 Participants
Participants Receiving CABENUVA	Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Communication for CABENUVA Administration in Participants by Quantitative Questionnaires Prior to Month 1	Preferred mode of communication between HIV provider and IC when a patient discontinues CABENUVA	Text	0 Participants
Participants Receiving CABENUVA	Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Communication for CABENUVA Administration in Participants by Quantitative Questionnaires Prior to Month 1	Preferred mode of communication between HIV provider and IC when a patient discontinues CABENUVA	Email	0 Participants
Participants Receiving CABENUVA	Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Communication for CABENUVA Administration in Participants by Quantitative Questionnaires Prior to Month 1	Preferred mode of communication between HIV provider and IC when a patient discontinues CABENUVA	Other	0 Participants
Participants Receiving CABENUVA	Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Communication for CABENUVA Administration in Participants by Quantitative Questionnaires Prior to Month 1	Preferred mode of communication between HIV provider and IC when a patient discontinues CABENUVA	Unsure/ Not applicable to role	0 Participants
Participants Receiving CABENUVA	Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Communication for CABENUVA Administration in Participants by Quantitative Questionnaires Prior to Month 1	Preferred mode of communication between HIV provider and IC when a patient discontinues CABENUVA	Missing	0 Participants
Participants Receiving CABENUVA	Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Communication for CABENUVA Administration in Participants by Quantitative Questionnaires Prior to Month 1	Preferred mode of communication about AEs from IC to HIV provider	Fax	5 Participants
Participants Receiving CABENUVA	Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Communication for CABENUVA Administration in Participants by Quantitative Questionnaires Prior to Month 1	Preferred mode of communication about AEs from IC to HIV provider	Phone call	2 Participants
Participants Receiving CABENUVA	Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Communication for CABENUVA Administration in Participants by Quantitative Questionnaires Prior to Month 1	Preferred mode of communication about AEs from IC to HIV provider	Secure Electronic Medical Record message	1 Participants
Participants Receiving CABENUVA	Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Communication for CABENUVA Administration in Participants by Quantitative Questionnaires Prior to Month 1	Preferred mode of communication about AEs from IC to HIV provider	Text	0 Participants
Participants Receiving CABENUVA	Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Communication for CABENUVA Administration in Participants by Quantitative Questionnaires Prior to Month 1	Preferred mode of communication about AEs from IC to HIV provider	Email	0 Participants
Participants Receiving CABENUVA	Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Communication for CABENUVA Administration in Participants by Quantitative Questionnaires Prior to Month 1	Preferred mode of communication about AEs from IC to HIV provider	Other	0 Participants
Participants Receiving CABENUVA	Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Communication for CABENUVA Administration in Participants by Quantitative Questionnaires Prior to Month 1	Preferred mode of communication about AEs from IC to HIV provider	Unsure/ Not applicable to role	0 Participants
Participants Receiving CABENUVA	Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Communication for CABENUVA Administration in Participants by Quantitative Questionnaires Prior to Month 1	Preferred mode of communication about AEs from IC to HIV provider	Missing	0 Participants

Secondary

Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Insurance and Communication for CABENUVA Administration in Participants by Quantitative Questionnaires at Month 3

Time frame: At Month 3

Population: Analysis was performed on the Expert Panel which includes any Expert Panel member who completed any portion of any questionnaire at the specified timepoint.

Arm	Measure	Group	Category	Value (COUNT_OF_PARTICIPANTS)
Participants Receiving CABENUVA	Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Insurance and Communication for CABENUVA Administration in Participants by Quantitative Questionnaires at Month 3	Acceptability of insurance verification/confirmation process for patients referred to the IC	Extremely acceptable	0 Participants
Participants Receiving CABENUVA	Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Insurance and Communication for CABENUVA Administration in Participants by Quantitative Questionnaires at Month 3	Acceptability of insurance verification/confirmation process for patients referred to the IC	Very acceptable	0 Participants
Participants Receiving CABENUVA	Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Insurance and Communication for CABENUVA Administration in Participants by Quantitative Questionnaires at Month 3	Acceptability of insurance verification/confirmation process for patients referred to the IC	Somewhat acceptable	1 Participants
Participants Receiving CABENUVA	Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Insurance and Communication for CABENUVA Administration in Participants by Quantitative Questionnaires at Month 3	Acceptability of insurance verification/confirmation process for patients referred to the IC	Neither acceptable nor unacceptable	0 Participants
Participants Receiving CABENUVA	Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Insurance and Communication for CABENUVA Administration in Participants by Quantitative Questionnaires at Month 3	Acceptability of insurance verification/confirmation process for patients referred to the IC	Somewhat unacceptable	0 Participants
Participants Receiving CABENUVA	Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Insurance and Communication for CABENUVA Administration in Participants by Quantitative Questionnaires at Month 3	Acceptability of insurance verification/confirmation process for patients referred to the IC	Very unacceptable	1 Participants
Participants Receiving CABENUVA	Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Insurance and Communication for CABENUVA Administration in Participants by Quantitative Questionnaires at Month 3	Acceptability of insurance verification/confirmation process for patients referred to the IC	Extremely unacceptable	0 Participants
Participants Receiving CABENUVA	Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Insurance and Communication for CABENUVA Administration in Participants by Quantitative Questionnaires at Month 3	Acceptability of insurance verification/confirmation process for patients referred to the IC	I do not have knowledge of/not involved in this process	1 Participants
Participants Receiving CABENUVA	Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Insurance and Communication for CABENUVA Administration in Participants by Quantitative Questionnaires at Month 3	How acceptable has the process been for relaying insurance coverage information to patients?	Extremely acceptable	1 Participants
Participants Receiving CABENUVA	Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Insurance and Communication for CABENUVA Administration in Participants by Quantitative Questionnaires at Month 3	How acceptable has the process been for relaying insurance coverage information to patients?	Very acceptable	1 Participants
Participants Receiving CABENUVA	Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Insurance and Communication for CABENUVA Administration in Participants by Quantitative Questionnaires at Month 3	How acceptable has the process been for relaying insurance coverage information to patients?	Somewhat acceptable	0 Participants
Participants Receiving CABENUVA	Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Insurance and Communication for CABENUVA Administration in Participants by Quantitative Questionnaires at Month 3	How acceptable has the process been for relaying insurance coverage information to patients?	Neither acceptable nor unacceptable	0 Participants
Participants Receiving CABENUVA	Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Insurance and Communication for CABENUVA Administration in Participants by Quantitative Questionnaires at Month 3	How acceptable has the process been for relaying insurance coverage information to patients?	Somewhat unacceptable	1 Participants
Participants Receiving CABENUVA	Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Insurance and Communication for CABENUVA Administration in Participants by Quantitative Questionnaires at Month 3	How acceptable has the process been for relaying insurance coverage information to patients?	Very unacceptable	0 Participants
Participants Receiving CABENUVA	Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Insurance and Communication for CABENUVA Administration in Participants by Quantitative Questionnaires at Month 3	How acceptable has the process been for relaying insurance coverage information to patients?	Extremely unacceptable	0 Participants
Participants Receiving CABENUVA	Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Insurance and Communication for CABENUVA Administration in Participants by Quantitative Questionnaires at Month 3	How acceptable has the process been for relaying insurance coverage information to patients?	I do not have knowledge of/not involved in this process	0 Participants
Participants Receiving CABENUVA	Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Insurance and Communication for CABENUVA Administration in Participants by Quantitative Questionnaires at Month 3	Acceptability of communication between yourself and the IC during the oral lead-in phase?	Extremely acceptable	0 Participants
Participants Receiving CABENUVA	Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Insurance and Communication for CABENUVA Administration in Participants by Quantitative Questionnaires at Month 3	Acceptability of communication between yourself and the IC during the oral lead-in phase?	Very acceptable	1 Participants
Participants Receiving CABENUVA	Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Insurance and Communication for CABENUVA Administration in Participants by Quantitative Questionnaires at Month 3	Acceptability of communication between yourself and the IC during the oral lead-in phase?	Somewhat acceptable	1 Participants
Participants Receiving CABENUVA	Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Insurance and Communication for CABENUVA Administration in Participants by Quantitative Questionnaires at Month 3	Acceptability of communication between yourself and the IC during the oral lead-in phase?	Neither acceptable nor unacceptable	1 Participants
Participants Receiving CABENUVA	Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Insurance and Communication for CABENUVA Administration in Participants by Quantitative Questionnaires at Month 3	Acceptability of communication between yourself and the IC during the oral lead-in phase?	Somewhat unacceptable	1 Participants
Participants Receiving CABENUVA	Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Insurance and Communication for CABENUVA Administration in Participants by Quantitative Questionnaires at Month 3	Acceptability of communication between yourself and the IC during the oral lead-in phase?	Very unacceptable	0 Participants
Participants Receiving CABENUVA	Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Insurance and Communication for CABENUVA Administration in Participants by Quantitative Questionnaires at Month 3	Acceptability of communication between yourself and the IC during the oral lead-in phase?	Extremely unacceptable	0 Participants
Participants Receiving CABENUVA	Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Insurance and Communication for CABENUVA Administration in Participants by Quantitative Questionnaires at Month 3	Acceptability of communication between yourself and the IC during the oral lead-in phase?	I do not have knowledge of/not involved in this process	3 Participants

Secondary

Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Insurance and Communication for CABENUVA Administration in Participants by Quantitative Questionnaires at Month 6

Time frame: At Month 6

Population: Analysis was performed on the Expert Panel which includes any Expert Panel member who completed any portion of any questionnaire at the specified timepoint.

Arm	Measure	Group	Category	Value (COUNT_OF_PARTICIPANTS)
Participants Receiving CABENUVA	Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Insurance and Communication for CABENUVA Administration in Participants by Quantitative Questionnaires at Month 6	Acceptability of insurance verification/confirmation process for patients referred to the IC	Extremely acceptable	0 Participants
Participants Receiving CABENUVA	Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Insurance and Communication for CABENUVA Administration in Participants by Quantitative Questionnaires at Month 6	Acceptability of insurance verification/confirmation process for patients referred to the IC	Very acceptable	0 Participants
Participants Receiving CABENUVA	Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Insurance and Communication for CABENUVA Administration in Participants by Quantitative Questionnaires at Month 6	Acceptability of insurance verification/confirmation process for patients referred to the IC	Somewhat acceptable	1 Participants
Participants Receiving CABENUVA	Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Insurance and Communication for CABENUVA Administration in Participants by Quantitative Questionnaires at Month 6	Acceptability of insurance verification/confirmation process for patients referred to the IC	Neither acceptable nor unacceptable	0 Participants
Participants Receiving CABENUVA	Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Insurance and Communication for CABENUVA Administration in Participants by Quantitative Questionnaires at Month 6	Acceptability of insurance verification/confirmation process for patients referred to the IC	Somewhat unacceptable	0 Participants
Participants Receiving CABENUVA	Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Insurance and Communication for CABENUVA Administration in Participants by Quantitative Questionnaires at Month 6	Acceptability of insurance verification/confirmation process for patients referred to the IC	Very unacceptable	0 Participants
Participants Receiving CABENUVA	Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Insurance and Communication for CABENUVA Administration in Participants by Quantitative Questionnaires at Month 6	Acceptability of insurance verification/confirmation process for patients referred to the IC	Extremely unacceptable	0 Participants
Participants Receiving CABENUVA	Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Insurance and Communication for CABENUVA Administration in Participants by Quantitative Questionnaires at Month 6	Acceptability of insurance verification/confirmation process for patients referred to the IC	I do not have knowledge of/not involved in this process	1 Participants
Participants Receiving CABENUVA	Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Insurance and Communication for CABENUVA Administration in Participants by Quantitative Questionnaires at Month 6	How acceptable has the process been for relaying insurance coverage information to patients?	Extremely acceptable	0 Participants
Participants Receiving CABENUVA	Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Insurance and Communication for CABENUVA Administration in Participants by Quantitative Questionnaires at Month 6	How acceptable has the process been for relaying insurance coverage information to patients?	Very acceptable	1 Participants
Participants Receiving CABENUVA	Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Insurance and Communication for CABENUVA Administration in Participants by Quantitative Questionnaires at Month 6	How acceptable has the process been for relaying insurance coverage information to patients?	Somewhat acceptable	0 Participants
Participants Receiving CABENUVA	Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Insurance and Communication for CABENUVA Administration in Participants by Quantitative Questionnaires at Month 6	How acceptable has the process been for relaying insurance coverage information to patients?	Neither acceptable nor unacceptable	0 Participants
Participants Receiving CABENUVA	Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Insurance and Communication for CABENUVA Administration in Participants by Quantitative Questionnaires at Month 6	How acceptable has the process been for relaying insurance coverage information to patients?	Somewhat unacceptable	0 Participants
Participants Receiving CABENUVA	Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Insurance and Communication for CABENUVA Administration in Participants by Quantitative Questionnaires at Month 6	How acceptable has the process been for relaying insurance coverage information to patients?	Very unacceptable	0 Participants
Participants Receiving CABENUVA	Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Insurance and Communication for CABENUVA Administration in Participants by Quantitative Questionnaires at Month 6	How acceptable has the process been for relaying insurance coverage information to patients?	Extremely unacceptable	0 Participants
Participants Receiving CABENUVA	Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Insurance and Communication for CABENUVA Administration in Participants by Quantitative Questionnaires at Month 6	How acceptable has the process been for relaying insurance coverage information to patients?	I do not have knowledge of/not involved in this process	0 Participants
Participants Receiving CABENUVA	Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Insurance and Communication for CABENUVA Administration in Participants by Quantitative Questionnaires at Month 6	Acceptability of communication between yourself and the IC during the oral lead-in phase?	Extremely acceptable	0 Participants
Participants Receiving CABENUVA	Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Insurance and Communication for CABENUVA Administration in Participants by Quantitative Questionnaires at Month 6	Acceptability of communication between yourself and the IC during the oral lead-in phase?	Very acceptable	1 Participants
Participants Receiving CABENUVA	Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Insurance and Communication for CABENUVA Administration in Participants by Quantitative Questionnaires at Month 6	Acceptability of communication between yourself and the IC during the oral lead-in phase?	Somewhat acceptable	1 Participants
Participants Receiving CABENUVA	Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Insurance and Communication for CABENUVA Administration in Participants by Quantitative Questionnaires at Month 6	Acceptability of communication between yourself and the IC during the oral lead-in phase?	Neither acceptable nor unacceptable	0 Participants
Participants Receiving CABENUVA	Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Insurance and Communication for CABENUVA Administration in Participants by Quantitative Questionnaires at Month 6	Acceptability of communication between yourself and the IC during the oral lead-in phase?	Somewhat unacceptable	0 Participants
Participants Receiving CABENUVA	Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Insurance and Communication for CABENUVA Administration in Participants by Quantitative Questionnaires at Month 6	Acceptability of communication between yourself and the IC during the oral lead-in phase?	Very unacceptable	0 Participants
Participants Receiving CABENUVA	Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Insurance and Communication for CABENUVA Administration in Participants by Quantitative Questionnaires at Month 6	Acceptability of communication between yourself and the IC during the oral lead-in phase?	Extremely unacceptable	0 Participants
Participants Receiving CABENUVA	Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Insurance and Communication for CABENUVA Administration in Participants by Quantitative Questionnaires at Month 6	Acceptability of communication between yourself and the IC during the oral lead-in phase?	I do not have knowledge of/not involved in this process	4 Participants

Secondary

Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Insurance Coverage for CABENUVA Administration in Participants by Quantitative Questionnaires Prior to Month 1

Time frame: Prior to Month 1 (Baseline)

Population: Analysis was performed on the Expert Panel which includes any Expert Panel member who completed any portion of any questionnaire at the specified timepoint.

Arm	Measure	Group	Category	Value (COUNT_OF_PARTICIPANTS)
Participants Receiving CABENUVA	Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Insurance Coverage for CABENUVA Administration in Participants by Quantitative Questionnaires Prior to Month 1	What is your preference for who will conduct the insurance benefit verification?	Infusion Center Staff	4 Participants
Participants Receiving CABENUVA	Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Insurance Coverage for CABENUVA Administration in Participants by Quantitative Questionnaires Prior to Month 1	What is your preference for who will conduct the insurance benefit verification?	Unsure/Not applicable to role	2 Participants
Participants Receiving CABENUVA	Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Insurance Coverage for CABENUVA Administration in Participants by Quantitative Questionnaires Prior to Month 1	What is your preference for who will conduct the insurance benefit verification?	HIV Provider/ Clinic Staff	1 Participants
Participants Receiving CABENUVA	Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Insurance Coverage for CABENUVA Administration in Participants by Quantitative Questionnaires Prior to Month 1	What is your preference for who will conduct the insurance benefit verification?	ViiV Connect (reimbursement hub)	1 Participants
Participants Receiving CABENUVA	Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Insurance Coverage for CABENUVA Administration in Participants by Quantitative Questionnaires Prior to Month 1	What is your preference for who will conduct the insurance benefit verification?	Missing	0 Participants
Participants Receiving CABENUVA	Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Insurance Coverage for CABENUVA Administration in Participants by Quantitative Questionnaires Prior to Month 1	What is your preference for who notifies the patient about insurance coverage?	Infusion Center Staff	6 Participants
Participants Receiving CABENUVA	Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Insurance Coverage for CABENUVA Administration in Participants by Quantitative Questionnaires Prior to Month 1	What is your preference for who notifies the patient about insurance coverage?	Unsure/Not applicable to role	2 Participants
Participants Receiving CABENUVA	Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Insurance Coverage for CABENUVA Administration in Participants by Quantitative Questionnaires Prior to Month 1	What is your preference for who notifies the patient about insurance coverage?	HIV Provider/ Clinic Staff	2 Participants
Participants Receiving CABENUVA	Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Insurance Coverage for CABENUVA Administration in Participants by Quantitative Questionnaires Prior to Month 1	What is your preference for who notifies the patient about insurance coverage?	ViiV Connect (reimbursement hub)	NA Participants
Participants Receiving CABENUVA	Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Insurance Coverage for CABENUVA Administration in Participants by Quantitative Questionnaires Prior to Month 1	What is your preference for who notifies the patient about insurance coverage?	Missing	0 Participants

Secondary

Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Referring Participants for CABENUVA Administration by Quantitative Questionnaires Prior to Month 1

Time frame: Prior to Month 1 (Baseline)

Population: Analysis was performed on the Expert Panel which includes any Expert Panel member who completed any portion of any questionnaire at the specified timepoint.

Arm	Measure	Category	Value (COUNT_OF_PARTICIPANTS)
Participants Receiving CABENUVA	Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Referring Participants for CABENUVA Administration by Quantitative Questionnaires Prior to Month 1	Fax	5 Participants
Participants Receiving CABENUVA	Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Referring Participants for CABENUVA Administration by Quantitative Questionnaires Prior to Month 1	Unsure/Not applicable to role	2 Participants
Participants Receiving CABENUVA	Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Referring Participants for CABENUVA Administration by Quantitative Questionnaires Prior to Month 1	Secure Electronic Medical Record message	1 Participants
Participants Receiving CABENUVA	Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Referring Participants for CABENUVA Administration by Quantitative Questionnaires Prior to Month 1	Phone call	0 Participants
Participants Receiving CABENUVA	Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Referring Participants for CABENUVA Administration by Quantitative Questionnaires Prior to Month 1	Email	0 Participants
Participants Receiving CABENUVA	Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Referring Participants for CABENUVA Administration by Quantitative Questionnaires Prior to Month 1	Other	0 Participants
Participants Receiving CABENUVA	Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Referring Participants for CABENUVA Administration by Quantitative Questionnaires Prior to Month 1	Missing	0 Participants

Secondary

Number of Expert Panel That Agree or Completely Agree (a Score of 4 or Higher) Across All Items on the AIM Scale

Time frame: Prior to Month 1 (Baseline), and at Month 3 and 6

Population: Analysis was performed on the Expert Panel which includes any Expert Panel member who completed any portion of any questionnaire at the specified timepoint.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Participants Receiving CABENUVA	Number of Expert Panel That Agree or Completely Agree (a Score of 4 or Higher) Across All Items on the AIM Scale	Prior to Month 1 (Baseline)	6 Participants
Participants Receiving CABENUVA	Number of Expert Panel That Agree or Completely Agree (a Score of 4 or Higher) Across All Items on the AIM Scale	Month 3	6 Participants
Participants Receiving CABENUVA	Number of Expert Panel That Agree or Completely Agree (a Score of 4 or Higher) Across All Items on the AIM Scale	Month 6	6 Participants

Secondary

Number of Expert Panel That Agree or Completely Agree (a Score of 4 or Higher) Across All Items on the FIM Scale

Time frame: Prior to Month 1 (Baseline), and at Month 3 and 6

Population: Analysis was performed on the Expert Panel which includes any Expert Panel member who completed any portion of any questionnaire at the specified timepoint.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Participants Receiving CABENUVA	Number of Expert Panel That Agree or Completely Agree (a Score of 4 or Higher) Across All Items on the FIM Scale	Prior to Month 1 (Baseline)	5 Participants
Participants Receiving CABENUVA	Number of Expert Panel That Agree or Completely Agree (a Score of 4 or Higher) Across All Items on the FIM Scale	Month 3	5 Participants
Participants Receiving CABENUVA	Number of Expert Panel That Agree or Completely Agree (a Score of 4 or Higher) Across All Items on the FIM Scale	Month 6	5 Participants

Secondary

Number of HIV Care Providers Assessed for Acceptability of CABENUVA Administration in Participants at IC/ ASA by Other Quantitative Questionnaire at Months 1, 4 and 8

Time frame: At Months 1, 4 and 8

Population: Analysis was performed on the HIV care providers which includes any HIV care provider who completed any portion of any questionnaire at the specified timepoint.

Arm	Measure	Group	Category	Value (COUNT_OF_PARTICIPANTS)
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Acceptability of CABENUVA Administration in Participants at IC/ ASA by Other Quantitative Questionnaire at Months 1, 4 and 8	Month 1- How acceptable was the overall process of interacting with the infusion center so far?	Very acceptable	1 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Acceptability of CABENUVA Administration in Participants at IC/ ASA by Other Quantitative Questionnaire at Months 1, 4 and 8	Month 1- How acceptable was the overall process of interacting with the infusion center so far?	Somewhat acceptable	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Acceptability of CABENUVA Administration in Participants at IC/ ASA by Other Quantitative Questionnaire at Months 1, 4 and 8	Month 1- How acceptable was the overall process of interacting with the infusion center so far?	A little acceptable	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Acceptability of CABENUVA Administration in Participants at IC/ ASA by Other Quantitative Questionnaire at Months 1, 4 and 8	Month 1- How acceptable was the overall process of interacting with the infusion center so far?	Neutral	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Acceptability of CABENUVA Administration in Participants at IC/ ASA by Other Quantitative Questionnaire at Months 1, 4 and 8	Month 1- How acceptable was the overall process of interacting with the infusion center so far?	A little unacceptable	1 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Acceptability of CABENUVA Administration in Participants at IC/ ASA by Other Quantitative Questionnaire at Months 1, 4 and 8	Month 1- How acceptable was the overall process of interacting with the infusion center so far?	Somewhat unacceptable	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Acceptability of CABENUVA Administration in Participants at IC/ ASA by Other Quantitative Questionnaire at Months 1, 4 and 8	Month 1- How acceptable was the overall process of interacting with the infusion center so far?	Very unacceptable	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Acceptability of CABENUVA Administration in Participants at IC/ ASA by Other Quantitative Questionnaire at Months 1, 4 and 8	Month 1- How acceptable was the overall process of interacting with the infusion center so far?	I have not interacted with the infusion center yet.	1 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Acceptability of CABENUVA Administration in Participants at IC/ ASA by Other Quantitative Questionnaire at Months 1, 4 and 8	Month 1- How acceptable was the overall process of interacting with the infusion center so far?	Missing	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Acceptability of CABENUVA Administration in Participants at IC/ ASA by Other Quantitative Questionnaire at Months 1, 4 and 8	Month 4- How acceptable was the overall process of interacting with the infusion center so far?	Somewhat acceptable	1 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Acceptability of CABENUVA Administration in Participants at IC/ ASA by Other Quantitative Questionnaire at Months 1, 4 and 8	Month 4- How acceptable was the overall process of interacting with the infusion center so far?	A little acceptable	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Acceptability of CABENUVA Administration in Participants at IC/ ASA by Other Quantitative Questionnaire at Months 1, 4 and 8	Month 4- How acceptable was the overall process of interacting with the infusion center so far?	Neutral	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Acceptability of CABENUVA Administration in Participants at IC/ ASA by Other Quantitative Questionnaire at Months 1, 4 and 8	Month 4- How acceptable was the overall process of interacting with the infusion center so far?	A little unacceptable	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Acceptability of CABENUVA Administration in Participants at IC/ ASA by Other Quantitative Questionnaire at Months 1, 4 and 8	Month 4- How acceptable was the overall process of interacting with the infusion center so far?	Somewhat unacceptable	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Acceptability of CABENUVA Administration in Participants at IC/ ASA by Other Quantitative Questionnaire at Months 1, 4 and 8	Month 4- How acceptable was the overall process of interacting with the infusion center so far?	Very unacceptable	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Acceptability of CABENUVA Administration in Participants at IC/ ASA by Other Quantitative Questionnaire at Months 1, 4 and 8	Month 4- How acceptable was the overall process of interacting with the infusion center so far?	I have not interacted with the infusion center yet.	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Acceptability of CABENUVA Administration in Participants at IC/ ASA by Other Quantitative Questionnaire at Months 1, 4 and 8	Month 4- How acceptable was the overall process of interacting with the infusion center so far?	Missing	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Acceptability of CABENUVA Administration in Participants at IC/ ASA by Other Quantitative Questionnaire at Months 1, 4 and 8	Month 8- How acceptable was the overall process of interacting with the infusion center so far?	Very acceptable	1 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Acceptability of CABENUVA Administration in Participants at IC/ ASA by Other Quantitative Questionnaire at Months 1, 4 and 8	Month 8- How acceptable was the overall process of interacting with the infusion center so far?	Somewhat acceptable	1 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Acceptability of CABENUVA Administration in Participants at IC/ ASA by Other Quantitative Questionnaire at Months 1, 4 and 8	Month 8- How acceptable was the overall process of interacting with the infusion center so far?	A little acceptable	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Acceptability of CABENUVA Administration in Participants at IC/ ASA by Other Quantitative Questionnaire at Months 1, 4 and 8	Month 8- How acceptable was the overall process of interacting with the infusion center so far?	Neutral	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Acceptability of CABENUVA Administration in Participants at IC/ ASA by Other Quantitative Questionnaire at Months 1, 4 and 8	Month 8- How acceptable was the overall process of interacting with the infusion center so far?	A little unacceptable	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Acceptability of CABENUVA Administration in Participants at IC/ ASA by Other Quantitative Questionnaire at Months 1, 4 and 8	Month 8- How acceptable was the overall process of interacting with the infusion center so far?	Somewhat unacceptable	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Acceptability of CABENUVA Administration in Participants at IC/ ASA by Other Quantitative Questionnaire at Months 1, 4 and 8	Month 8- How acceptable was the overall process of interacting with the infusion center so far?	Very unacceptable	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Acceptability of CABENUVA Administration in Participants at IC/ ASA by Other Quantitative Questionnaire at Months 1, 4 and 8	Month 8- How acceptable was the overall process of interacting with the infusion center so far?	I have not interacted with the infusion center yet.	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Acceptability of CABENUVA Administration in Participants at IC/ ASA by Other Quantitative Questionnaire at Months 1, 4 and 8	Month 8- How acceptable was the overall process of interacting with the infusion center so far?	Missing	1 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Acceptability of CABENUVA Administration in Participants at IC/ ASA by Other Quantitative Questionnaire at Months 1, 4 and 8	Month 4- How acceptable was the overall process of interacting with the infusion center so far?	Very acceptable	2 Participants

Secondary

Number of HIV Care Providers Assessed for Acceptability of CABENUVA Administration in Participants at IC/ASA by Qualitative Interviews at Month 8

HIV care providers were asked about their opinion on the acceptability of participants receiving CABENUVA at the IC/ASA.

Time frame: At Month 8

Population: Analysis was performed on the HIV care providers which includes any HIV care provider who completed any portion of any questionnaire at the specified timepoint.

Arm	Measure	Value (COUNT_OF_PARTICIPANTS)
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Acceptability of CABENUVA Administration in Participants at IC/ASA by Qualitative Interviews at Month 8	2 Participants

Secondary

Number of HIV Care Providers Assessed for Acceptability of the Process of Participants Receiving Injections at ICs/ ASAs by Qualitative Interviews at Month 8

Time frame: At Month 8

Population: Analysis was performed on the HIV care providers which includes any HIV care provider who completed any portion of any questionnaire at the specified timepoint.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Acceptability of the Process of Participants Receiving Injections at ICs/ ASAs by Qualitative Interviews at Month 8	Reinforcing to have it as an option	1 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Acceptability of the Process of Participants Receiving Injections at ICs/ ASAs by Qualitative Interviews at Month 8	Not reported	1 Participants

Secondary

Number of HIV Care Providers Assessed for Acceptability of the Process of Referring Participants to the IC/ ASA for CABENUVA by Other Quantitative Questionnaires at Months 1, 4 and 8

HIV care providers were asked about the type of patients they found acceptable to refer to an IC to receive CABENUVA.

Time frame: At Months 1, 4 and 8

Population: Analysis was performed on the HIV care providers which includes any HIV care provider who completed any portion of any questionnaire at the specified timepoint.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Acceptability of the Process of Referring Participants to the IC/ ASA for CABENUVA by Other Quantitative Questionnaires at Months 1, 4 and 8	All patients, Month 1	1 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Acceptability of the Process of Referring Participants to the IC/ ASA for CABENUVA by Other Quantitative Questionnaires at Months 1, 4 and 8	All patients, Month 4	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Acceptability of the Process of Referring Participants to the IC/ ASA for CABENUVA by Other Quantitative Questionnaires at Months 1, 4 and 8	All patients, Month 8	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Acceptability of the Process of Referring Participants to the IC/ ASA for CABENUVA by Other Quantitative Questionnaires at Months 1, 4 and 8	Patients who want to start CABENUVA but prefer not to come to HIV clinic for each injection, Month 1	1 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Acceptability of the Process of Referring Participants to the IC/ ASA for CABENUVA by Other Quantitative Questionnaires at Months 1, 4 and 8	Patients who want to start CABENUVA but prefer not to come to HIV clinic for each injection, Month 4	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Acceptability of the Process of Referring Participants to the IC/ ASA for CABENUVA by Other Quantitative Questionnaires at Months 1, 4 and 8	Patients who want to start CABENUVA but prefer not to come to HIV clinic for each injection, Month 8	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Acceptability of the Process of Referring Participants to the IC/ ASA for CABENUVA by Other Quantitative Questionnaires at Months 1, 4 and 8	Patients who have had difficulty maintaining their daily oral treatment regimen, Month 1	1 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Acceptability of the Process of Referring Participants to the IC/ ASA for CABENUVA by Other Quantitative Questionnaires at Months 1, 4 and 8	Patients who have had difficulty maintaining their daily oral treatment regimen, Month 4	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Acceptability of the Process of Referring Participants to the IC/ ASA for CABENUVA by Other Quantitative Questionnaires at Months 1, 4 and 8	Patients who have had difficulty maintaining their daily oral treatment regimen, Month 8	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Acceptability of the Process of Referring Participants to the IC/ ASA for CABENUVA by Other Quantitative Questionnaires at Months 1, 4 and 8	Patients already receiving CABENUVA, Month 1	1 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Acceptability of the Process of Referring Participants to the IC/ ASA for CABENUVA by Other Quantitative Questionnaires at Months 1, 4 and 8	Patients already receiving CABENUVA, Month 4	1 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Acceptability of the Process of Referring Participants to the IC/ ASA for CABENUVA by Other Quantitative Questionnaires at Months 1, 4 and 8	Patients already receiving CABENUVA, Month 8	1 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Acceptability of the Process of Referring Participants to the IC/ ASA for CABENUVA by Other Quantitative Questionnaires at Months 1, 4 and 8	Other, Month 1	1 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Acceptability of the Process of Referring Participants to the IC/ ASA for CABENUVA by Other Quantitative Questionnaires at Months 1, 4 and 8	Other, Month 4	1 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Acceptability of the Process of Referring Participants to the IC/ ASA for CABENUVA by Other Quantitative Questionnaires at Months 1, 4 and 8	Other, Month 8	1 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Acceptability of the Process of Referring Participants to the IC/ ASA for CABENUVA by Other Quantitative Questionnaires at Months 1, 4 and 8	Patients who have concerns about disclosure of their HIV status to others, Month 1	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Acceptability of the Process of Referring Participants to the IC/ ASA for CABENUVA by Other Quantitative Questionnaires at Months 1, 4 and 8	Patients who have concerns about disclosure of their HIV status to others, Month 4	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Acceptability of the Process of Referring Participants to the IC/ ASA for CABENUVA by Other Quantitative Questionnaires at Months 1, 4 and 8	Patients who have concerns about disclosure of their HIV status to others, Month 8	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Acceptability of the Process of Referring Participants to the IC/ ASA for CABENUVA by Other Quantitative Questionnaires at Months 1, 4 and 8	Patients who feel stigmatized by their HIV, Month 1	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Acceptability of the Process of Referring Participants to the IC/ ASA for CABENUVA by Other Quantitative Questionnaires at Months 1, 4 and 8	Patients who feel stigmatized by their HIV, Month 4	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Acceptability of the Process of Referring Participants to the IC/ ASA for CABENUVA by Other Quantitative Questionnaires at Months 1, 4 and 8	Patients who feel stigmatized by their HIV, Month 8	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Acceptability of the Process of Referring Participants to the IC/ ASA for CABENUVA by Other Quantitative Questionnaires at Months 1, 4 and 8	Patients with more chaotic lifestyles (variable work schedules, frequent travel etc), Month 1	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Acceptability of the Process of Referring Participants to the IC/ ASA for CABENUVA by Other Quantitative Questionnaires at Months 1, 4 and 8	Patients with more chaotic lifestyles (variable work schedules, frequent travel etc), Month 4	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Acceptability of the Process of Referring Participants to the IC/ ASA for CABENUVA by Other Quantitative Questionnaires at Months 1, 4 and 8	Patients with more chaotic lifestyles (variable work schedules, frequent travel etc), Month 8	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Acceptability of the Process of Referring Participants to the IC/ ASA for CABENUVA by Other Quantitative Questionnaires at Months 1, 4 and 8	Patients with more structured lifestyles, Month 1	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Acceptability of the Process of Referring Participants to the IC/ ASA for CABENUVA by Other Quantitative Questionnaires at Months 1, 4 and 8	Patients with more structured lifestyles, Month 4	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Acceptability of the Process of Referring Participants to the IC/ ASA for CABENUVA by Other Quantitative Questionnaires at Months 1, 4 and 8	Patients with more structured lifestyles, Month 8	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Acceptability of the Process of Referring Participants to the IC/ ASA for CABENUVA by Other Quantitative Questionnaires at Months 1, 4 and 8	Newly diagnosed (<2 years since diagnosis), Month 1	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Acceptability of the Process of Referring Participants to the IC/ ASA for CABENUVA by Other Quantitative Questionnaires at Months 1, 4 and 8	Newly diagnosed (<2 years since diagnosis), Month 4	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Acceptability of the Process of Referring Participants to the IC/ ASA for CABENUVA by Other Quantitative Questionnaires at Months 1, 4 and 8	Newly diagnosed (<2 years since diagnosis), Month 8	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Acceptability of the Process of Referring Participants to the IC/ ASA for CABENUVA by Other Quantitative Questionnaires at Months 1, 4 and 8	Treatment experienced, Month 1	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Acceptability of the Process of Referring Participants to the IC/ ASA for CABENUVA by Other Quantitative Questionnaires at Months 1, 4 and 8	Treatment experienced, Month 4	1 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Acceptability of the Process of Referring Participants to the IC/ ASA for CABENUVA by Other Quantitative Questionnaires at Months 1, 4 and 8	Treatment experienced, Month 8	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Acceptability of the Process of Referring Participants to the IC/ ASA for CABENUVA by Other Quantitative Questionnaires at Months 1, 4 and 8	Younger patients (<35 years old), Month 1	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Acceptability of the Process of Referring Participants to the IC/ ASA for CABENUVA by Other Quantitative Questionnaires at Months 1, 4 and 8	Younger patients (<35 years old), Month 4	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Acceptability of the Process of Referring Participants to the IC/ ASA for CABENUVA by Other Quantitative Questionnaires at Months 1, 4 and 8	Younger patients (<35 years old), Month 8	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Acceptability of the Process of Referring Participants to the IC/ ASA for CABENUVA by Other Quantitative Questionnaires at Months 1, 4 and 8	Older patients (>50 years old), Month 1	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Acceptability of the Process of Referring Participants to the IC/ ASA for CABENUVA by Other Quantitative Questionnaires at Months 1, 4 and 8	Older patients (>50 years old), Month 4	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Acceptability of the Process of Referring Participants to the IC/ ASA for CABENUVA by Other Quantitative Questionnaires at Months 1, 4 and 8	Older patients (>50 years old), Month 8	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Acceptability of the Process of Referring Participants to the IC/ ASA for CABENUVA by Other Quantitative Questionnaires at Months 1, 4 and 8	Missing, Month 1	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Acceptability of the Process of Referring Participants to the IC/ ASA for CABENUVA by Other Quantitative Questionnaires at Months 1, 4 and 8	Missing, Month 4	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Acceptability of the Process of Referring Participants to the IC/ ASA for CABENUVA by Other Quantitative Questionnaires at Months 1, 4 and 8	Missing, Month 8	1 Participants

Secondary

Number of HIV Care Providers Assessed for Advantages of Participants Receiving CABENUVA at IC/ ASA by Qualitative Interviews at Month 8

Time frame: At Month 8

Population: Analysis was performed on the HIV care providers which includes any HIV care provider who completed any portion of any questionnaire at the specified timepoint.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Advantages of Participants Receiving CABENUVA at IC/ ASA by Qualitative Interviews at Month 8	Convenience	2 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Advantages of Participants Receiving CABENUVA at IC/ ASA by Qualitative Interviews at Month 8	Efficiency	2 Participants

Secondary

Number of HIV Care Providers Assessed for Advantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Month 1, 4 and 8

In this outcome measure, HIV care providers were asked about their views on the IC/ASA administration model (advantages of referring patients to an infusion center for CABENUVA).

Time frame: At Months 1, 4 and 8

Population: Analysis was performed on the HIV care providers which includes any HIV care provider who completed any portion of any questionnaire at the specified timepoint.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Advantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Month 1, 4 and 8	Month 1- Missing	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Advantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Month 1, 4 and 8	Month 4- Infusions centers have more clinic space	1 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Advantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Month 1, 4 and 8	Month 1- Convenience for the patient	3 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Advantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Month 1, 4 and 8	Month 1- Infusions centers have more clinic space	1 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Advantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Month 1, 4 and 8	Month 1- Infusion centers have more time to add visits to their schedules	1 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Advantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Month 1, 4 and 8	Month 1- Infusion centers have more staff to manage scheduling or rescheduling appointments	1 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Advantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Month 1, 4 and 8	Month 1- Infusion centers have more staff to administer it	1 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Advantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Month 1, 4 and 8	Month 1- Infusion centers have the space to store the medication	1 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Advantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Month 1, 4 and 8	Month 1- Infusion center handles the logistics of administration	1 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Advantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Month 1, 4 and 8	Month 1- Infusion centers manage the insurance verification process	1 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Advantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Month 1, 4 and 8	Month 1- Infusion centers manage acquisition of the medication	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Advantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Month 1, 4 and 8	Month 1- Infusion centers manage the insurance reimbursement	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Advantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Month 1, 4 and 8	Month 1- Financial considerations for my clinic	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Advantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Month 1, 4 and 8	Month 1- Other	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Advantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Month 1, 4 and 8	Month 4- Convenience for the patient	2 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Advantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Month 1, 4 and 8	Month 4- Infusion centers have more time to add visits to their schedules	1 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Advantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Month 1, 4 and 8	Month 4- Infusion centers have more staff to manage scheduling or rescheduling appointments	2 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Advantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Month 1, 4 and 8	Month 4- Infusion centers have more staff to administer it	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Advantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Month 1, 4 and 8	Month 4- Infusion centers have the space to store the medication	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Advantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Month 1, 4 and 8	Month 4- Infusion center handles the logistics of administration	2 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Advantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Month 1, 4 and 8	Month 4- Infusion centers manage the insurance verification process	1 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Advantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Month 1, 4 and 8	Month 4- Infusion centers manage acquisition of the medication	2 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Advantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Month 1, 4 and 8	Month 4- Infusion centers manage the insurance reimbursement	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Advantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Month 1, 4 and 8	Month 4- Financial considerations for my clinic	1 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Advantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Month 1, 4 and 8	Month 4- Other	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Advantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Month 1, 4 and 8	Month 4- Missing	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Advantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Month 1, 4 and 8	Month 8- Convenience for the patient	2 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Advantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Month 1, 4 and 8	Month 8- Infusions centers have more clinic space	1 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Advantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Month 1, 4 and 8	Month 8- Infusion centers have more time to add visits to their schedules	2 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Advantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Month 1, 4 and 8	Month 8- Infusion centers have more staff to manage scheduling or rescheduling appointments	1 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Advantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Month 1, 4 and 8	Month 8- Infusion centers have more staff to administer it	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Advantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Month 1, 4 and 8	Month 8- Infusion centers have the space to store the medication	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Advantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Month 1, 4 and 8	Month 8- Infusion center handles the logistics of administration	1 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Advantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Month 1, 4 and 8	Month 8- Infusion centers manage the insurance verification process	2 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Advantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Month 1, 4 and 8	Month 8- Infusion centers manage acquisition of the medication	1 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Advantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Month 1, 4 and 8	Month 8- Infusion centers manage the insurance reimbursement	2 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Advantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Month 1, 4 and 8	Month 8- Financial considerations for my clinic	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Advantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Month 1, 4 and 8	Month 8- Other	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Advantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Month 1, 4 and 8	Month 8- Missing	1 Participants

Secondary

Number of HIV Care Providers Assessed for Disadvantages for Participants Receiving CABENUVA at IC/ ASA by Qualitative Interviews at Month 8

In this outcome measure, HIV care providers were asked about their views on the IC/ASA administration model (disadvantages for participants receiving CABENUVA at IC/ASAs).

Time frame: At Month 8

Population: Analysis was performed on the HIV care providers which includes any HIV care provider who completed any portion of any questionnaire at the specified timepoint.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Disadvantages for Participants Receiving CABENUVA at IC/ ASA by Qualitative Interviews at Month 8	Stigma	2 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Disadvantages for Participants Receiving CABENUVA at IC/ ASA by Qualitative Interviews at Month 8	Does not see how it is easier for participants	1 Participants

Secondary

Number of HIV Care Providers Assessed for Disadvantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Month 1

In this outcome measure, HIV care providers were asked about their views on the IC/ASA administration model (potential disadvantages of referring patients to an IC for CABENUVA).

Time frame: At Month 1

Population: Analysis was performed on the HIV care providers which includes any HIV care provider who completed any portion of any questionnaire at the specified timepoint.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Disadvantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Month 1	Concern I won't be aware if my patient does not receive CABENUVA on time	3 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Disadvantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Month 1	Concern about adverse event management	2 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Disadvantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Month 1	Inconvenience for patients to go to two locations (clinic for routine visits and IC for injections)	2 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Disadvantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Month 1	Concern about management of injection site reactions	1 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Disadvantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Month 1	Concern patient won't want to go to infusion center	1 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Disadvantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Month 1	Concern about stigma patient may experience receiving an CABENUVA at infusion center	1 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Disadvantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Month 1	Missed opportunity for revenue for my HIV clinic	1 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Disadvantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Month 1	Issues with ICs handling logistics associated with insurance verification and approval	1 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Disadvantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Month 1	Concern I won't be aware when my patient receives CABENUVA	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Disadvantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Month 1	Concern about reduced involvement in management of HIV-related care	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Disadvantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Month 1	Issues with infusion centers handling the logistics associated with insurance reimbursement	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Disadvantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Month 1	Fear of losing my patient to another provider	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Disadvantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Month 1	Other	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Disadvantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Month 1	Missing	0 Participants

Secondary

Number of HIV Care Providers Assessed for Disadvantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Months 4 and 8

In this outcome measure, HIV care providers were asked about their views on the IC/ASA administration model (disadvantages of referring patients to an IC for CABENUVA).

Time frame: At Months 4 and 8

Population: Analysis was performed on the HIV care providers which includes any HIV care provider who completed any portion of any questionnaire at the specified timepoint.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Disadvantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Months 4 and 8	Month 4- Concern I won't be aware if my patient does not receive CABENUVA on time	1 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Disadvantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Months 4 and 8	Month 4- Concern about adverse event management	1 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Disadvantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Months 4 and 8	Month4-Inconvenience for patients to go to 2 locations(clinic for routine visits & IC for injections	1 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Disadvantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Months 4 and 8	Month 4- Concern about management of injection site reactions	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Disadvantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Months 4 and 8	Month 4- Concern patient won't want to go to infusion center	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Disadvantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Months 4 and 8	Month 4- Concern about stigma patient may experience receiving an CABENUVA at infusion center	1 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Disadvantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Months 4 and 8	Month 4- Missed opportunity for revenue for my HIV clinic	1 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Disadvantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Months 4 and 8	Month 4- Issues with ICs handling logistics associated with insurance verification and approval	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Disadvantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Months 4 and 8	Month 4- Concern I won't be aware when my patient receives CABENUVA	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Disadvantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Months 4 and 8	Month 4- Concern about reduced involvement in management of HIV-related care	2 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Disadvantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Months 4 and 8	Month 4- Issues with infusion centers handling the logistics associated with insurance reimbursement	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Disadvantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Months 4 and 8	Month 4- Fear of losing my patient to another provider	1 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Disadvantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Months 4 and 8	Month 4- Other	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Disadvantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Months 4 and 8	Month 4- Missing	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Disadvantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Months 4 and 8	Month 8- Concern I won't be aware if my patient does not receive CABENUVA on time	1 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Disadvantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Months 4 and 8	Month 8- Concern about adverse event management	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Disadvantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Months 4 and 8	Month8-Inconvenience for patients to go to 2 locations(clinic for routine visits & IC for injections	1 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Disadvantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Months 4 and 8	Month 8- Concern about management of injection site reactions	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Disadvantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Months 4 and 8	Month 8- Concern patient won't want to go to infusion center	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Disadvantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Months 4 and 8	Month 8- Concern about stigma patient may experience receiving an CABENUVA at infusion center	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Disadvantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Months 4 and 8	Month 8- Missed opportunity for revenue for my HIV clinic	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Disadvantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Months 4 and 8	Month 8- Issues with ICs handling logistics associated with insurance verification and approval	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Disadvantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Months 4 and 8	Month 8- Concern I won't be aware when my patient receives CABENUVA	1 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Disadvantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Months 4 and 8	Month 8- Concern about reduced involvement in management of HIV-related care	2 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Disadvantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Months 4 and 8	Month 8- Issues with infusion centers handling the logistics associated with insurance reimbursement	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Disadvantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Months 4 and 8	Month 8- Fear of losing my patient to another provider	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Disadvantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Months 4 and 8	Month 8- Other	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Disadvantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Months 4 and 8	Month 8- Missing	1 Participants

Secondary

Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 1

The tailored HIV care provider/clinical staff questionnaire was developed specifically for this study and contains items regarding the provider's practice and experience, as well as their attitudes, expectations, and concerns regarding the use of CABENUVA/long-acting injectable administered by ICs/ASAs.

Time frame: At Month 1

Population: Analysis was performed on the HIV care providers which includes any HIV care provider who completed any portion of any questionnaire at the specified timepoint.

Arm	Measure	Group	Category	Value (COUNT_OF_PARTICIPANTS)
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 1	Being informed (in a timely manner) when a patient misses a CABENUVA visit	Extremely concerned	1 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 1	Being informed (in a timely manner) when a patient misses a CABENUVA visit	Moderately concerned	1 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 1	Being informed (in a timely manner) when a patient misses a CABENUVA visit	Somewhat concerned	1 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 1	Being informed (in a timely manner) when a patient misses a CABENUVA visit	Slightly concerned	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 1	Being informed (in a timely manner) when a patient misses a CABENUVA visit	Not at all concerned	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 1	Being informed (in a timely manner) when a patient misses a CABENUVA visit	Missing	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 1	Infusion Center's (lack of) persistence to follow up with patients on missed appointments	Extremely concerned	1 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 1	Infusion Center's (lack of) persistence to follow up with patients on missed appointments	Moderately concerned	1 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 1	Infusion Center's (lack of) persistence to follow up with patients on missed appointments	Somewhat concerned	1 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 1	Infusion Center's (lack of) persistence to follow up with patients on missed appointments	Slightly concerned	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 1	Infusion Center's (lack of) persistence to follow up with patients on missed appointments	Not at all concerned	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 1	Infusion Center's (lack of) persistence to follow up with patients on missed appointments	Missing	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 1	Patients not being virologically suppressed due to missed injections	Extremely concerned	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 1	Patients not being virologically suppressed due to missed injections	Moderately concerned	2 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 1	Patients not being virologically suppressed due to missed injections	Somewhat concerned	1 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 1	Patients not being virologically suppressed due to missed injections	Slightly concerned	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 1	Patients not being virologically suppressed due to missed injections	Not at all concerned	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 1	Patients not being virologically suppressed due to missed injections	Missing	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 1	Being informed (in a timely manner) of adverse events	Extremely concerned	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 1	Being informed (in a timely manner) of adverse events	Moderately concerned	2 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 1	Being informed (in a timely manner) of adverse events	Somewhat concerned	1 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 1	Being informed (in a timely manner) of adverse events	Slightly concerned	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 1	Being informed (in a timely manner) of adverse events	Not at all concerned	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 1	Being informed (in a timely manner) of adverse events	Missing	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 1	IC's ability to address other care needs of patients presenting to CABENUVA appointments	Extremely concerned	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 1	IC's ability to address other care needs of patients presenting to CABENUVA appointments	Moderately concerned	2 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 1	IC's ability to address other care needs of patients presenting to CABENUVA appointments	Somewhat concerned	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 1	IC's ability to address other care needs of patients presenting to CABENUVA appointments	Slightly concerned	1 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 1	IC's ability to address other care needs of patients presenting to CABENUVA appointments	Not at all concerned	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 1	IC's ability to address other care needs of patients presenting to CABENUVA appointments	Missing	0 Participants

Secondary

Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 4

Time frame: At Month 4

Population: Analysis was performed on the HIV care providers which includes any HIV care provider who completed any portion of any questionnaire at the specified timepoint.

Arm	Measure	Group	Category	Value (COUNT_OF_PARTICIPANTS)
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 4	Being informed (in a timely manner) when a patient misses a CABENUVA visit	Extremely concerned	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 4	Being informed (in a timely manner) when a patient misses a CABENUVA visit	Moderately concerned	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 4	Being informed (in a timely manner) when a patient misses a CABENUVA visit	Somewhat concerned	3 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 4	Being informed (in a timely manner) when a patient misses a CABENUVA visit	Slightly concerned	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 4	Being informed (in a timely manner) when a patient misses a CABENUVA visit	Not at all concerned	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 4	Being informed (in a timely manner) when a patient misses a CABENUVA visit	Missing	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 4	Infusion Center's (lack of) persistence to follow up with patients on missed appointments	Extremely concerned	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 4	Infusion Center's (lack of) persistence to follow up with patients on missed appointments	Moderately concerned	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 4	Infusion Center's (lack of) persistence to follow up with patients on missed appointments	Somewhat concerned	3 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 4	Infusion Center's (lack of) persistence to follow up with patients on missed appointments	Slightly concerned	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 4	Infusion Center's (lack of) persistence to follow up with patients on missed appointments	Not at all concerned	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 4	Infusion Center's (lack of) persistence to follow up with patients on missed appointments	Missing	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 4	Patients not being virologically suppressed due to missed injections	Extremely concerned	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 4	Patients not being virologically suppressed due to missed injections	Moderately concerned	2 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 4	Patients not being virologically suppressed due to missed injections	Somewhat concerned	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 4	Patients not being virologically suppressed due to missed injections	Slightly concerned	1 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 4	Patients not being virologically suppressed due to missed injections	Not at all concerned	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 4	Patients not being virologically suppressed due to missed injections	Missing	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 4	Being informed (in a timely manner) of adverse events	Extremely concerned	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 4	Being informed (in a timely manner) of adverse events	Moderately concerned	1 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 4	Being informed (in a timely manner) of adverse events	Somewhat concerned	1 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 4	Being informed (in a timely manner) of adverse events	Slightly concerned	1 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 4	Being informed (in a timely manner) of adverse events	Not at all concerned	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 4	Being informed (in a timely manner) of adverse events	Missing	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 4	IC's ability to address other care needs of patients presenting to CABENUVA appointments	Extremely concerned	1 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 4	IC's ability to address other care needs of patients presenting to CABENUVA appointments	Moderately concerned	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 4	IC's ability to address other care needs of patients presenting to CABENUVA appointments	Somewhat concerned	1 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 4	IC's ability to address other care needs of patients presenting to CABENUVA appointments	Slightly concerned	1 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 4	IC's ability to address other care needs of patients presenting to CABENUVA appointments	Not at all concerned	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 4	IC's ability to address other care needs of patients presenting to CABENUVA appointments	Missing	0 Participants

Secondary

Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8

Time frame: At Month 8

Population: Analysis was performed on the HIV care providers which includes any HIV care provider who completed any portion of any questionnaire at the specified timepoint.

Arm	Measure	Group	Category	Value (COUNT_OF_PARTICIPANTS)
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8	Being informed (in a timely manner) when a patient misses a CABENUVA visit	Extremely concerned	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8	Being informed (in a timely manner) when a patient misses a CABENUVA visit	Moderately concerned	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8	Being informed (in a timely manner) when a patient misses a CABENUVA visit	Somewhat concerned	1 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8	Being informed (in a timely manner) when a patient misses a CABENUVA visit	Slightly concerned	1 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8	Being informed (in a timely manner) when a patient misses a CABENUVA visit	Not at all concerned	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8	Being informed (in a timely manner) when a patient misses a CABENUVA visit	Missing	1 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8	Infusion Center's (lack of) persistence to follow up with patients on missed appointments	Extremely concerned	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8	Infusion Center's (lack of) persistence to follow up with patients on missed appointments	Moderately concerned	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8	Infusion Center's (lack of) persistence to follow up with patients on missed appointments	Somewhat concerned	1 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8	Infusion Center's (lack of) persistence to follow up with patients on missed appointments	Slightly concerned	1 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8	Infusion Center's (lack of) persistence to follow up with patients on missed appointments	Not at all concerned	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8	Infusion Center's (lack of) persistence to follow up with patients on missed appointments	Missing	1 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8	Patients not being virologically suppressed due to missed injections	Extremely concerned	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8	Patients not being virologically suppressed due to missed injections	Moderately concerned	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8	Patients not being virologically suppressed due to missed injections	Somewhat concerned	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8	Patients not being virologically suppressed due to missed injections	Slightly concerned	2 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8	Patients not being virologically suppressed due to missed injections	Not at all concerned	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8	Patients not being virologically suppressed due to missed injections	Missing	1 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8	Being informed (in a timely manner) of adverse events	Somewhat concerned	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8	Being informed (in a timely manner) of adverse events	Slightly concerned	1 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8	Being informed (in a timely manner) of adverse events	Not at all concerned	1 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8	Being informed (in a timely manner) of adverse events	Missing	1 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8	IC's ability to address other care needs of patients presenting to CABENUVA appointments	Extremely concerned	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8	IC's ability to address other care needs of patients presenting to CABENUVA appointments	Moderately concerned	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8	IC's ability to address other care needs of patients presenting to CABENUVA appointments	Somewhat concerned	1 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8	IC's ability to address other care needs of patients presenting to CABENUVA appointments	Slightly concerned	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8	IC's ability to address other care needs of patients presenting to CABENUVA appointments	Not at all concerned	1 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8	IC's ability to address other care needs of patients presenting to CABENUVA appointments	Missing	1 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8	Being informed (in a timely manner) of adverse events	Extremely concerned	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8	Being informed (in a timely manner) of adverse events	Moderately concerned	0 Participants

Secondary

Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Qualitative Interviews at Month 8

Qualitative interviews were conducted at Month 8 to evaluate the general opinion of HIV care providers on the feasibility of referring participants to receive CABENUVA at the IC/ASA.

Time frame: At Month 8

Population: Analysis was performed on the HIV care providers which includes any HIV care provider who completed any portion of any questionnaire at the specified timepoint.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Qualitative Interviews at Month 8	Only if insurance requires	1 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Qualitative Interviews at Month 8	Positive experience thus far	1 Participants

Secondary

Number of HIV Care Providers Assessed for Overall Opinion of Continuing to Refer Participants to an IC/ ASA by Other Quantitative Questionnaires at Month 8

Time frame: At Month 8

Population: Analysis was performed on the HIV care providers which includes any HIV care provider who completed any portion of any questionnaire at the specified timepoint.

Arm	Measure	Category	Value (COUNT_OF_PARTICIPANTS)
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Overall Opinion of Continuing to Refer Participants to an IC/ ASA by Other Quantitative Questionnaires at Month 8	Extremely likely	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Overall Opinion of Continuing to Refer Participants to an IC/ ASA by Other Quantitative Questionnaires at Month 8	Very likely	1 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Overall Opinion of Continuing to Refer Participants to an IC/ ASA by Other Quantitative Questionnaires at Month 8	Somewhat likely	1 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Overall Opinion of Continuing to Refer Participants to an IC/ ASA by Other Quantitative Questionnaires at Month 8	Neutral	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Overall Opinion of Continuing to Refer Participants to an IC/ ASA by Other Quantitative Questionnaires at Month 8	Somewhat unlikely	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Overall Opinion of Continuing to Refer Participants to an IC/ ASA by Other Quantitative Questionnaires at Month 8	Very unlikely	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Overall Opinion of Continuing to Refer Participants to an IC/ ASA by Other Quantitative Questionnaires at Month 8	Extremely unlikely	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Overall Opinion of Continuing to Refer Participants to an IC/ ASA by Other Quantitative Questionnaires at Month 8	I was not involved in this process	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Overall Opinion of Continuing to Refer Participants to an IC/ ASA by Other Quantitative Questionnaires at Month 8	Missing	1 Participants

Secondary

Number of HIV Care Providers Assessed for Overall Opinion of Referring Patients to an IC/ ASA by Qualitative Interview at Month 8

HIV care providers were asked about their overall favoring and non-favoring opinions on referring participants to IC/ASA for CABENUVA administration.

Time frame: At Month 8

Population: Analysis was performed on the HIV care providers which includes any HIV care provider who completed any portion of any questionnaire at the specified timepoint.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Overall Opinion of Referring Patients to an IC/ ASA by Qualitative Interview at Month 8	Alternative treatment option for participants	1 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Overall Opinion of Referring Patients to an IC/ ASA by Qualitative Interview at Month 8	Advantages of CABENUVA over daily pill regimen	2 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Overall Opinion of Referring Patients to an IC/ ASA by Qualitative Interview at Month 8	Lack of effectiveness	1 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Overall Opinion of Referring Patients to an IC/ ASA by Qualitative Interview at Month 8	Painful for participants	1 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Overall Opinion of Referring Patients to an IC/ ASA by Qualitative Interview at Month 8	Injection location on participant	1 Participants

Secondary

Number of HIV Care Providers Assessed for Overall Opinion of Referring the Participant to an IC/ ASA by Other Quantitative Questionnaires at Month 1

Time frame: At Month 1

Population: Analysis was performed on the HIV care providers which includes any HIV care provider who completed any portion of any questionnaire at the specified timepoint.

Arm	Measure	Category	Value (COUNT_OF_PARTICIPANTS)
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Overall Opinion of Referring the Participant to an IC/ ASA by Other Quantitative Questionnaires at Month 1	Always	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Overall Opinion of Referring the Participant to an IC/ ASA by Other Quantitative Questionnaires at Month 1	Often	1 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Overall Opinion of Referring the Participant to an IC/ ASA by Other Quantitative Questionnaires at Month 1	Occasionally	1 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Overall Opinion of Referring the Participant to an IC/ ASA by Other Quantitative Questionnaires at Month 1	Rarely	1 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Overall Opinion of Referring the Participant to an IC/ ASA by Other Quantitative Questionnaires at Month 1	Never	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Overall Opinion of Referring the Participant to an IC/ ASA by Other Quantitative Questionnaires at Month 1	Missing	0 Participants

Secondary

Number of HIV Care Providers Assessed for Overall Opinion of Referring the Participant to an IC/ ASA by Other Quantitative Questionnaires at Month 4

Time frame: At Month 4

Population: Analysis was performed on the HIV care providers which includes any HIV care provider who completed any portion of any questionnaire at the specified timepoint.

Arm	Measure	Category	Value (COUNT_OF_PARTICIPANTS)
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Overall Opinion of Referring the Participant to an IC/ ASA by Other Quantitative Questionnaires at Month 4	Very acceptable	2 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Overall Opinion of Referring the Participant to an IC/ ASA by Other Quantitative Questionnaires at Month 4	Somewhat acceptable	1 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Overall Opinion of Referring the Participant to an IC/ ASA by Other Quantitative Questionnaires at Month 4	A little acceptable	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Overall Opinion of Referring the Participant to an IC/ ASA by Other Quantitative Questionnaires at Month 4	Neutral	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Overall Opinion of Referring the Participant to an IC/ ASA by Other Quantitative Questionnaires at Month 4	A little unacceptable	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Overall Opinion of Referring the Participant to an IC/ ASA by Other Quantitative Questionnaires at Month 4	Somewhat unacceptable	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Overall Opinion of Referring the Participant to an IC/ ASA by Other Quantitative Questionnaires at Month 4	Very unacceptable	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Overall Opinion of Referring the Participant to an IC/ ASA by Other Quantitative Questionnaires at Month 4	I have not interacted with the infusion center yet.	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Overall Opinion of Referring the Participant to an IC/ ASA by Other Quantitative Questionnaires at Month 4	Missing	0 Participants

Secondary

Number of HIV Care Providers Assessed for Overall Opinion of Referring the Participant to an IC/ ASA by Other Quantitative Questionnaires at Month 8

Time frame: At Month 8

Population: Analysis was performed on the HIV care providers which includes any HIV care provider who completed any portion of any questionnaire at the specified timepoint.

Arm	Measure	Category	Value (COUNT_OF_PARTICIPANTS)
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Overall Opinion of Referring the Participant to an IC/ ASA by Other Quantitative Questionnaires at Month 8	Very dissatisfied	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Overall Opinion of Referring the Participant to an IC/ ASA by Other Quantitative Questionnaires at Month 8	Extremely satisfied	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Overall Opinion of Referring the Participant to an IC/ ASA by Other Quantitative Questionnaires at Month 8	Very satisfied	2 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Overall Opinion of Referring the Participant to an IC/ ASA by Other Quantitative Questionnaires at Month 8	Somewhat satisfied	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Overall Opinion of Referring the Participant to an IC/ ASA by Other Quantitative Questionnaires at Month 8	Neutral	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Overall Opinion of Referring the Participant to an IC/ ASA by Other Quantitative Questionnaires at Month 8	Somewhat dissatisfied	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Overall Opinion of Referring the Participant to an IC/ ASA by Other Quantitative Questionnaires at Month 8	Extremely dissatisfied	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Overall Opinion of Referring the Participant to an IC/ ASA by Other Quantitative Questionnaires at Month 8	I was not involved in this process	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Overall Opinion of Referring the Participant to an IC/ ASA by Other Quantitative Questionnaires at Month 8	Missing	1 Participants

Secondary

Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants by Qualitative Interviews at Month 8

HIV care providers were asked about the facilitators and challenges related to referring participants to IC/ASAs.

Time frame: At Month 8

Population: Analysis was performed on the HIV care providers which includes any HIV care provider who completed any portion of any questionnaire at the specified timepoint.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants by Qualitative Interviews at Month 8	Sending of prescription is not through EMR	1 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants by Qualitative Interviews at Month 8	Knowing which IC/ASAs offer CABENUVA	1 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants by Qualitative Interviews at Month 8	Multiple labs for participants	1 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants by Qualitative Interviews at Month 8	IC/ASA managing insurance	1 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants by Qualitative Interviews at Month 8	Participant self-motivation to manage care	1 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants by Qualitative Interviews at Month 8	IC/ASA staff support of process	1 Participants

Secondary

Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 1

Time frame: At Month 1

Population: Analysis was performed on the HIV care providers which includes any HIV care provider who completed any portion of any questionnaire at the specified timepoint.

Arm	Measure	Group	Category	Value (COUNT_OF_PARTICIPANTS)
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 1	Being informed (in a timely manner) when a patient misses a CABENUVA visit	Extremely concerned	1 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 1	Being informed (in a timely manner) when a patient misses a CABENUVA visit	Moderately concerned	1 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 1	Being informed (in a timely manner) when a patient misses a CABENUVA visit	Somewhat concerned	1 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 1	Being informed (in a timely manner) when a patient misses a CABENUVA visit	Slightly concerned	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 1	Being informed (in a timely manner) when a patient misses a CABENUVA visit	Not at all concerned	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 1	Being informed (in a timely manner) when a patient misses a CABENUVA visit	Missing	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 1	Infusion Center's (lack of) persistence to follow up with patients on missed appointments	Extremely concerned	1 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 1	Infusion Center's (lack of) persistence to follow up with patients on missed appointments	Moderately concerned	1 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 1	Infusion Center's (lack of) persistence to follow up with patients on missed appointments	Somewhat concerned	1 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 1	Infusion Center's (lack of) persistence to follow up with patients on missed appointments	Slightly concerned	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 1	Infusion Center's (lack of) persistence to follow up with patients on missed appointments	Not at all concerned	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 1	Infusion Center's (lack of) persistence to follow up with patients on missed appointments	Missing	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 1	Patients not being virologically suppressed due to missed injections	Extremely concerned	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 1	Patients not being virologically suppressed due to missed injections	Moderately concerned	2 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 1	Patients not being virologically suppressed due to missed injections	Somewhat concerned	1 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 1	Patients not being virologically suppressed due to missed injections	Slightly concerned	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 1	Patients not being virologically suppressed due to missed injections	Not at all concerned	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 1	Patients not being virologically suppressed due to missed injections	Missing	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 1	Being informed (in a timely manner) of adverse events	Extremely concerned	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 1	Being informed (in a timely manner) of adverse events	Moderately concerned	2 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 1	Being informed (in a timely manner) of adverse events	Somewhat concerned	1 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 1	Being informed (in a timely manner) of adverse events	Slightly concerned	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 1	Being informed (in a timely manner) of adverse events	Not at all concerned	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 1	Being informed (in a timely manner) of adverse events	Missing	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 1	IC's ability to manage other care needs of patients presenting to CABENUVA appointments	Extremely concerned	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 1	IC's ability to manage other care needs of patients presenting to CABENUVA appointments	Moderately concerned	2 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 1	IC's ability to manage other care needs of patients presenting to CABENUVA appointments	Somewhat concerned	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 1	IC's ability to manage other care needs of patients presenting to CABENUVA appointments	Slightly concerned	1 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 1	IC's ability to manage other care needs of patients presenting to CABENUVA appointments	Not at all concerned	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 1	IC's ability to manage other care needs of patients presenting to CABENUVA appointments	Missing	0 Participants

Secondary

Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 4

Time frame: At Month 4

Population: Analysis was performed on the HIV care providers which includes any HIV care provider who completed any portion of any questionnaire at the specified timepoint.

Arm	Measure	Group	Category	Value (COUNT_OF_PARTICIPANTS)
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 4	Being informed (in a timely manner) when a patient misses a CABENUVA visit	Extremely concerned	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 4	Being informed (in a timely manner) when a patient misses a CABENUVA visit	Moderately concerned	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 4	Being informed (in a timely manner) when a patient misses a CABENUVA visit	Somewhat concerned	3 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 4	Being informed (in a timely manner) when a patient misses a CABENUVA visit	Slightly concerned	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 4	Being informed (in a timely manner) when a patient misses a CABENUVA visit	Not at all concerned	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 4	Being informed (in a timely manner) when a patient misses a CABENUVA visit	Missing	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 4	Infusion Center's (lack of) persistence to follow up with patients on missed appointments	Extremely concerned	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 4	Infusion Center's (lack of) persistence to follow up with patients on missed appointments	Moderately concerned	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 4	Infusion Center's (lack of) persistence to follow up with patients on missed appointments	Somewhat concerned	3 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 4	Infusion Center's (lack of) persistence to follow up with patients on missed appointments	Slightly concerned	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 4	Infusion Center's (lack of) persistence to follow up with patients on missed appointments	Not at all concerned	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 4	Infusion Center's (lack of) persistence to follow up with patients on missed appointments	Missing	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 4	Patients not being virologically suppressed due to missed injections	Extremely concerned	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 4	Patients not being virologically suppressed due to missed injections	Moderately concerned	2 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 4	Patients not being virologically suppressed due to missed injections	Somewhat concerned	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 4	Patients not being virologically suppressed due to missed injections	Slightly concerned	1 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 4	Patients not being virologically suppressed due to missed injections	Not at all concerned	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 4	Patients not being virologically suppressed due to missed injections	Missing	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 4	Being informed (in a timely manner) of adverse events	Extremely concerned	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 4	Being informed (in a timely manner) of adverse events	Moderately concerned	1 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 4	Being informed (in a timely manner) of adverse events	Somewhat concerned	1 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 4	Being informed (in a timely manner) of adverse events	Slightly concerned	1 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 4	Being informed (in a timely manner) of adverse events	Not at all concerned	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 4	Being informed (in a timely manner) of adverse events	Missing	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 4	IC's ability to manage other care needs of patients presenting to CABENUVA appointments	Extremely concerned	1 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 4	IC's ability to manage other care needs of patients presenting to CABENUVA appointments	Moderately concerned	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 4	IC's ability to manage other care needs of patients presenting to CABENUVA appointments	Somewhat concerned	1 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 4	IC's ability to manage other care needs of patients presenting to CABENUVA appointments	Slightly concerned	1 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 4	IC's ability to manage other care needs of patients presenting to CABENUVA appointments	Not at all concerned	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 4	IC's ability to manage other care needs of patients presenting to CABENUVA appointments	Missing	0 Participants

Secondary

Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 8

Time frame: At Month 8

Population: Analysis was performed on the HIV care providers which includes any HIV care provider who completed any portion of any questionnaire at the specified timepoint.

Arm	Measure	Group	Category	Value (COUNT_OF_PARTICIPANTS)
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 8	Being informed (in a timely manner) when a patient misses a CABENUVA visit	Extremely concerned	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 8	Being informed (in a timely manner) when a patient misses a CABENUVA visit	Moderately concerned	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 8	Being informed (in a timely manner) when a patient misses a CABENUVA visit	Somewhat concerned	1 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 8	Being informed (in a timely manner) when a patient misses a CABENUVA visit	Slightly concerned	1 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 8	Being informed (in a timely manner) when a patient misses a CABENUVA visit	Not at all concerned	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 8	Being informed (in a timely manner) when a patient misses a CABENUVA visit	Missing	1 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 8	Infusion Center's (lack of) persistence to follow up with patients on missed appointments	Extremely concerned	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 8	Infusion Center's (lack of) persistence to follow up with patients on missed appointments	Moderately concerned	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 8	Infusion Center's (lack of) persistence to follow up with patients on missed appointments	Somewhat concerned	1 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 8	Infusion Center's (lack of) persistence to follow up with patients on missed appointments	Slightly concerned	1 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 8	Infusion Center's (lack of) persistence to follow up with patients on missed appointments	Not at all concerned	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 8	Infusion Center's (lack of) persistence to follow up with patients on missed appointments	Missing	1 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 8	Patients not being virologically suppressed due to missed injections	Extremely concerned	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 8	Patients not being virologically suppressed due to missed injections	Moderately concerned	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 8	Patients not being virologically suppressed due to missed injections	Somewhat concerned	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 8	Patients not being virologically suppressed due to missed injections	Slightly concerned	2 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 8	Patients not being virologically suppressed due to missed injections	Not at all concerned	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 8	Patients not being virologically suppressed due to missed injections	Missing	1 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 8	Being informed (in a timely manner) of adverse events	Extremely concerned	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 8	Being informed (in a timely manner) of adverse events	Moderately concerned	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 8	Being informed (in a timely manner) of adverse events	Somewhat concerned	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 8	Being informed (in a timely manner) of adverse events	Slightly concerned	1 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 8	Being informed (in a timely manner) of adverse events	Not at all concerned	1 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 8	Being informed (in a timely manner) of adverse events	Missing	1 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 8	IC's ability to manage other care needs of patients presenting to CABENUVA appointments	Extremely concerned	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 8	IC's ability to manage other care needs of patients presenting to CABENUVA appointments	Moderately concerned	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 8	IC's ability to manage other care needs of patients presenting to CABENUVA appointments	Somewhat concerned	1 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 8	IC's ability to manage other care needs of patients presenting to CABENUVA appointments	Slightly concerned	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 8	IC's ability to manage other care needs of patients presenting to CABENUVA appointments	Not at all concerned	1 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 8	IC's ability to manage other care needs of patients presenting to CABENUVA appointments	Missing	1 Participants

Secondary

Number of HIV Care Providers Assessed for Usefulness of Plan of Treatment (POT) by Other Quantitative Questionnaires at Months 4 and 8

Time frame: At Months 4 and 8

Population: Analysis was performed on the HIV care providers which includes any HIV care provider who completed any portion of any questionnaire at the specified timepoint.

Arm	Measure	Group	Category	Value (COUNT_OF_PARTICIPANTS)
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Usefulness of Plan of Treatment (POT) by Other Quantitative Questionnaires at Months 4 and 8	Month 4- Information in the POT is comprehensive enough for IC to administer CABENUVA to patients	Strongly Agree	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Usefulness of Plan of Treatment (POT) by Other Quantitative Questionnaires at Months 4 and 8	Month 4- Information in the POT is comprehensive enough for IC to administer CABENUVA to patients	Agree	2 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Usefulness of Plan of Treatment (POT) by Other Quantitative Questionnaires at Months 4 and 8	Month 4- Information in the POT is comprehensive enough for IC to administer CABENUVA to patients	Occasionally	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Usefulness of Plan of Treatment (POT) by Other Quantitative Questionnaires at Months 4 and 8	Month 4- Information in the POT is comprehensive enough for IC to administer CABENUVA to patients	Neither agree nor disagree	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Usefulness of Plan of Treatment (POT) by Other Quantitative Questionnaires at Months 4 and 8	Month 4- Information in the POT is comprehensive enough for IC to administer CABENUVA to patients	Disagree	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Usefulness of Plan of Treatment (POT) by Other Quantitative Questionnaires at Months 4 and 8	Month 4- Information in the POT is comprehensive enough for IC to administer CABENUVA to patients	Strongly disagree	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Usefulness of Plan of Treatment (POT) by Other Quantitative Questionnaires at Months 4 and 8	Month 4- The POT has all information it should have for the infusion center to administer CABENUVA	Strongly Agree	1 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Usefulness of Plan of Treatment (POT) by Other Quantitative Questionnaires at Months 4 and 8	Month 4- The POT has all information it should have for the infusion center to administer CABENUVA	Agree	1 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Usefulness of Plan of Treatment (POT) by Other Quantitative Questionnaires at Months 4 and 8	Month 4- The POT has all information it should have for the infusion center to administer CABENUVA	Occasionally	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Usefulness of Plan of Treatment (POT) by Other Quantitative Questionnaires at Months 4 and 8	Month 4- The POT has all information it should have for the infusion center to administer CABENUVA	Neither agree nor disagree	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Usefulness of Plan of Treatment (POT) by Other Quantitative Questionnaires at Months 4 and 8	Month 4- The POT has all information it should have for the infusion center to administer CABENUVA	Disagree	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Usefulness of Plan of Treatment (POT) by Other Quantitative Questionnaires at Months 4 and 8	Month 4- The POT has all information it should have for the infusion center to administer CABENUVA	Strongly disagree	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Usefulness of Plan of Treatment (POT) by Other Quantitative Questionnaires at Months 4 and 8	Month 8- Information in the POT is comprehensive enough for IC to administer CABENUVA to patients	Strongly Agree	1 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Usefulness of Plan of Treatment (POT) by Other Quantitative Questionnaires at Months 4 and 8	Month 8- Information in the POT is comprehensive enough for IC to administer CABENUVA to patients	Agree	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Usefulness of Plan of Treatment (POT) by Other Quantitative Questionnaires at Months 4 and 8	Month 8- Information in the POT is comprehensive enough for IC to administer CABENUVA to patients	Occasionally	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Usefulness of Plan of Treatment (POT) by Other Quantitative Questionnaires at Months 4 and 8	Month 8- Information in the POT is comprehensive enough for IC to administer CABENUVA to patients	Neither agree nor disagree	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Usefulness of Plan of Treatment (POT) by Other Quantitative Questionnaires at Months 4 and 8	Month 8- Information in the POT is comprehensive enough for IC to administer CABENUVA to patients	Disagree	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Usefulness of Plan of Treatment (POT) by Other Quantitative Questionnaires at Months 4 and 8	Month 8- Information in the POT is comprehensive enough for IC to administer CABENUVA to patients	Strongly disagree	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Usefulness of Plan of Treatment (POT) by Other Quantitative Questionnaires at Months 4 and 8	Month 8- The POT has all information it should have for the infusion center to administer CABENUVA	Strongly Agree	1 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Usefulness of Plan of Treatment (POT) by Other Quantitative Questionnaires at Months 4 and 8	Month 8- The POT has all information it should have for the infusion center to administer CABENUVA	Agree	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Usefulness of Plan of Treatment (POT) by Other Quantitative Questionnaires at Months 4 and 8	Month 8- The POT has all information it should have for the infusion center to administer CABENUVA	Occasionally	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Usefulness of Plan of Treatment (POT) by Other Quantitative Questionnaires at Months 4 and 8	Month 8- The POT has all information it should have for the infusion center to administer CABENUVA	Neither agree nor disagree	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Usefulness of Plan of Treatment (POT) by Other Quantitative Questionnaires at Months 4 and 8	Month 8- The POT has all information it should have for the infusion center to administer CABENUVA	Disagree	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Usefulness of Plan of Treatment (POT) by Other Quantitative Questionnaires at Months 4 and 8	Month 8- The POT has all information it should have for the infusion center to administer CABENUVA	Strongly disagree	0 Participants

Secondary

Number of HIV Care Providers Assessed for Usefulness of the Blueprint Intervention and POT by Qualitative Interviews at Month 8

The blueprint guides HIV care providers on what to do with referrals to receive CABENUVA at the IC/ASA.

Time frame: Month 8

Population: Analysis was performed on the HIV care providers which includes any HIV care provider who completed any portion of any questionnaire at the specified timepoint.

Arm	Measure	Group	Category	Value (COUNT_OF_PARTICIPANTS)
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Usefulness of the Blueprint Intervention and POT by Qualitative Interviews at Month 8	Usefulness of POT	Sufficient in providing information to the IC/ASA	1 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Usefulness of the Blueprint Intervention and POT by Qualitative Interviews at Month 8	Usefulness of POT	Not reported	1 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Usefulness of the Blueprint Intervention and POT by Qualitative Interviews at Month 8	Usefulness of blueprint	Sufficient in providing information to the IC/ASA	0 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Assessed for Usefulness of the Blueprint Intervention and POT by Qualitative Interviews at Month 8	Usefulness of blueprint	Not reported	2 Participants

Secondary

Number of HIV Care Providers Who Agree or Completely Agree (a Score of 4 or Higher) Across All Items on the Acceptability of Intervention Measure (AIM)

AIM was employed to evaluate the acceptability of CABENUVA administration at Infusion Centers/ ASAs. Higher scores for AIM indicate greater acceptability, where each item was scored from 1 to 5: Completely disagree (score=1), disagree (score=2), neither agree or disagree (score=3), agree (score=4), completely agree (score=5).

Time frame: Months 1 (Baseline), 4, and 8

Population: Analysis was performed on the HIV care providers which includes any HIV care provider who completed any portion of any questionnaire at the specified timepoint.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Participants Receiving CABENUVA	Number of HIV Care Providers Who Agree or Completely Agree (a Score of 4 or Higher) Across All Items on the Acceptability of Intervention Measure (AIM)	At Month 1 (baseline)	1 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Who Agree or Completely Agree (a Score of 4 or Higher) Across All Items on the Acceptability of Intervention Measure (AIM)	At month 4	2 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Who Agree or Completely Agree (a Score of 4 or Higher) Across All Items on the Acceptability of Intervention Measure (AIM)	At month 8	1 Participants

Secondary

Number of HIV Care Providers Who Agree or Completely Agree (a Score of 4 or Higher) Across All Items on the FIM at Month 1, 4 and 8

Time frame: At Months 1, 4, and 8

Population: Analysis was performed on the HIV care providers which includes any HIV care provider who completed any portion of any questionnaire at the specified timepoint.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Participants Receiving CABENUVA	Number of HIV Care Providers Who Agree or Completely Agree (a Score of 4 or Higher) Across All Items on the FIM at Month 1, 4 and 8	Month 1	1 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Who Agree or Completely Agree (a Score of 4 or Higher) Across All Items on the FIM at Month 1, 4 and 8	Month 4	1 Participants
Participants Receiving CABENUVA	Number of HIV Care Providers Who Agree or Completely Agree (a Score of 4 or Higher) Across All Items on the FIM at Month 1, 4 and 8	Month 8	0 Participants

Secondary

Number of IC/ ASA Staff Assessed for Acceptability of CABENUVA Administration in Participants at IC/ ASA by Other Quantitative Questionnaire at Months 3 and 8

Time frame: At Months 3 and 8

Population: Analysis was performed on the IC/ASA staff which includes any IC/ASA staff who completed any portion of any questionnaire at the specified timepoint.

Arm	Measure	Group	Category	Value (COUNT_OF_PARTICIPANTS)
Participants Receiving CABENUVA	Number of IC/ ASA Staff Assessed for Acceptability of CABENUVA Administration in Participants at IC/ ASA by Other Quantitative Questionnaire at Months 3 and 8	Month 3- Concern from a personal safety perspective about administering CABENUVA to people with HIV?	Extremely concerned	0 Participants
Participants Receiving CABENUVA	Number of IC/ ASA Staff Assessed for Acceptability of CABENUVA Administration in Participants at IC/ ASA by Other Quantitative Questionnaire at Months 3 and 8	Month 3- Concern from a personal safety perspective about administering CABENUVA to people with HIV?	Moderately concerned	0 Participants
Participants Receiving CABENUVA	Number of IC/ ASA Staff Assessed for Acceptability of CABENUVA Administration in Participants at IC/ ASA by Other Quantitative Questionnaire at Months 3 and 8	Month 3- Concern from a personal safety perspective about administering CABENUVA to people with HIV?	Somewhat concerned	5 Participants
Participants Receiving CABENUVA	Number of IC/ ASA Staff Assessed for Acceptability of CABENUVA Administration in Participants at IC/ ASA by Other Quantitative Questionnaire at Months 3 and 8	Month 3- Concern from a personal safety perspective about administering CABENUVA to people with HIV?	Slightly concerned	6 Participants
Participants Receiving CABENUVA	Number of IC/ ASA Staff Assessed for Acceptability of CABENUVA Administration in Participants at IC/ ASA by Other Quantitative Questionnaire at Months 3 and 8	Month 3- Concern from a personal safety perspective about administering CABENUVA to people with HIV?	Not at all concerned	22 Participants
Participants Receiving CABENUVA	Number of IC/ ASA Staff Assessed for Acceptability of CABENUVA Administration in Participants at IC/ ASA by Other Quantitative Questionnaire at Months 3 and 8	Month 3- Concern from a personal safety perspective about administering CABENUVA to people with HIV?	Unsure/not applicable to role	1 Participants
Participants Receiving CABENUVA	Number of IC/ ASA Staff Assessed for Acceptability of CABENUVA Administration in Participants at IC/ ASA by Other Quantitative Questionnaire at Months 3 and 8	Month 3- Concern from a personal safety perspective about administering CABENUVA to people with HIV?	Missing	4 Participants
Participants Receiving CABENUVA	Number of IC/ ASA Staff Assessed for Acceptability of CABENUVA Administration in Participants at IC/ ASA by Other Quantitative Questionnaire at Months 3 and 8	Month 8- Concern from a personal safety perspective about administering CABENUVA to people with HIV?	Extremely concerned	0 Participants
Participants Receiving CABENUVA	Number of IC/ ASA Staff Assessed for Acceptability of CABENUVA Administration in Participants at IC/ ASA by Other Quantitative Questionnaire at Months 3 and 8	Month 8- Concern from a personal safety perspective about administering CABENUVA to people with HIV?	Moderately concerned	1 Participants
Participants Receiving CABENUVA	Number of IC/ ASA Staff Assessed for Acceptability of CABENUVA Administration in Participants at IC/ ASA by Other Quantitative Questionnaire at Months 3 and 8	Month 8- Concern from a personal safety perspective about administering CABENUVA to people with HIV?	Somewhat concerned	3 Participants
Participants Receiving CABENUVA	Number of IC/ ASA Staff Assessed for Acceptability of CABENUVA Administration in Participants at IC/ ASA by Other Quantitative Questionnaire at Months 3 and 8	Month 8- Concern from a personal safety perspective about administering CABENUVA to people with HIV?	Slightly concerned	4 Participants
Participants Receiving CABENUVA	Number of IC/ ASA Staff Assessed for Acceptability of CABENUVA Administration in Participants at IC/ ASA by Other Quantitative Questionnaire at Months 3 and 8	Month 8- Concern from a personal safety perspective about administering CABENUVA to people with HIV?	Not at all concerned	11 Participants
Participants Receiving CABENUVA	Number of IC/ ASA Staff Assessed for Acceptability of CABENUVA Administration in Participants at IC/ ASA by Other Quantitative Questionnaire at Months 3 and 8	Month 8- Concern from a personal safety perspective about administering CABENUVA to people with HIV?	Unsure/not applicable to role	1 Participants
Participants Receiving CABENUVA	Number of IC/ ASA Staff Assessed for Acceptability of CABENUVA Administration in Participants at IC/ ASA by Other Quantitative Questionnaire at Months 3 and 8	Month 8- Concern from a personal safety perspective about administering CABENUVA to people with HIV?	Missing	6 Participants

Secondary

Number of IC/ ASA Staff Assessed for Acceptability of CABENUVA Administration in Participants at IC/ ASA by Other Quantitative Questionnaire Prior to Month 1

Time frame: Prior to Month 1 (Baseline)

Population: Analysis was performed on the IC/ASA staff which includes any IC/ASA staff who completed any portion of any questionnaire at the specified timepoint.

Arm	Measure	Category	Value (COUNT_OF_PARTICIPANTS)
Participants Receiving CABENUVA	Number of IC/ ASA Staff Assessed for Acceptability of CABENUVA Administration in Participants at IC/ ASA by Other Quantitative Questionnaire Prior to Month 1	Extremely concerned	6 Participants
Participants Receiving CABENUVA	Number of IC/ ASA Staff Assessed for Acceptability of CABENUVA Administration in Participants at IC/ ASA by Other Quantitative Questionnaire Prior to Month 1	Moderately concerned	13 Participants
Participants Receiving CABENUVA	Number of IC/ ASA Staff Assessed for Acceptability of CABENUVA Administration in Participants at IC/ ASA by Other Quantitative Questionnaire Prior to Month 1	Somewhat concerned	22 Participants
Participants Receiving CABENUVA	Number of IC/ ASA Staff Assessed for Acceptability of CABENUVA Administration in Participants at IC/ ASA by Other Quantitative Questionnaire Prior to Month 1	Slightly concerned	21 Participants
Participants Receiving CABENUVA	Number of IC/ ASA Staff Assessed for Acceptability of CABENUVA Administration in Participants at IC/ ASA by Other Quantitative Questionnaire Prior to Month 1	Not at all concerned	51 Participants
Participants Receiving CABENUVA	Number of IC/ ASA Staff Assessed for Acceptability of CABENUVA Administration in Participants at IC/ ASA by Other Quantitative Questionnaire Prior to Month 1	Missing	0 Participants

Secondary

Number of IC/ASA Staff Assessed for Acceptability of CABENUVA Administration in Participants at IC/ASA by Qualitative Interviews at Month 8

IC/ASA staff were asked about their opinion on the acceptability of administering CABENUVA at an IC/ASA.

Time frame: At Month 8

Population: Analysis was performed on the IC/ASA staff which includes any IC/ASA staff who completed any portion of any questionnaire at the specified timepoint.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Acceptability of CABENUVA Administration in Participants at IC/ASA by Qualitative Interviews at Month 8	Learned more about CABENUVA	2 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Acceptability of CABENUVA Administration in Participants at IC/ASA by Qualitative Interviews at Month 8	Improved outlook about CABENUVA	1 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Acceptability of CABENUVA Administration in Participants at IC/ASA by Qualitative Interviews at Month 8	Ease of administration over time	2 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Acceptability of CABENUVA Administration in Participants at IC/ASA by Qualitative Interviews at Month 8	Quick and easy administration process	4 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Acceptability of CABENUVA Administration in Participants at IC/ASA by Qualitative Interviews at Month 8	Easy to integrate into IC/ASA workflow	4 Participants

Secondary

Number of IC/ASA Staff Assessed for Barriers/Concerns of CABENUVA Administration in Participants by Qualitative Interviews at Month 8

IC/ASA staff were asked their opinion on the infrastructure impact of administering CABENUVA.

Time frame: At Month 8

Population: Analysis was performed on the IC/ASA staff which includes any IC/ASA staff who completed any portion of any questionnaire at the specified timepoint.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Barriers/Concerns of CABENUVA Administration in Participants by Qualitative Interviews at Month 8	Facilitates implementation	12 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Barriers/Concerns of CABENUVA Administration in Participants by Qualitative Interviews at Month 8	Scheduling system work arounds to accommodate visit window	1 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Barriers/Concerns of CABENUVA Administration in Participants by Qualitative Interviews at Month 8	Modifying visit duration to account for all the pieces of administering CABENUVA	2 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Barriers/Concerns of CABENUVA Administration in Participants by Qualitative Interviews at Month 8	Shortage of private rooms	4 Participants

Secondary

Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3

The IC/ASA staff members were asked to indicate their level of concern across 16 areas of potential concern, on a five-point scale from not at all concerned to extremely concerned.

Time frame: At Month 3

Population: Analysis was performed on the IC/ASA staff which includes any IC/ASA staff who completed any portion of any questionnaire at the specified timepoint.

Arm	Measure	Group	Category	Value (COUNT_OF_PARTICIPANTS)
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3	Understanding of how to provide patients with oral medication for planned missed doses	Extremely concerned	0 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3	Understanding of how to provide patients with oral medication for planned missed doses	Moderately concerned	5 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3	Understanding of how to provide patients with oral medication for planned missed doses	Somewhat concerned	14 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3	Understanding of how to provide patients with oral medication for planned missed doses	Slightly concerned	7 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3	Understanding of how to provide patients with oral medication for planned missed doses	Not at all concerned	8 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3	Understanding of how to provide patients with oral medication for planned missed doses	Missing	4 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3	Management of reporting abnormal lab results with HIV providers	Extremely concerned	1 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3	Management of reporting abnormal lab results with HIV providers	Moderately concerned	4 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3	Management of reporting abnormal lab results with HIV providers	Somewhat concerned	3 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3	Management of reporting abnormal lab results with HIV providers	Slightly concerned	9 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3	Management of reporting abnormal lab results with HIV providers	Not at all concerned	17 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3	Management of reporting abnormal lab results with HIV providers	Missing	4 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3	Understanding of when patients should receive oral medication for planned missed doses	Extremely concerned	1 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3	Understanding of when patients should receive oral medication for planned missed doses	Moderately concerned	5 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3	Understanding of when patients should receive oral medication for planned missed doses	Somewhat concerned	8 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3	Understanding of when patients should receive oral medication for planned missed doses	Slightly concerned	9 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3	Understanding of when patients should receive oral medication for planned missed doses	Not at all concerned	11 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3	Understanding of when patients should receive oral medication for planned missed doses	Missing	4 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3	Managing patients presenting to CABENUVA appointments with other care needs to be addressed	Extremely concerned	2 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3	Managing patients presenting to CABENUVA appointments with other care needs to be addressed	Moderately concerned	3 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3	Managing patients presenting to CABENUVA appointments with other care needs to be addressed	Somewhat concerned	5 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3	Managing patients presenting to CABENUVA appointments with other care needs to be addressed	Slightly concerned	13 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3	Managing patients presenting to CABENUVA appointments with other care needs to be addressed	Not at all concerned	11 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3	Managing patients presenting to CABENUVA appointments with other care needs to be addressed	Missing	4 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3	Frequency of lab draws at the infusion center	Extremely concerned	0 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3	Frequency of lab draws at the infusion center	Moderately concerned	4 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3	Frequency of lab draws at the infusion center	Somewhat concerned	4 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3	Frequency of lab draws at the infusion center	Slightly concerned	14 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3	Frequency of lab draws at the infusion center	Not at all concerned	12 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3	Frequency of lab draws at the infusion center	Missing	4 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3	Management of rescheduling appointments during correct treatment windows	Extremely concerned	0 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3	Management of rescheduling appointments during correct treatment windows	Moderately concerned	1 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3	Management of rescheduling appointments during correct treatment windows	Somewhat concerned	4 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3	Management of rescheduling appointments during correct treatment windows	Slightly concerned	10 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3	Management of rescheduling appointments during correct treatment windows	Not at all concerned	19 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3	Management of rescheduling appointments during correct treatment windows	Missing	4 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3	Management of scheduling appointments during correct treatment windows	Extremely concerned	0 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3	Management of scheduling appointments during correct treatment windows	Moderately concerned	0 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3	Management of scheduling appointments during correct treatment windows	Somewhat concerned	2 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3	Management of scheduling appointments during correct treatment windows	Slightly concerned	7 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3	Management of scheduling appointments during correct treatment windows	Not at all concerned	25 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3	Management of scheduling appointments during correct treatment windows	Missing	4 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3	Answering patient questions between visits	Extremely concerned	1 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3	Answering patient questions between visits	Moderately concerned	1 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3	Answering patient questions between visits	Somewhat concerned	6 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3	Answering patient questions between visits	Slightly concerned	9 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3	Answering patient questions between visits	Not at all concerned	17 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3	Answering patient questions between visits	Missing	4 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3	Management of confirming patient insurance coverage	Extremely concerned	0 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3	Management of confirming patient insurance coverage	Moderately concerned	0 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3	Management of confirming patient insurance coverage	Somewhat concerned	3 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3	Management of confirming patient insurance coverage	Slightly concerned	11 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3	Management of confirming patient insurance coverage	Not at all concerned	20 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3	Management of confirming patient insurance coverage	Missing	4 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3	Patient insurance coverage clearing for payment	Extremely concerned	0 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3	Patient insurance coverage clearing for payment	Moderately concerned	0 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3	Patient insurance coverage clearing for payment	Somewhat concerned	5 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3	Patient insurance coverage clearing for payment	Slightly concerned	9 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3	Patient insurance coverage clearing for payment	Not at all concerned	20 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3	Patient insurance coverage clearing for payment	Missing	4 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3	Management of patient injection-related pain/soreness	Extremely concerned	0 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3	Management of patient injection-related pain/soreness	Moderately concerned	2 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3	Management of patient injection-related pain/soreness	Somewhat concerned	6 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3	Management of patient injection-related pain/soreness	Slightly concerned	7 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3	Management of patient injection-related pain/soreness	Not at all concerned	19 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3	Management of patient injection-related pain/soreness	Missing	4 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3	Management of reporting of adverse events	Extremely concerned	0 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3	Management of reporting of adverse events	Moderately concerned	3 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3	Management of reporting of adverse events	Somewhat concerned	3 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3	Management of reporting of adverse events	Slightly concerned	11 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3	Management of reporting of adverse events	Not at all concerned	17 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3	Management of reporting of adverse events	Missing	4 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3	Patients' willingness to travel to an infusion center for each injection visit	Extremely concerned	0 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3	Patients' willingness to travel to an infusion center for each injection visit	Moderately concerned	1 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3	Patients' willingness to travel to an infusion center for each injection visit	Somewhat concerned	6 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3	Patients' willingness to travel to an infusion center for each injection visit	Slightly concerned	7 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3	Patients' willingness to travel to an infusion center for each injection visit	Not at all concerned	20 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3	Patients' willingness to travel to an infusion center for each injection visit	Missing	4 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3	Timely reporting of adverse events to HIV providers	Extremely concerned	0 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3	Timely reporting of adverse events to HIV providers	Moderately concerned	1 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3	Timely reporting of adverse events to HIV providers	Somewhat concerned	5 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3	Timely reporting of adverse events to HIV providers	Slightly concerned	5 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3	Timely reporting of adverse events to HIV providers	Not at all concerned	23 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3	Timely reporting of adverse events to HIV providers	Missing	4 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3	Timely reporting to the provider when a patient misses a CABENUVA visit	Extremely concerned	0 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3	Timely reporting to the provider when a patient misses a CABENUVA visit	Moderately concerned	1 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3	Timely reporting to the provider when a patient misses a CABENUVA visit	Somewhat concerned	5 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3	Timely reporting to the provider when a patient misses a CABENUVA visit	Slightly concerned	6 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3	Timely reporting to the provider when a patient misses a CABENUVA visit	Not at all concerned	22 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3	Timely reporting to the provider when a patient misses a CABENUVA visit	Missing	4 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3	Timely reporting to the provider when a patient receives CABENUVA	Extremely concerned	0 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3	Timely reporting to the provider when a patient receives CABENUVA	Moderately concerned	1 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3	Timely reporting to the provider when a patient receives CABENUVA	Somewhat concerned	6 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3	Timely reporting to the provider when a patient receives CABENUVA	Slightly concerned	1 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3	Timely reporting to the provider when a patient receives CABENUVA	Not at all concerned	26 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3	Timely reporting to the provider when a patient receives CABENUVA	Missing	4 Participants

Secondary

Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8

The IC/ASA staff members were asked to indicate their level of concern across 16 areas of potential concern, on a five-point scale from not at all concerned to extremely concerned.

Time frame: At Month 8

Population: Analysis was performed on the IC/ASA staff which includes any IC/ASA staff who completed any portion of any questionnaire at the specified timepoint.

Arm	Measure	Group	Category	Value (COUNT_OF_PARTICIPANTS)
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8	Understanding of how to provide patients with oral medication for planned missed doses	Extremely concerned	1 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8	Understanding of how to provide patients with oral medication for planned missed doses	Moderately concerned	6 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8	Understanding of how to provide patients with oral medication for planned missed doses	Somewhat concerned	4 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8	Understanding of how to provide patients with oral medication for planned missed doses	Slightly concerned	3 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8	Understanding of how to provide patients with oral medication for planned missed doses	Not at all concerned	6 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8	Understanding of how to provide patients with oral medication for planned missed doses	Missing	6 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8	Management of reporting abnormal lab results with HIV providers	Extremely concerned	0 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8	Management of reporting abnormal lab results with HIV providers	Moderately concerned	0 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8	Management of reporting abnormal lab results with HIV providers	Somewhat concerned	1 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8	Management of reporting abnormal lab results with HIV providers	Slightly concerned	9 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8	Management of reporting abnormal lab results with HIV providers	Not at all concerned	10 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8	Management of reporting abnormal lab results with HIV providers	Missing	6 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8	Understanding of when patients should receive oral medication for planned missed doses	Extremely concerned	1 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8	Understanding of when patients should receive oral medication for planned missed doses	Moderately concerned	1 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8	Understanding of when patients should receive oral medication for planned missed doses	Somewhat concerned	5 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8	Understanding of when patients should receive oral medication for planned missed doses	Slightly concerned	6 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8	Understanding of when patients should receive oral medication for planned missed doses	Not at all concerned	7 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8	Understanding of when patients should receive oral medication for planned missed doses	Missing	6 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8	Managing patients presenting to CABENUVA appointments with other care needs to be addressed	Extremely concerned	1 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8	Managing patients presenting to CABENUVA appointments with other care needs to be addressed	Moderately concerned	1 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8	Managing patients presenting to CABENUVA appointments with other care needs to be addressed	Somewhat concerned	3 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8	Managing patients presenting to CABENUVA appointments with other care needs to be addressed	Slightly concerned	6 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8	Managing patients presenting to CABENUVA appointments with other care needs to be addressed	Not at all concerned	9 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8	Managing patients presenting to CABENUVA appointments with other care needs to be addressed	Missing	6 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8	Frequency of lab draws at the infusion center	Extremely concerned	1 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8	Frequency of lab draws at the infusion center	Moderately concerned	1 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8	Frequency of lab draws at the infusion center	Somewhat concerned	2 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8	Frequency of lab draws at the infusion center	Slightly concerned	7 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8	Frequency of lab draws at the infusion center	Not at all concerned	9 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8	Frequency of lab draws at the infusion center	Missing	6 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8	Management of rescheduling appointments during correct treatment windows	Extremely concerned	0 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8	Management of rescheduling appointments during correct treatment windows	Moderately concerned	0 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8	Management of rescheduling appointments during correct treatment windows	Somewhat concerned	4 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8	Management of rescheduling appointments during correct treatment windows	Slightly concerned	6 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8	Management of rescheduling appointments during correct treatment windows	Not at all concerned	10 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8	Management of rescheduling appointments during correct treatment windows	Missing	6 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8	Management of scheduling appointments during correct treatment windows	Extremely concerned	0 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8	Management of scheduling appointments during correct treatment windows	Moderately concerned	0 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8	Management of scheduling appointments during correct treatment windows	Somewhat concerned	2 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8	Management of scheduling appointments during correct treatment windows	Slightly concerned	8 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8	Management of scheduling appointments during correct treatment windows	Not at all concerned	10 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8	Management of scheduling appointments during correct treatment windows	Missing	6 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8	Answering patient questions between visits	Extremely concerned	0 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8	Answering patient questions between visits	Moderately concerned	0 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8	Answering patient questions between visits	Somewhat concerned	4 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8	Answering patient questions between visits	Slightly concerned	5 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8	Answering patient questions between visits	Not at all concerned	11 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8	Answering patient questions between visits	Missing	6 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8	Management of confirming patient insurance coverage	Extremely concerned	0 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8	Management of confirming patient insurance coverage	Moderately concerned	0 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8	Management of confirming patient insurance coverage	Somewhat concerned	0 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8	Management of confirming patient insurance coverage	Slightly concerned	4 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8	Management of confirming patient insurance coverage	Not at all concerned	16 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8	Management of confirming patient insurance coverage	Missing	6 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8	Patient insurance coverage clearing for payment	Extremely concerned	0 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8	Patient insurance coverage clearing for payment	Moderately concerned	0 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8	Patient insurance coverage clearing for payment	Somewhat concerned	1 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8	Patient insurance coverage clearing for payment	Slightly concerned	5 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8	Patient insurance coverage clearing for payment	Not at all concerned	14 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8	Patient insurance coverage clearing for payment	Missing	6 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8	Management of patient injection-related pain/soreness	Extremely concerned	0 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8	Management of patient injection-related pain/soreness	Moderately concerned	0 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8	Management of patient injection-related pain/soreness	Somewhat concerned	2 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8	Management of patient injection-related pain/soreness	Slightly concerned	5 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8	Management of patient injection-related pain/soreness	Not at all concerned	13 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8	Management of patient injection-related pain/soreness	Missing	6 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8	Management of reporting of adverse events	Extremely concerned	0 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8	Management of reporting of adverse events	Moderately concerned	0 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8	Management of reporting of adverse events	Somewhat concerned	1 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8	Management of reporting of adverse events	Slightly concerned	7 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8	Management of reporting of adverse events	Not at all concerned	12 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8	Management of reporting of adverse events	Missing	6 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8	Patients' willingness to travel to an infusion center for each injection visit	Extremely concerned	0 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8	Patients' willingness to travel to an infusion center for each injection visit	Moderately concerned	0 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8	Patients' willingness to travel to an infusion center for each injection visit	Somewhat concerned	1 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8	Patients' willingness to travel to an infusion center for each injection visit	Slightly concerned	3 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8	Patients' willingness to travel to an infusion center for each injection visit	Not at all concerned	15 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8	Patients' willingness to travel to an infusion center for each injection visit	Missing	7 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8	Timely reporting of adverse events to HIV providers	Extremely concerned	0 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8	Timely reporting of adverse events to HIV providers	Moderately concerned	0 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8	Timely reporting of adverse events to HIV providers	Somewhat concerned	2 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8	Timely reporting of adverse events to HIV providers	Slightly concerned	4 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8	Timely reporting of adverse events to HIV providers	Not at all concerned	13 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8	Timely reporting of adverse events to HIV providers	Missing	7 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8	Timely reporting to the provider when a patient misses a CABENUVA visit	Extremely concerned	0 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8	Timely reporting to the provider when a patient misses a CABENUVA visit	Moderately concerned	0 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8	Timely reporting to the provider when a patient misses a CABENUVA visit	Somewhat concerned	1 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8	Timely reporting to the provider when a patient misses a CABENUVA visit	Slightly concerned	5 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8	Timely reporting to the provider when a patient misses a CABENUVA visit	Not at all concerned	13 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8	Timely reporting to the provider when a patient misses a CABENUVA visit	Missing	7 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8	Timely reporting to the provider when a patient receives CABENUVA	Extremely concerned	0 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8	Timely reporting to the provider when a patient receives CABENUVA	Moderately concerned	0 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8	Timely reporting to the provider when a patient receives CABENUVA	Somewhat concerned	0 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8	Timely reporting to the provider when a patient receives CABENUVA	Slightly concerned	3 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8	Timely reporting to the provider when a patient receives CABENUVA	Not at all concerned	16 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8	Timely reporting to the provider when a patient receives CABENUVA	Missing	7 Participants

Secondary

Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1

The tailored IC staff questionnaire was developed specifically for this study and contains items regarding the staff member's role at the IC, as well as their attitudes, concerns, and anticipated/implemented procedures regarding the use of CABENUVA/long-acting injectable administered by ICs. The IC/ASA staff members were asked to indicate their level of concern across 16 areas of potential concern, on a five-point scale from not at all concerned to extremely concerned.

Time frame: Prior to Month 1 (Baseline)

Population: Analysis was performed on the IC/ASA staff which includes any IC/ASA staff who completed any portion of any questionnaire at the specified timepoint.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1	Understanding how to bridge patients on oral dose for planned missed doses- Extremely concerned	9 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1	Understanding how to bridge patients on oral dose for planned missed doses- Moderately concerned	16 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1	Understanding how to bridge patients on oral dose for planned missed doses- Somewhat concerned	17 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1	Understanding how to bridge patients on oral dose for planned missed doses- Slightly concerned	37 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1	Understanding how to bridge patients on oral dose for planned missed doses- Not at all concerned	33 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1	Understanding how to bridge patients on oral dose for planned missed doses-Missing	1 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1	Management of reporting abnormal lab results with HIV providers- Extremely concerned	9 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1	Management of reporting abnormal lab results with HIV providers- Moderately concerned	11 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1	Management of reporting abnormal lab results with HIV providers- Somewhat concerned	15 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1	Management of reporting abnormal lab results with HIV providers- Slightly concerned	22 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1	Management of reporting abnormal lab results with HIV providers- Not at all concerned	55 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1	Management of reporting abnormal lab results with HIV providers- Missing	1 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1	Understanding when to bridge patients on oral dose for planned missed doses- Extremely concerned	8 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1	Understanding when to bridge patients on oral dose for planned missed doses Moderately concerned	18 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1	Understanding when to bridge patients on oral dose for planned missed doses Somewhat concerned	20 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1	Understanding when to bridge patients on oral dose for planned missed doses- Slightly concerned	36 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1	Understanding when to bridge patients on oral dose for planned missed doses Not at all concerned	30 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1	Understanding when to bridge patients on oral dose for planned missed doses- Missing	1 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1	IC's ability to address other care needs of patients at CABENUVA appointments- Extremely concerned	6 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1	IC's ability to address other care needs of patients at CABENUVA appointments- Moderately concerned	19 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1	IC's ability to address other care needs of patients at CABENUVA appointments- Somewhat concerned	20 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1	IC's ability to address other care needs of patients at CABENUVA appointments- Slightly concerned	24 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1	IC's ability to address other care needs of patients at CABENUVA appointments- Not at all concerned	42 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1	IC's ability to address other care needs of patients at CABENUVA appointments- Missing	2 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1	Frequency of lab draws at the infusion center- Extremely concerned	6 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1	Frequency of lab draws at the infusion center- Moderately concerned	12 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1	Frequency of lab draws at the infusion center- Somewhat concerned	23 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1	Frequency of lab draws at the infusion center- Slightly concerned	23 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1	Frequency of lab draws at the infusion center- Not at all concerned	48 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1	Frequency of lab draws at the infusion center- Missing	1 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1	Management of rescheduling appointments during correct treatment windows- Extremely concerned	4 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1	Management of rescheduling appointments during correct treatment windows- Moderately concerned	5 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1	Management of rescheduling appointments during correct treatment windows- Somewhat concerned	8 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1	Management of rescheduling appointments during correct treatment windows- Slightly concerned	32 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1	Management of rescheduling appointments during correct treatment windows- Not at all concerned	63 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1	Management of rescheduling appointments during correct treatment windows- Missing	1 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1	Management of scheduling appointments during correct treatment windows- Extremely concerned	4 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1	Management of scheduling appointments during correct treatment windows- Moderately concerned	4 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1	Management of scheduling appointments during correct treatment windows- Somewhat concerned	10 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1	Management of scheduling appointments during correct treatment windows- Slightly concerned	25 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1	Management of scheduling appointments during correct treatment windows- Not at all concerned	69 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1	Management of scheduling appointments during correct treatment windows- Missing	1 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1	Answering patient questions between visits- Extremely concerned	3 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1	Answering patient questions between visits- Moderately concerned	10 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1	Answering patient questions between visits- Somewhat concerned	18 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1	Answering patient questions between visits- Slightly concerned	38 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1	Answering patient questions between visits- Not at all concerned	43 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1	Answering patient questions between visits- Missing	1 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1	Management of confirming patient insurance coverage- Extremely concerned	3 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1	Management of confirming patient insurance coverage- Moderately concerned	4 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1	Management of confirming patient insurance coverage- Somewhat- concerned	7 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1	Management of confirming patient insurance coverage- Slightly concerned	16 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1	Management of confirming patient insurance coverage- Not at all concerned	82 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1	Management of confirming patient insurance coverage- Missing	1 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1	Patient insurance coverage clearing for payment- Extremely concerned	3 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1	Patient insurance coverage clearing for payment- Moderately concerned	1 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1	Patient insurance coverage clearing for payment- Somewhat concerned	12 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1	Patient insurance coverage clearing for payment- Slightly concerned	17 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1	Patient insurance coverage clearing for payment- Not at all concerned	79 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1	Patient insurance coverage clearing for payment- Missing	1 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1	Management of patient injection-related pain/soreness- Extremely concerned	2 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1	Management of patient injection-related pain/soreness- Moderately concerned	5 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1	Management of patient injection-related pain/soreness- Somewhat concerned	10 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1	Management of patient injection-related pain/soreness- Slightly concerned	28 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1	Management of patient injection-related pain/soreness- Not at all concerned	67 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1	Management of patient injection-related pain/soreness- Missing	1 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1	Management of reporting of adverse events- Extremely concerned	2 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1	Management of reporting of adverse events- Moderately concerned	4 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1	Management of reporting of adverse events- Somewhat concerned	9 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1	Management of reporting of adverse events- Slightly concerned	25 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1	Management of reporting of adverse events- Not at all concerned	72 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1	Management of reporting of adverse events- Missing	1 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1	Patients' willingness to travel to an infusion center for each injection visit- Extremely concerned	1 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1	Patients' willingness to travel to an infusion center for each injection visit- Moderately concerned	10 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1	Patients' willingness to travel to an infusion center for each injection visit- Somewhat concerned	26 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1	Patients' willingness to travel to an infusion center for each injection visit- Slightly concerned	14 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1	Patients' willingness to travel to an infusion center for each injection visit- Not at all concerned	61 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1	Patients' willingness to travel to an infusion center for each injection visit- Missing	1 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1	Timely reporting of adverse events to HIV providers- Extremely concerned	0 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1	Timely reporting of adverse events to HIV providers- Moderately concerned	5 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1	Timely reporting of adverse events to HIV providers- Somewhat concerned	5 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1	Timely reporting of adverse events to HIV providers- Slightly concerned	17 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1	Timely reporting of adverse events to HIV providers- Not at all concerned	85 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1	Timely reporting of adverse events to HIV providers- Missing	1 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1	Timely reporting to the provider when a patient misses a CABENUVA visit- Extremely concerned	0 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1	Timely reporting to the provider when a patient misses a CABENUVA visit- Moderately concerned	2 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1	Timely reporting to the provider when a patient misses a CABENUVA visit- Somewhat concerned	6 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1	Timely reporting to the provider when a patient misses a CABENUVA visit- Slightly concerned	21 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1	Timely reporting to the provider when a patient misses a CABENUVA visit- Not at all concerned	83 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1	Timely reporting to the provider when a patient misses a CABENUVA visit- Missing	1 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1	Timely reporting to the provider when a patient receives CABENUVA- Extremely concerned	0 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1	Timely reporting to the provider when a patient receives CABENUVA- Moderately concerned	1 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1	Timely reporting to the provider when a patient receives CABENUVA- Somewhat concerned	7 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1	Timely reporting to the provider when a patient receives CABENUVA- Slightly concerned	16 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1	Timely reporting to the provider when a patient receives CABENUVA- Not at all concerned	88 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1	Timely reporting to the provider when a patient receives CABENUVA- Missing	1 Participants

Secondary

Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Qualitative Interviews at Month 8

Qualitative interviews were conducted at Month 8 to evaluate the general opinion of IC/ ASA staff on feasibility of CABENUVA administration at the IC/ASA.

Time frame: At Month 8

Population: Analysis was performed on the IC/ASA staff which includes any IC/ASA staff who completed any portion of any questionnaire at the specified timepoint.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Qualitative Interviews at Month 8	Fits into existing process and practices	12 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Qualitative Interviews at Month 8	Administration of injection gets easier with experience	3 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Qualitative Interviews at Month 8	Facilitates implementation	12 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Qualitative Interviews at Month 8	Scheduling system work arounds to accommodate visit window	1 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Qualitative Interviews at Month 8	Modifying visit duration to account for all the pieces of administering CABENUVA	2 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Qualitative Interviews at Month 8	Shortage of private rooms	4 Participants

Secondary

Number of IC/ASA Staff Assessed for Overall Opinion of Administering the Injection at an IC/ ASA by Other Quantitative Questionnaires Prior to Month 1 and at Months 3 and 8

Time frame: Prior to Month 1 (Baseline) and Months 3 and 8

Population: Analysis was performed on the IC/ASA staff which includes any IC/ASA staff who completed any portion of any questionnaire at the specified timepoint.

Arm	Measure	Group	Category	Value (COUNT_OF_PARTICIPANTS)
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Overall Opinion of Administering the Injection at an IC/ ASA by Other Quantitative Questionnaires Prior to Month 1 and at Months 3 and 8	Baseline- Overall opinion about administering CABENUVA for participants at your infusion center?	Extremely positive	14 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Overall Opinion of Administering the Injection at an IC/ ASA by Other Quantitative Questionnaires Prior to Month 1 and at Months 3 and 8	Baseline- Overall opinion about administering CABENUVA for participants at your infusion center?	Very positive	21 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Overall Opinion of Administering the Injection at an IC/ ASA by Other Quantitative Questionnaires Prior to Month 1 and at Months 3 and 8	Baseline- Overall opinion about administering CABENUVA for participants at your infusion center?	Somewhat positive	21 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Overall Opinion of Administering the Injection at an IC/ ASA by Other Quantitative Questionnaires Prior to Month 1 and at Months 3 and 8	Baseline- Overall opinion about administering CABENUVA for participants at your infusion center?	Neutral	37 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Overall Opinion of Administering the Injection at an IC/ ASA by Other Quantitative Questionnaires Prior to Month 1 and at Months 3 and 8	Baseline- Overall opinion about administering CABENUVA for participants at your infusion center?	Somewhat negative	15 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Overall Opinion of Administering the Injection at an IC/ ASA by Other Quantitative Questionnaires Prior to Month 1 and at Months 3 and 8	Baseline- Overall opinion about administering CABENUVA for participants at your infusion center?	Very negative	3 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Overall Opinion of Administering the Injection at an IC/ ASA by Other Quantitative Questionnaires Prior to Month 1 and at Months 3 and 8	Baseline- Overall opinion about administering CABENUVA for participants at your infusion center?	Extremely negative	1 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Overall Opinion of Administering the Injection at an IC/ ASA by Other Quantitative Questionnaires Prior to Month 1 and at Months 3 and 8	Baseline- Overall opinion about administering CABENUVA for participants at your infusion center?	Missing	1 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Overall Opinion of Administering the Injection at an IC/ ASA by Other Quantitative Questionnaires Prior to Month 1 and at Months 3 and 8	Month 3- Overall opinion about administering CABENUVA for participants at your infusion center?	Extremely positive	3 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Overall Opinion of Administering the Injection at an IC/ ASA by Other Quantitative Questionnaires Prior to Month 1 and at Months 3 and 8	Month 3- Overall opinion about administering CABENUVA for participants at your infusion center?	Very positive	6 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Overall Opinion of Administering the Injection at an IC/ ASA by Other Quantitative Questionnaires Prior to Month 1 and at Months 3 and 8	Month 3- Overall opinion about administering CABENUVA for participants at your infusion center?	Somewhat positive	3 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Overall Opinion of Administering the Injection at an IC/ ASA by Other Quantitative Questionnaires Prior to Month 1 and at Months 3 and 8	Month 3- Overall opinion about administering CABENUVA for participants at your infusion center?	Neutral	17 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Overall Opinion of Administering the Injection at an IC/ ASA by Other Quantitative Questionnaires Prior to Month 1 and at Months 3 and 8	Month 3- Overall opinion about administering CABENUVA for participants at your infusion center?	Somewhat negative	5 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Overall Opinion of Administering the Injection at an IC/ ASA by Other Quantitative Questionnaires Prior to Month 1 and at Months 3 and 8	Month 3- Overall opinion about administering CABENUVA for participants at your infusion center?	Very negative	0 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Overall Opinion of Administering the Injection at an IC/ ASA by Other Quantitative Questionnaires Prior to Month 1 and at Months 3 and 8	Month 3- Overall opinion about administering CABENUVA for participants at your infusion center?	Extremely negative	0 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Overall Opinion of Administering the Injection at an IC/ ASA by Other Quantitative Questionnaires Prior to Month 1 and at Months 3 and 8	Month 3- Overall opinion about administering CABENUVA for participants at your infusion center?	Missing	4 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Overall Opinion of Administering the Injection at an IC/ ASA by Other Quantitative Questionnaires Prior to Month 1 and at Months 3 and 8	Month 8- Overall opinion about administering CABENUVA for participants at your infusion center?	Extremely positive	4 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Overall Opinion of Administering the Injection at an IC/ ASA by Other Quantitative Questionnaires Prior to Month 1 and at Months 3 and 8	Month 8- Overall opinion about administering CABENUVA for participants at your infusion center?	Very positive	3 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Overall Opinion of Administering the Injection at an IC/ ASA by Other Quantitative Questionnaires Prior to Month 1 and at Months 3 and 8	Month 8- Overall opinion about administering CABENUVA for participants at your infusion center?	Somewhat positive	5 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Overall Opinion of Administering the Injection at an IC/ ASA by Other Quantitative Questionnaires Prior to Month 1 and at Months 3 and 8	Month 8- Overall opinion about administering CABENUVA for participants at your infusion center?	Neutral	7 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Overall Opinion of Administering the Injection at an IC/ ASA by Other Quantitative Questionnaires Prior to Month 1 and at Months 3 and 8	Month 8- Overall opinion about administering CABENUVA for participants at your infusion center?	Somewhat negative	0 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Overall Opinion of Administering the Injection at an IC/ ASA by Other Quantitative Questionnaires Prior to Month 1 and at Months 3 and 8	Month 8- Overall opinion about administering CABENUVA for participants at your infusion center?	Very negative	0 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Overall Opinion of Administering the Injection at an IC/ ASA by Other Quantitative Questionnaires Prior to Month 1 and at Months 3 and 8	Month 8- Overall opinion about administering CABENUVA for participants at your infusion center?	Extremely negative	0 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Overall Opinion of Administering the Injection at an IC/ ASA by Other Quantitative Questionnaires Prior to Month 1 and at Months 3 and 8	Month 8- Overall opinion about administering CABENUVA for participants at your infusion center?	Missing	7 Participants

Secondary

Number of IC/ASA Staff Assessed for Overall Opinion of Administering the Injection at an IC/ ASA by Qualitative Interview at Month 8

IC/ASA staff was asked about their overall opinion on the participants referral process.

Time frame: At Month 8

Population: Analysis was performed on the IC/ASA staff which includes any IC/ASA staff who completed any portion of any questionnaire at the specified timepoint.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Overall Opinion of Administering the Injection at an IC/ ASA by Qualitative Interview at Month 8	Clinical staff not involved	12 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Overall Opinion of Administering the Injection at an IC/ ASA by Qualitative Interview at Month 8	Field questions from participants regarding referring friends	1 Participants

Secondary

Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires at Month 3

Since CABENUVA must be administered within a two-week treatment window (+/-)7 days relative to the target treatment date), the IC/ASA staff was asked their opinion about the ease or difficulty in appointment scheduling and re-scheduling and implementation of CABENUVA administration in their workflow.

Time frame: At Month 3

Population: Analysis was performed on the IC/ASA staff which includes any IC/ASA staff who completed any portion of any questionnaire at the specified timepoint.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires at Month 3	Ease or difficulty in appointment scheduling for CABENUVA injections-Extremely easy	2 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires at Month 3	Ease or difficulty in appointment scheduling for CABENUVA injections-Very easy	2 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires at Month 3	Ease or difficulty in appointment scheduling for CABENUVA injections-Somewhat easy	7 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires at Month 3	Ease or difficulty in appointment scheduling for CABENUVA injections-Neither easy nor difficult	6 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires at Month 3	Ease or difficulty in appointment scheduling for CABENUVA injections-Somewhat difficult	2 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires at Month 3	Ease or difficulty in appointment scheduling for CABENUVA injections-Very difficult	0 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires at Month 3	Ease or difficulty in appointment scheduling for CABENUVA injections-Extremely difficult	0 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires at Month 3	Ease or difficulty in appointment scheduling for CABENUVA injections-Unsure/not applicable to role	15 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires at Month 3	Ease or difficulty in appointment scheduling for CABENUVA injections- Missing	4 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires at Month 3	Ease or difficulty in appointment re-scheduling for CABENUVA injections- Extremely easy	1 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires at Month 3	Ease or difficulty in appointment re-scheduling for CABENUVA injections- Very easy	2 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires at Month 3	Ease or difficulty in appointment re-scheduling for CABENUVA injections- Somewhat easy	6 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires at Month 3	Ease or difficulty in appointment re-scheduling for CABENUVA injections- Neither easy nor difficult	5 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires at Month 3	Ease or difficulty in appointment re-scheduling for CABENUVA injections- Somewhat difficult	1 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires at Month 3	Ease or difficulty in appointment re-scheduling for CABENUVA injections- Very difficult	0 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires at Month 3	Ease or difficulty in appointment re-scheduling for CABENUVA injections- Extremely difficult	0 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires at Month 3	Ease or difficulty in appointment re-scheduling for CABENUVA injections-Unsure/NA to role	4 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires at Month 3	Ease or difficulty in appointment re-scheduling for CABENUVA injections- Missing	4 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires at Month 3	Ease or difficulty in implementation of CABENUVA administration- Extremely easy	2 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires at Month 3	Ease or difficulty in implementation of CABENUVA administration- Very easy	6 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires at Month 3	Ease or difficulty in implementation of CABENUVA administration- Somewhat easy	3 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires at Month 3	Ease or difficulty in implementation of CABENUVA administration- Neither easy nor difficult	16 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires at Month 3	Ease or difficulty in implementation of CABENUVA administration- Somewhat difficult	4 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires at Month 3	Ease or difficulty in implementation of CABENUVA administration- Very difficult	2 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires at Month 3	Ease or difficulty in implementation of CABENUVA administration- Extremely difficult	1 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires at Month 3	Ease or difficulty in implementation of CABENUVA administration- Unsure/not applicable to role	NA Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires at Month 3	Ease or difficulty in implementation of CABENUVA administration- Missing	4 Participants

Secondary

Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires at Month 8

Time frame: At Month 8

Population: Analysis was performed on the IC/ASA staff which includes any IC/ASA staff who completed any portion of any questionnaire at the specified timepoint.

Arm	Measure	Group	Category	Value (COUNT_OF_PARTICIPANTS)
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires at Month 8	How easy or difficult has it been to schedule appointments for CABENUVA injections.	Extremely easy	2 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires at Month 8	How easy or difficult has it been to schedule appointments for CABENUVA injections.	Very easy	2 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires at Month 8	How easy or difficult has it been to schedule appointments for CABENUVA injections.	Somewhat easy	4 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires at Month 8	How easy or difficult has it been to schedule appointments for CABENUVA injections.	Neither easy nor difficult	1 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires at Month 8	How easy or difficult has it been to schedule appointments for CABENUVA injections.	Somewhat difficult	1 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires at Month 8	How easy or difficult has it been to schedule appointments for CABENUVA injections.	Very difficult	1 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires at Month 8	How easy or difficult has it been to schedule appointments for CABENUVA injections.	Extremely difficult	0 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires at Month 8	How easy or difficult has it been to schedule appointments for CABENUVA injections.	Unsure/not applicable to role	8 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires at Month 8	How easy or difficult has it been to schedule appointments for CABENUVA injections.	Missing	7 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires at Month 8	How easy or difficult has it been to reschedule appointments for CABENUVA injections?	Extremely easy	0 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires at Month 8	How easy or difficult has it been to reschedule appointments for CABENUVA injections?	Very easy	6 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires at Month 8	How easy or difficult has it been to reschedule appointments for CABENUVA injections?	Somewhat easy	1 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires at Month 8	How easy or difficult has it been to reschedule appointments for CABENUVA injections?	Neither easy nor difficult	1 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires at Month 8	How easy or difficult has it been to reschedule appointments for CABENUVA injections?	Somewhat difficult	2 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires at Month 8	How easy or difficult has it been to reschedule appointments for CABENUVA injections?	Very difficult	1 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires at Month 8	How easy or difficult has it been to reschedule appointments for CABENUVA injections?	Extremely difficult	0 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires at Month 8	How easy or difficult has it been to reschedule appointments for CABENUVA injections?	Unsure/not applicable to role	1 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires at Month 8	How easy or difficult has it been to reschedule appointments for CABENUVA injections?	Missing	6 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires at Month 8	How easy or difficult has CABENUVA administration been to implement in your current work-flow?	Extremely easy	3 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires at Month 8	How easy or difficult has CABENUVA administration been to implement in your current work-flow?	Very easy	3 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires at Month 8	How easy or difficult has CABENUVA administration been to implement in your current work-flow?	Somewhat easy	2 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires at Month 8	How easy or difficult has CABENUVA administration been to implement in your current work-flow?	Neither easy nor difficult	5 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires at Month 8	How easy or difficult has CABENUVA administration been to implement in your current work-flow?	Somewhat difficult	7 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires at Month 8	How easy or difficult has CABENUVA administration been to implement in your current work-flow?	Very difficult	0 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires at Month 8	How easy or difficult has CABENUVA administration been to implement in your current work-flow?	Extremely difficult	0 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires at Month 8	How easy or difficult has CABENUVA administration been to implement in your current work-flow?	Unsure/not applicable to role	NA Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires at Month 8	How easy or difficult has CABENUVA administration been to implement in your current work-flow?	Missing	6 Participants

Secondary

Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires Prior to Month 1

Since CABENUVA must be administered within a two-week treatment window every month, IC/ASA staff were asked their opinion about the ease or difficulty in appointment re-scheduling and implementation of CABENUVA administration in their work-flow.

Time frame: Prior to Month 1 (Baseline)

Population: Analysis was performed on the IC/ASA staff which includes any IC/ASA staff who completed any portion of any questionnaire at the specified timepoint.

Arm	Measure	Group	Category	Value (COUNT_OF_PARTICIPANTS)
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires Prior to Month 1	How easy or difficult do you think the appointment re-scheduling will be?	Extremely easy	6 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires Prior to Month 1	How easy or difficult do you think the appointment re-scheduling will be?	Very easy	24 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires Prior to Month 1	How easy or difficult do you think the appointment re-scheduling will be?	Somewhat easy	16 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires Prior to Month 1	How easy or difficult do you think the appointment re-scheduling will be?	Neutral	46 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires Prior to Month 1	How easy or difficult do you think the appointment re-scheduling will be?	Somewhat difficult	15 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires Prior to Month 1	How easy or difficult do you think the appointment re-scheduling will be?	Very difficult	6 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires Prior to Month 1	How easy or difficult do you think the appointment re-scheduling will be?	Extremely difficult	0 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires Prior to Month 1	How easy or difficult CABENUVA administration will be to implement in your current work-flow?	Extremely easy	9 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires Prior to Month 1	How easy or difficult CABENUVA administration will be to implement in your current work-flow?	Very easy	21 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires Prior to Month 1	How easy or difficult CABENUVA administration will be to implement in your current work-flow?	Somewhat easy	21 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires Prior to Month 1	How easy or difficult CABENUVA administration will be to implement in your current work-flow?	Neutral	31 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires Prior to Month 1	How easy or difficult CABENUVA administration will be to implement in your current work-flow?	Somewhat difficult	19 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires Prior to Month 1	How easy or difficult CABENUVA administration will be to implement in your current work-flow?	Very difficult	9 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires Prior to Month 1	How easy or difficult CABENUVA administration will be to implement in your current work-flow?	Extremely difficult	3 Participants

Secondary

Number of IC/ASA Staff Assessed for Usefulness of the Blueprint Intervention and POT Assessed by Qualitative Interviews at Month 8

Time frame: Month 8

Population: Analysis was performed on the IC/ASA staff which includes any IC/ASA staff who completed any portion of any questionnaire at the specified timepoint.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Usefulness of the Blueprint Intervention and POT Assessed by Qualitative Interviews at Month 8	Usefulness of the blueprint- Not reported	7 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Usefulness of the Blueprint Intervention and POT Assessed by Qualitative Interviews at Month 8	Usefulness of POT - Usage	1 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Usefulness of the Blueprint Intervention and POT Assessed by Qualitative Interviews at Month 8	Usefulness of the blueprint - Usage	2 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Usefulness of the Blueprint Intervention and POT Assessed by Qualitative Interviews at Month 8	Usefulness of the blueprint - Familiarity	3 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Usefulness of the Blueprint Intervention and POT Assessed by Qualitative Interviews at Month 8	Usefulness of POT- Not reported	11 Participants

Secondary

Number of IC/ASA Staff Assessed for Usefulness of the Blueprint Intervention With Other Quantitative Questionnaires at Month 3 and 8

The blueprint guides IC/ASA staff on what to do with referrals to receive CABENUVA at the IC/ASA.

Time frame: At Months 3 and 8

Population: Analysis was performed on the IC/ASA staff which includes any IC/ASA staff who completed any portion of any questionnaire at the specified timepoint.

Arm	Measure	Group	Category	Value (COUNT_OF_PARTICIPANTS)
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Usefulness of the Blueprint Intervention With Other Quantitative Questionnaires at Month 3 and 8	At month 3 - How useful is the blueprint?	Extremely useful	2 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Usefulness of the Blueprint Intervention With Other Quantitative Questionnaires at Month 3 and 8	At month 3 - How useful is the blueprint?	Very useful	6 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Usefulness of the Blueprint Intervention With Other Quantitative Questionnaires at Month 3 and 8	At month 3 - How useful is the blueprint?	Somewhat useful	7 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Usefulness of the Blueprint Intervention With Other Quantitative Questionnaires at Month 3 and 8	At month 3 - How useful is the blueprint?	Neutral	4 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Usefulness of the Blueprint Intervention With Other Quantitative Questionnaires at Month 3 and 8	At month 3 - How useful is the blueprint?	Not very useful	0 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Usefulness of the Blueprint Intervention With Other Quantitative Questionnaires at Month 3 and 8	At month 3 - How useful is the blueprint?	Not useful at all	1 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Usefulness of the Blueprint Intervention With Other Quantitative Questionnaires at Month 3 and 8	At month 8 - How useful is the blueprint?	Extremely useful	2 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Usefulness of the Blueprint Intervention With Other Quantitative Questionnaires at Month 3 and 8	At month 8 - How useful is the blueprint?	Very useful	3 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Usefulness of the Blueprint Intervention With Other Quantitative Questionnaires at Month 3 and 8	At month 8 - How useful is the blueprint?	Somewhat useful	5 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Usefulness of the Blueprint Intervention With Other Quantitative Questionnaires at Month 3 and 8	At month 8 - How useful is the blueprint?	Neutral	2 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Usefulness of the Blueprint Intervention With Other Quantitative Questionnaires at Month 3 and 8	At month 8 - How useful is the blueprint?	Not very useful	2 Participants
Participants Receiving CABENUVA	Number of IC/ASA Staff Assessed for Usefulness of the Blueprint Intervention With Other Quantitative Questionnaires at Month 3 and 8	At month 8 - How useful is the blueprint?	Not useful at all	1 Participants

Secondary

Number of IC/ASA Staff Assessed for Usefulness of the Blueprint Intervention With Other Quantitative Questionnaires Prior to Month 1

The blueprint guides IC/ASA staff on what to do with referrals to receive CABENUVA at the IC/ASA.

Time frame: Prior to Month 1 (Baseline)

Population: Analysis was planned to be performed on the IC/ASA staff which includes any IC/ASA staff who completed any portion of any questionnaire at the specified timepoint. Prior to Month 1 there were no referrals given; hence the blueprint was not used and therefore it was not assessed.

Secondary

Number of IC/ ASA Staff Who Agree or Completely Agree (a Score of 4 or Higher) Across All Items on the AIM

AIM were employed to evaluate the acceptability of CABENUVA administration at Infusion Centers/ ASAs. Higher scores for AIM indicate greater acceptability, where each item was scored from 1 to 5: Completely disagree (score=1), disagree (score=2), neither agree or disagree (score=3), agree (score=4), completely agree (score=5).

Time frame: Prior to Month 1 (Baseline), and at Month 3 and 8

Population: Analysis was performed on the IC/ASA staff which includes any IC/ASA staff who completed any portion of any questionnaire at the specified timepoint.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Participants Receiving CABENUVA	Number of IC/ ASA Staff Who Agree or Completely Agree (a Score of 4 or Higher) Across All Items on the AIM	Prior to Month 1 (baseline)	47 Participants
Participants Receiving CABENUVA	Number of IC/ ASA Staff Who Agree or Completely Agree (a Score of 4 or Higher) Across All Items on the AIM	At month 3	13 Participants
Participants Receiving CABENUVA	Number of IC/ ASA Staff Who Agree or Completely Agree (a Score of 4 or Higher) Across All Items on the AIM	At month 8	13 Participants

Secondary

Number of IC/ ASA Staff Who Agree or Completely Agree (a Score of 4 or Higher) Across All Items on the FIM Prior to Month 1 and at Months 3 and 8

Time frame: Prior to Month 1 (Baseline) and at Months 3 and 8

Population: Analysis was performed on the IC/ASA staff which includes any IC/ASA staff who completed any portion of any questionnaire at the specified timepoint.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Participants Receiving CABENUVA	Number of IC/ ASA Staff Who Agree or Completely Agree (a Score of 4 or Higher) Across All Items on the FIM Prior to Month 1 and at Months 3 and 8	Prior to Month 1 (Baseline)	50 Participants
Participants Receiving CABENUVA	Number of IC/ ASA Staff Who Agree or Completely Agree (a Score of 4 or Higher) Across All Items on the FIM Prior to Month 1 and at Months 3 and 8	Month 3	19 Participants
Participants Receiving CABENUVA	Number of IC/ ASA Staff Who Agree or Completely Agree (a Score of 4 or Higher) Across All Items on the FIM Prior to Month 1 and at Months 3 and 8	Month 8	11 Participants

Secondary

Number of Injections Occurring Within Target Window From Target Date

This outcome measure evaluates the fidelity to treatment and dosing window. Fidelity to treatment and dosing window was defined based on a ±7-day window from target treatment date based on the calendar date of baseline injection.

Time frame: Up to and including Month 8

Population: Analysis was performed on the Safety set which includes any participant who completed any portion of any questionnaire at the specified timepoint.

Arm	Measure	Category	Value (COUNT_OF_UNITS)
Participants Receiving CABENUVA	Number of Injections Occurring Within Target Window From Target Date	<-14 days	0 Injections
Participants Receiving CABENUVA	Number of Injections Occurring Within Target Window From Target Date	-14 to -8 days	3 Injections
Participants Receiving CABENUVA	Number of Injections Occurring Within Target Window From Target Date	-7 to -4 days	37 Injections
Participants Receiving CABENUVA	Number of Injections Occurring Within Target Window From Target Date	-3 to -2 days	27 Injections
Participants Receiving CABENUVA	Number of Injections Occurring Within Target Window From Target Date	-1 day	9 Injections
Participants Receiving CABENUVA	Number of Injections Occurring Within Target Window From Target Date	0 day	36 Injections
Participants Receiving CABENUVA	Number of Injections Occurring Within Target Window From Target Date	1 day	16 Injections
Participants Receiving CABENUVA	Number of Injections Occurring Within Target Window From Target Date	2 to 3 days	24 Injections
Participants Receiving CABENUVA	Number of Injections Occurring Within Target Window From Target Date	4 to 7 days	38 Injections
Participants Receiving CABENUVA	Number of Injections Occurring Within Target Window From Target Date	8 to 14 days	3 Injections
Participants Receiving CABENUVA	Number of Injections Occurring Within Target Window From Target Date	>14 days	1 Injections
Participants Receiving CABENUVA	Number of Injections Occurring Within Target Window From Target Date	Missed injection	1 Injections

Secondary

Number of Participants Assessed for Acceptability of CABENUVA Administration at IC/ ASA by Other Quantitative Questionnaire in at Months 1, 3 and 8

The participants were asked how acceptable it was to come to the IC/ASA for CABENUVA using a 7-point scale from very acceptable to very unacceptable where 1= very acceptable, 2= somewhat acceptable, 3= a little acceptable, 4= neutral, 5= a little unacceptable, 6= somewhat unacceptable and 7= very unacceptable.

Time frame: At Months 1, 3 and 8

Population: Analysis was performed on the Safety set which includes any participant who completed any portion of any questionnaire at the specified timepoint.

Arm	Measure	Group	Category	Value (COUNT_OF_PARTICIPANTS)
Participants Receiving CABENUVA	Number of Participants Assessed for Acceptability of CABENUVA Administration at IC/ ASA by Other Quantitative Questionnaire in at Months 1, 3 and 8	Month 1- How acceptable is it to you to come to the infusion center for CABENUVA?	Very acceptable	34 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Acceptability of CABENUVA Administration at IC/ ASA by Other Quantitative Questionnaire in at Months 1, 3 and 8	Month 1- How acceptable is it to you to come to the infusion center for CABENUVA?	Somewhat acceptable	6 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Acceptability of CABENUVA Administration at IC/ ASA by Other Quantitative Questionnaire in at Months 1, 3 and 8	Month 1- How acceptable is it to you to come to the infusion center for CABENUVA?	A little acceptable	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Acceptability of CABENUVA Administration at IC/ ASA by Other Quantitative Questionnaire in at Months 1, 3 and 8	Month 1- How acceptable is it to you to come to the infusion center for CABENUVA?	Neutral	2 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Acceptability of CABENUVA Administration at IC/ ASA by Other Quantitative Questionnaire in at Months 1, 3 and 8	Month 1- How acceptable is it to you to come to the infusion center for CABENUVA?	A little unacceptable	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Acceptability of CABENUVA Administration at IC/ ASA by Other Quantitative Questionnaire in at Months 1, 3 and 8	Month 1- How acceptable is it to you to come to the infusion center for CABENUVA?	Somewhat unacceptable	1 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Acceptability of CABENUVA Administration at IC/ ASA by Other Quantitative Questionnaire in at Months 1, 3 and 8	Month 1- How acceptable is it to you to come to the infusion center for CABENUVA?	Very unacceptable	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Acceptability of CABENUVA Administration at IC/ ASA by Other Quantitative Questionnaire in at Months 1, 3 and 8	Month 1- How acceptable is it to you to come to the infusion center for CABENUVA?	Missing	1 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Acceptability of CABENUVA Administration at IC/ ASA by Other Quantitative Questionnaire in at Months 1, 3 and 8	Month 3- How acceptable is it to you to come to the infusion center for CABENUVA?	Very acceptable	24 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Acceptability of CABENUVA Administration at IC/ ASA by Other Quantitative Questionnaire in at Months 1, 3 and 8	Month 3- How acceptable is it to you to come to the infusion center for CABENUVA?	Somewhat acceptable	9 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Acceptability of CABENUVA Administration at IC/ ASA by Other Quantitative Questionnaire in at Months 1, 3 and 8	Month 3- How acceptable is it to you to come to the infusion center for CABENUVA?	A little acceptable	1 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Acceptability of CABENUVA Administration at IC/ ASA by Other Quantitative Questionnaire in at Months 1, 3 and 8	Month 3- How acceptable is it to you to come to the infusion center for CABENUVA?	Neutral	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Acceptability of CABENUVA Administration at IC/ ASA by Other Quantitative Questionnaire in at Months 1, 3 and 8	Month 3- How acceptable is it to you to come to the infusion center for CABENUVA?	A little unacceptable	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Acceptability of CABENUVA Administration at IC/ ASA by Other Quantitative Questionnaire in at Months 1, 3 and 8	Month 3- How acceptable is it to you to come to the infusion center for CABENUVA?	Somewhat unacceptable	1 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Acceptability of CABENUVA Administration at IC/ ASA by Other Quantitative Questionnaire in at Months 1, 3 and 8	Month 3- How acceptable is it to you to come to the infusion center for CABENUVA?	Very unacceptable	1 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Acceptability of CABENUVA Administration at IC/ ASA by Other Quantitative Questionnaire in at Months 1, 3 and 8	Month 3- How acceptable is it to you to come to the infusion center for CABENUVA?	Missing	5 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Acceptability of CABENUVA Administration at IC/ ASA by Other Quantitative Questionnaire in at Months 1, 3 and 8	Month 8- How acceptable is it to you to come to the infusion center for CABENUVA?	Very acceptable	23 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Acceptability of CABENUVA Administration at IC/ ASA by Other Quantitative Questionnaire in at Months 1, 3 and 8	Month 8- How acceptable is it to you to come to the infusion center for CABENUVA?	Somewhat acceptable	8 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Acceptability of CABENUVA Administration at IC/ ASA by Other Quantitative Questionnaire in at Months 1, 3 and 8	Month 8- How acceptable is it to you to come to the infusion center for CABENUVA?	A little acceptable	1 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Acceptability of CABENUVA Administration at IC/ ASA by Other Quantitative Questionnaire in at Months 1, 3 and 8	Month 8- How acceptable is it to you to come to the infusion center for CABENUVA?	Neutral	4 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Acceptability of CABENUVA Administration at IC/ ASA by Other Quantitative Questionnaire in at Months 1, 3 and 8	Month 8- How acceptable is it to you to come to the infusion center for CABENUVA?	A little unacceptable	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Acceptability of CABENUVA Administration at IC/ ASA by Other Quantitative Questionnaire in at Months 1, 3 and 8	Month 8- How acceptable is it to you to come to the infusion center for CABENUVA?	Somewhat unacceptable	1 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Acceptability of CABENUVA Administration at IC/ ASA by Other Quantitative Questionnaire in at Months 1, 3 and 8	Month 8- How acceptable is it to you to come to the infusion center for CABENUVA?	Very unacceptable	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Acceptability of CABENUVA Administration at IC/ ASA by Other Quantitative Questionnaire in at Months 1, 3 and 8	Month 8- How acceptable is it to you to come to the infusion center for CABENUVA?	Missing	1 Participants

Secondary

Number of Participants Assessed for Acceptability of CABENUVA Administration at IC/ASA by Qualitative Interviews at Month 8

Participants were asked about their opinion on acceptability of CABENUVA administration at the IC/ASA.

Time frame: At Month 8

Population: Analysis was performed on the Safety set which includes any participant who completed any portion of any questionnaire at the specified timepoint.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Participants Receiving CABENUVA	Number of Participants Assessed for Acceptability of CABENUVA Administration at IC/ASA by Qualitative Interviews at Month 8	Good facilities/environment	8 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Acceptability of CABENUVA Administration at IC/ASA by Qualitative Interviews at Month 8	Professional and caring staff	23 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Acceptability of CABENUVA Administration at IC/ASA by Qualitative Interviews at Month 8	Consistency of providers	2 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Acceptability of CABENUVA Administration at IC/ASA by Qualitative Interviews at Month 8	Protects participants' privacy	14 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Acceptability of CABENUVA Administration at IC/ASA by Qualitative Interviews at Month 8	Scheduling flexibility	4 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Acceptability of CABENUVA Administration at IC/ASA by Qualitative Interviews at Month 8	Appointment reminders	1 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Acceptability of CABENUVA Administration at IC/ASA by Qualitative Interviews at Month 8	Quick and easy administration process	6 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Acceptability of CABENUVA Administration at IC/ASA by Qualitative Interviews at Month 8	Hassle-free for participants	1 Participants

Secondary

Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 1

Time frame: At Month 1

Population: Analysis was performed on the Safety set which includes any participant who completed any portion of any questionnaire at the specified timepoint.

Arm	Measure	Group	Category	Value (COUNT_OF_PARTICIPANTS)
Participants Receiving CABENUVA	Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 1	How acceptable is it to you to come to the infusion center for CABENUVA?	Very acceptable	34 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 1	How acceptable is it to you to come to the infusion center for CABENUVA?	Somewhat acceptable	6 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 1	How acceptable is it to you to come to the infusion center for CABENUVA?	A little acceptable	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 1	How acceptable is it to you to come to the infusion center for CABENUVA?	Neutral	2 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 1	How acceptable is it to you to come to the infusion center for CABENUVA?	A little unacceptable	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 1	How acceptable is it to you to come to the infusion center for CABENUVA?	Somewhat unacceptable	1 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 1	How acceptable is it to you to come to the infusion center for CABENUVA?	Very unacceptable	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 1	How acceptable is it to you to come to the infusion center for CABENUVA?	Missing	1 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 1	Acceptability to go to separate places for care (IC for CABENUVA and clinic for HIV appointments)?	Very acceptable	19 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 1	Acceptability to go to separate places for care (IC for CABENUVA and clinic for HIV appointments)?	Somewhat acceptable	11 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 1	Acceptability to go to separate places for care (IC for CABENUVA and clinic for HIV appointments)?	A little acceptable	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 1	Acceptability to go to separate places for care (IC for CABENUVA and clinic for HIV appointments)?	Neutral	6 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 1	Acceptability to go to separate places for care (IC for CABENUVA and clinic for HIV appointments)?	A little unacceptable	4 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 1	Acceptability to go to separate places for care (IC for CABENUVA and clinic for HIV appointments)?	Somewhat unacceptable	2 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 1	Acceptability to go to separate places for care (IC for CABENUVA and clinic for HIV appointments)?	Very unacceptable	1 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 1	Acceptability to go to separate places for care (IC for CABENUVA and clinic for HIV appointments)?	Missing	1 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 1	How acceptable is it for you to get labs drawn at the infusion center?	Very acceptable	32 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 1	How acceptable is it for you to get labs drawn at the infusion center?	Somewhat acceptable	5 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 1	How acceptable is it for you to get labs drawn at the infusion center?	A little acceptable	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 1	How acceptable is it for you to get labs drawn at the infusion center?	Neutral	5 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 1	How acceptable is it for you to get labs drawn at the infusion center?	A little unacceptable	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 1	How acceptable is it for you to get labs drawn at the infusion center?	Somewhat unacceptable	1 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 1	How acceptable is it for you to get labs drawn at the infusion center?	Very unacceptable	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 1	How acceptable is it for you to get labs drawn at the infusion center?	Missing	1 Participants

Secondary

Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 3

Time frame: At Month 3

Population: Analysis was performed on the Safety set which includes any participant who completed any portion of any questionnaire at the specified timepoint.

Arm	Measure	Group	Category	Value (COUNT_OF_PARTICIPANTS)
Participants Receiving CABENUVA	Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 3	How acceptable is it to you to come to the infusion center for CABENUVA?	Very acceptable	24 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 3	How acceptable is it to you to come to the infusion center for CABENUVA?	Somewhat acceptable	9 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 3	How acceptable is it to you to come to the infusion center for CABENUVA?	A little acceptable	1 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 3	How acceptable is it to you to come to the infusion center for CABENUVA?	Neutral	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 3	How acceptable is it to you to come to the infusion center for CABENUVA?	A little unacceptable	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 3	How acceptable is it to you to come to the infusion center for CABENUVA?	Somewhat unacceptable	1 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 3	How acceptable is it to you to come to the infusion center for CABENUVA?	Very unacceptable	1 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 3	How acceptable is it to you to come to the infusion center for CABENUVA?	Missing	5 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 3	Acceptability to go to separate places for care (IC for CABENUVA and clinic for HIV appointments)?	Very acceptable	14 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 3	Acceptability to go to separate places for care (IC for CABENUVA and clinic for HIV appointments)?	Somewhat acceptable	7 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 3	Acceptability to go to separate places for care (IC for CABENUVA and clinic for HIV appointments)?	A little acceptable	6 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 3	Acceptability to go to separate places for care (IC for CABENUVA and clinic for HIV appointments)?	Neutral	3 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 3	Acceptability to go to separate places for care (IC for CABENUVA and clinic for HIV appointments)?	A little unacceptable	2 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 3	Acceptability to go to separate places for care (IC for CABENUVA and clinic for HIV appointments)?	Somewhat unacceptable	2 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 3	Acceptability to go to separate places for care (IC for CABENUVA and clinic for HIV appointments)?	Very unacceptable	2 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 3	Acceptability to go to separate places for care (IC for CABENUVA and clinic for HIV appointments)?	Missing	5 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 3	How acceptable is it for you to get labs drawn at the infusion center?	Very acceptable	27 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 3	How acceptable is it for you to get labs drawn at the infusion center?	Somewhat acceptable	3 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 3	How acceptable is it for you to get labs drawn at the infusion center?	A little acceptable	1 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 3	How acceptable is it for you to get labs drawn at the infusion center?	Neutral	2 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 3	How acceptable is it for you to get labs drawn at the infusion center?	A little unacceptable	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 3	How acceptable is it for you to get labs drawn at the infusion center?	Somewhat unacceptable	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 3	How acceptable is it for you to get labs drawn at the infusion center?	Very unacceptable	3 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 3	How acceptable is it for you to get labs drawn at the infusion center?	Missing	5 Participants

Secondary

Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 8

Time frame: At Month 8

Population: Analysis was performed on the Safety set which includes any participant who completed any portion of any questionnaire at the specified timepoint.

Arm	Measure	Group	Category	Value (COUNT_OF_PARTICIPANTS)
Participants Receiving CABENUVA	Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 8	How acceptable is it to you to come to the infusion center for CABENUVA?	Very acceptable	23 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 8	How acceptable is it to you to come to the infusion center for CABENUVA?	Somewhat acceptable	8 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 8	How acceptable is it to you to come to the infusion center for CABENUVA?	A little acceptable	1 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 8	How acceptable is it to you to come to the infusion center for CABENUVA?	Neutral	4 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 8	How acceptable is it to you to come to the infusion center for CABENUVA?	A little unacceptable	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 8	How acceptable is it to you to come to the infusion center for CABENUVA?	Somewhat unacceptable	1 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 8	How acceptable is it to you to come to the infusion center for CABENUVA?	Very unacceptable	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 8	How acceptable is it to you to come to the infusion center for CABENUVA?	Missing	1 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 8	Acceptability to go to separate places for care (IC for CABENUVA and clinic for HIV appointments)?	Very acceptable	15 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 8	Acceptability to go to separate places for care (IC for CABENUVA and clinic for HIV appointments)?	Somewhat acceptable	9 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 8	Acceptability to go to separate places for care (IC for CABENUVA and clinic for HIV appointments)?	A little acceptable	4 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 8	Acceptability to go to separate places for care (IC for CABENUVA and clinic for HIV appointments)?	Neutral	4 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 8	Acceptability to go to separate places for care (IC for CABENUVA and clinic for HIV appointments)?	A little unacceptable	1 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 8	Acceptability to go to separate places for care (IC for CABENUVA and clinic for HIV appointments)?	Somewhat unacceptable	2 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 8	Acceptability to go to separate places for care (IC for CABENUVA and clinic for HIV appointments)?	Very unacceptable	2 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 8	Acceptability to go to separate places for care (IC for CABENUVA and clinic for HIV appointments)?	Missing	1 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 8	How acceptable is it for you to get labs drawn at the infusion center?	Very acceptable	33 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 8	How acceptable is it for you to get labs drawn at the infusion center?	Somewhat acceptable	1 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 8	How acceptable is it for you to get labs drawn at the infusion center?	A little acceptable	1 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 8	How acceptable is it for you to get labs drawn at the infusion center?	Neutral	1 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 8	How acceptable is it for you to get labs drawn at the infusion center?	A little unacceptable	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 8	How acceptable is it for you to get labs drawn at the infusion center?	Somewhat unacceptable	1 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 8	How acceptable is it for you to get labs drawn at the infusion center?	Very unacceptable	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 8	How acceptable is it for you to get labs drawn at the infusion center?	Missing	1 Participants

Secondary

Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Qualitative Interviews at Month 8

Participants were asked about their opinion on the acceptability of CABENUVA administration at the IC.

Time frame: At Month 8

Population: Analysis was performed on the Safety set which includes any participant who completed any portion of any questionnaire at the specified timepoint.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Participants Receiving CABENUVA	Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Qualitative Interviews at Month 8	Good facilities/environment	8 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Qualitative Interviews at Month 8	Professional and caring staff	23 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Qualitative Interviews at Month 8	Consistency of providers	2 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Qualitative Interviews at Month 8	Protects participants' privacy	14 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Qualitative Interviews at Month 8	Scheduling flexibility	4 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Qualitative Interviews at Month 8	Appointment reminders	1 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Qualitative Interviews at Month 8	Quick and easy administration process	6 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Qualitative Interviews at Month 8	Hassle-free for participants	1 Participants

Secondary

Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs (Time Spent at IC) by Other Quantitative Questionnaires at Months 3 and 8

Time frame: At Months 3 and 8

Population: Analysis was performed on the Safety set which includes any participant who completed any portion of any questionnaire at the specified timepoint.

Arm	Measure	Group	Category	Value (COUNT_OF_PARTICIPANTS)
Participants Receiving CABENUVA	Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs (Time Spent at IC) by Other Quantitative Questionnaires at Months 3 and 8	Month 3- Not including first visit, how much time have you spent at the IC for your CABENUVA visits?	1-15 minutes	1 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs (Time Spent at IC) by Other Quantitative Questionnaires at Months 3 and 8	Month 3- Not including first visit, how much time have you spent at the IC for your CABENUVA visits?	16-30 minutes	17 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs (Time Spent at IC) by Other Quantitative Questionnaires at Months 3 and 8	Month 3- Not including first visit, how much time have you spent at the IC for your CABENUVA visits?	31-45 minutes	15 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs (Time Spent at IC) by Other Quantitative Questionnaires at Months 3 and 8	Month 3- Not including first visit, how much time have you spent at the IC for your CABENUVA visits?	46-60 minutes	2 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs (Time Spent at IC) by Other Quantitative Questionnaires at Months 3 and 8	Month 3- Not including first visit, how much time have you spent at the IC for your CABENUVA visits?	More than 60 minutes	1 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs (Time Spent at IC) by Other Quantitative Questionnaires at Months 3 and 8	Month 3- Not including first visit, how much time have you spent at the IC for your CABENUVA visits?	Missing	5 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs (Time Spent at IC) by Other Quantitative Questionnaires at Months 3 and 8	Month 8- Not including first visit, how much time have you spent at the IC for your CABENUVA visits?	1-15 minutes	4 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs (Time Spent at IC) by Other Quantitative Questionnaires at Months 3 and 8	Month 8- Not including first visit, how much time have you spent at the IC for your CABENUVA visits?	16-30 minutes	10 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs (Time Spent at IC) by Other Quantitative Questionnaires at Months 3 and 8	Month 8- Not including first visit, how much time have you spent at the IC for your CABENUVA visits?	31-45 minutes	12 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs (Time Spent at IC) by Other Quantitative Questionnaires at Months 3 and 8	Month 8- Not including first visit, how much time have you spent at the IC for your CABENUVA visits?	46-60 minutes	10 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs (Time Spent at IC) by Other Quantitative Questionnaires at Months 3 and 8	Month 8- Not including first visit, how much time have you spent at the IC for your CABENUVA visits?	More than 60 minutes	1 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs (Time Spent at IC) by Other Quantitative Questionnaires at Months 3 and 8	Month 8- Not including first visit, how much time have you spent at the IC for your CABENUVA visits?	Missing	1 Participants

Secondary

Number of Participants Assessed for Advantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Month 1

In this outcome measure, participants were asked about their views on the IC/ASA administration model (advantages of going to the infusion center to receive CABENUVA).

Time frame: At Month 1

Population: Analysis was performed on the Safety set which includes any participant who completed any portion of any questionnaire at the specified timepoint.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Participants Receiving CABENUVA	Number of Participants Assessed for Advantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Month 1	Convenient location of the infusion center	22 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Advantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Month 1	Ease of parking at the infusion center	21 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Advantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Month 1	More privacy at the infusion center	19 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Advantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Month 1	Convenient hours for the infusion center	17 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Advantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Month 1	Reduced stigma	13 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Advantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Month 1	I like that people do not know what medication I am there to receive	12 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Advantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Month 1	Injections are not available at my provider's office	8 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Advantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Month 1	Other	2 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Advantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Month 1	No advantages of receiving CABENUVA at the infusion center	1 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Advantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Month 1	Missing	1 Participants

Secondary

Number of Participants Assessed for Advantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Months 3 and 8

In this outcome measure, participants were asked about their views on the IC/ASA administration model (advantages of going to the infusion center to receive CABENUVA).

Time frame: At Months 3 and 8

Population: Analysis was performed on the Safety set which includes any participant who completed any portion of any questionnaire at the specified timepoint.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Participants Receiving CABENUVA	Number of Participants Assessed for Advantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Months 3 and 8	Month 3- Other	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Advantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Months 3 and 8	Month 3- Convenient location of the infusion center	20 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Advantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Months 3 and 8	Month 3- Ease of parking at the infusion center	19 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Advantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Months 3 and 8	Month 3- Ease of scheduling and rescheduling appointments	17 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Advantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Months 3 and 8	Month 3- More privacy at the infusion center	17 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Advantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Months 3 and 8	Month 3- Convenient hours for the infusion center	13 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Advantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Months 3 and 8	Month 3- Reduced stigma	10 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Advantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Months 3 and 8	Month 3- I like that people do not know what medication I am there to receive	12 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Advantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Months 3 and 8	Month 3- Injections are not available at my provider's office	11 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Advantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Months 3 and 8	Month 3- No advantages of receiving CABENUVA at the infusion center	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Advantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Months 3 and 8	Month 3- Missing	5 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Advantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Months 3 and 8	Month 8- Convenient location of the infusion center	22 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Advantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Months 3 and 8	Month 8- Ease of parking at the infusion center	24 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Advantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Months 3 and 8	Month 8- Ease of scheduling and rescheduling appointments	21 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Advantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Months 3 and 8	Month 8- More privacy at the infusion center	18 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Advantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Months 3 and 8	Month 8- Convenient hours for the infusion center	13 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Advantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Months 3 and 8	Month 8- Reduced stigma	16 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Advantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Months 3 and 8	Month 8- I like that people do not know what medication I am there to receive	18 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Advantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Months 3 and 8	Month 8- Injections are not available at my provider's office	11 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Advantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Months 3 and 8	Month 8- Other	3 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Advantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Months 3 and 8	Month 8- No advantages of receiving CABENUVA at the infusion center	2 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Advantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Months 3 and 8	Month 8- Missing	1 Participants

Secondary

Number of Participants Assessed for Advantages of Receiving CABENUVA at IC/ ASA by Qualitative Interviews at Month 8

Time frame: At Month 8

Population: Analysis was performed on the Safety set which includes any participant who completed any portion of any questionnaire at the specified timepoint.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Participants Receiving CABENUVA	Number of Participants Assessed for Advantages of Receiving CABENUVA at IC/ ASA by Qualitative Interviews at Month 8	Privacy	9 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Advantages of Receiving CABENUVA at IC/ ASA by Qualitative Interviews at Month 8	Professionalism of staff	16 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Advantages of Receiving CABENUVA at IC/ ASA by Qualitative Interviews at Month 8	Overall convenience	14 Participants

Secondary

Number of Participants Assessed for Disadvantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Month 1

In this outcome measure, participants were asked about their views on the IC/ASA administration model (disadvantages of going to the infusion center to receive CABENUVA).

Time frame: At Month 1

Population: Analysis was performed on the Safety set which includes any participant who completed any portion of any questionnaire at the specified timepoint.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Participants Receiving CABENUVA	Number of Participants Assessed for Disadvantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Month 1	Decreased contact with my HIV provider	3 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Disadvantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Month 1	Too many appointments between the IC and the HIV doctors	3 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Disadvantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Month 1	Unfamiliar with the infusion center staff	2 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Disadvantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Month 1	Less privacy at the infusion center	2 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Disadvantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Month 1	Other	1 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Disadvantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Month 1	Difficulty scheduling and rescheduling appointments at the infusion center	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Disadvantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Month 1	Too many lab draws	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Disadvantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Month 1	Infusion center doesn't know how to manage the pain or side effects of CABENUVA	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Disadvantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Month 1	Missing	1 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Disadvantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Month 1	No disadvantages of receiving CABENUVA at the infusion center	23 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Disadvantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Month 1	Inconvenient location of the infusion center	8 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Disadvantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Month 1	Unfamiliar with routine at the infusion center	5 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Disadvantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Month 1	Inconvenient hours for the infusion center	4 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Disadvantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Month 1	I don't want other people at the infusion center to know I have HIV	4 Participants

Secondary

Number of Participants Assessed for Disadvantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Months 3 and 8

In this outcome measure, participants were asked about their views on the IC/ASA administration model (disadvantages of going to the infusion center to receive CABENUVA).

Time frame: At Months 3 and 8

Population: Analysis was performed on the Safety set which includes any participant who completed any portion of any questionnaire at the specified timepoint.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Participants Receiving CABENUVA	Number of Participants Assessed for Disadvantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Months 3 and 8	Month 8- More stigma at the infusion center	1 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Disadvantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Months 3 and 8	Month 3- No disadvantages of receiving CABENUVA at the infusion center	16 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Disadvantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Months 3 and 8	Month 3- Inconvenient location of the infusion center	7 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Disadvantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Months 3 and 8	Month 3- Unfamiliar with routine at the infusion center	1 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Disadvantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Months 3 and 8	Month 3- Inconvenient hours for the infusion center	3 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Disadvantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Months 3 and 8	Month 3- I don't want other people at the infusion center to know I have HIV	6 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Disadvantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Months 3 and 8	Month 3- Decreased contact with my HIV provider	7 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Disadvantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Months 3 and 8	Month 3- Too many appointments between the IC and the HIV doctors	2 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Disadvantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Months 3 and 8	Month 3- Unfamiliar with the infusion center staff	1 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Disadvantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Months 3 and 8	Month 3- Less privacy at the infusion center	2 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Disadvantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Months 3 and 8	Month 3- Other	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Disadvantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Months 3 and 8	Month 3- Difficulty scheduling and rescheduling appointments at the infusion center	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Disadvantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Months 3 and 8	Month 3- Too many lab draws	1 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Disadvantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Months 3 and 8	Month 3- Infusion center doesn't know how to manage the pain or side effects of CABENUVA	1 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Disadvantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Months 3 and 8	Month 3- More stigma at the infusion center	2 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Disadvantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Months 3 and 8	Month 3- Difficulty of parking at the infusion center	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Disadvantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Months 3 and 8	Month 3- Missing	7 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Disadvantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Months 3 and 8	Month 8- No disadvantages of receiving CABENUVA at the infusion center	17 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Disadvantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Months 3 and 8	Month 8- Inconvenient location of the infusion center	8 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Disadvantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Months 3 and 8	Month 8- Unfamiliar with routine at the infusion center	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Disadvantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Months 3 and 8	Month 8- Inconvenient hours for the infusion center	5 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Disadvantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Months 3 and 8	Month 8- I don't want other people at the infusion center to know I have HIV	5 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Disadvantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Months 3 and 8	Month 8- Decreased contact with my HIV provider	7 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Disadvantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Months 3 and 8	Month 8- Too many appointments between the IC and the HIV doctors	1 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Disadvantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Months 3 and 8	Month 8- Unfamiliar with the infusion center staff	1 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Disadvantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Months 3 and 8	Month 8- Less privacy at the infusion center	3 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Disadvantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Months 3 and 8	Month 8- Other	1 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Disadvantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Months 3 and 8	Month 8- Difficulty scheduling and rescheduling appointments at the infusion center	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Disadvantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Months 3 and 8	Month 8- Too many lab draws	1 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Disadvantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Months 3 and 8	Month 8- Infusion center doesn't know how to manage the pain or side effects of CABENUVA	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Disadvantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Months 3 and 8	Month 8- Difficulty of parking at the infusion center	2 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Disadvantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Months 3 and 8	Month 8- Missing	1 Participants

Secondary

Number of Participants Assessed for Disadvantages of Receiving CABENUVA at IC/ ASA by Qualitative Interviews at Month 8

Time frame: At Month 8

Population: Analysis was performed on the Safety set which includes any participant who completed any portion of any questionnaire at the specified timepoint.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Participants Receiving CABENUVA	Number of Participants Assessed for Disadvantages of Receiving CABENUVA at IC/ ASA by Qualitative Interviews at Month 8	Distance spent traveling to IC/ASA	17 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Disadvantages of Receiving CABENUVA at IC/ ASA by Qualitative Interviews at Month 8	Privacy due to traveling outside home for treatment	3 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Disadvantages of Receiving CABENUVA at IC/ ASA by Qualitative Interviews at Month 8	Not reported	8 Participants

Secondary

Number of Participants Assessed for Facilitators of CABENUVA Administration by Qualitative Interviews at Month 8

Participants were asked about facilitators that made the process of receiving CABENUVA at IC/ASAs easier.

Time frame: At Month 8

Population: Analysis was performed on the Safety set which includes any participant who completed any portion of any questionnaire at the specified timepoint.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Participants Receiving CABENUVA	Number of Participants Assessed for Facilitators of CABENUVA Administration by Qualitative Interviews at Month 8	Convenience/accessibility of IC/ASA location	4 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Facilitators of CABENUVA Administration by Qualitative Interviews at Month 8	Ease of scheduling appointments and timely reminders	1 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Facilitators of CABENUVA Administration by Qualitative Interviews at Month 8	Not reported	7 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Facilitators of CABENUVA Administration by Qualitative Interviews at Month 8	IC/ASA staff make treatment a positive experience	8 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Facilitators of CABENUVA Administration by Qualitative Interviews at Month 8	Efficiency of treatment	3 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Facilitators of CABENUVA Administration by Qualitative Interviews at Month 8	Clear communication by IC/ASA staff	5 Participants

Secondary

Number of Participants Assessed for Feasibility of CABENUVA Administration by Other Quantitative Questionnaires at Month 1

The tailored questionnaire for participants receiving CABENUVA was developed specifically for this study and contains items regarding the reasons for switching to CABENUVA, adherence to their previous oral HIV medication, preferences and attitudes regarding their medication regimen, and perceived advantages and disadvantages of receiving injections at the IC/ASA. In this outcome measure, participants were asked about their views on the IC/ASA administration model (any/biggest concerns about receiving CABENUVA at an infusion center).

Time frame: At Month 1

Population: Analysis was performed on the Safety set which includes any participant who completed any portion of any questionnaire at the specified timepoint.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Participants Receiving CABENUVA	Number of Participants Assessed for Feasibility of CABENUVA Administration by Other Quantitative Questionnaires at Month 1	No current worries about receiving CABENUVA at an infusion center	19 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Feasibility of CABENUVA Administration by Other Quantitative Questionnaires at Month 1	Scheduling upcoming CABENUVA visits	7 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Feasibility of CABENUVA Administration by Other Quantitative Questionnaires at Month 1	Forgetting my appointments for the CABENUVA visits	6 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Feasibility of CABENUVA Administration by Other Quantitative Questionnaires at Month 1	My doctor not knowing if I have a bad reaction	4 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Feasibility of CABENUVA Administration by Other Quantitative Questionnaires at Month 1	Other	4 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Feasibility of CABENUVA Administration by Other Quantitative Questionnaires at Month 1	The infusion center managing my pain or soreness from CABENUVA	3 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Feasibility of CABENUVA Administration by Other Quantitative Questionnaires at Month 1	The infusion center managing the side effects from CABENUVA	3 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Feasibility of CABENUVA Administration by Other Quantitative Questionnaires at Month 1	The infusion center not aware of my other medical history	3 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Feasibility of CABENUVA Administration by Other Quantitative Questionnaires at Month 1	Transportation to the infusion center for the CABENUVA visits	3 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Feasibility of CABENUVA Administration by Other Quantitative Questionnaires at Month 1	The infusion center hours for CABENUVA visits	3 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Feasibility of CABENUVA Administration by Other Quantitative Questionnaires at Month 1	Others at the clinic may find out that I am HIV positive	3 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Feasibility of CABENUVA Administration by Other Quantitative Questionnaires at Month 1	Frequency of the required visits to the infusion center clinic as well as my primary HIV doctor	2 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Feasibility of CABENUVA Administration by Other Quantitative Questionnaires at Month 1	Rescheduling missed CABENUVA visits	1 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Feasibility of CABENUVA Administration by Other Quantitative Questionnaires at Month 1	Infusion center not aware of my other medications and possible interactions	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Feasibility of CABENUVA Administration by Other Quantitative Questionnaires at Month 1	Parking at the infusion center for CABENUVA visits	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Feasibility of CABENUVA Administration by Other Quantitative Questionnaires at Month 1	Childcare during CABENUVA visits	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Feasibility of CABENUVA Administration by Other Quantitative Questionnaires at Month 1	Infusion center not being an HIV-specific clinic	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Feasibility of CABENUVA Administration by Other Quantitative Questionnaires at Month 1	Missing	1 Participants

Secondary

Number of Participants Assessed for Feasibility of CABENUVA Administration by Other Quantitative Questionnaires at Month 3 and 8

Participants were asked about their views on the IC/ASA administration model (biggest concerns about continuing to receive CABENUVA at an infusion center).

Time frame: At Month 3 and 8

Population: Analysis was performed on the Safety set which includes any participant who completed any portion of any questionnaire at the specified timepoint.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Participants Receiving CABENUVA	Number of Participants Assessed for Feasibility of CABENUVA Administration by Other Quantitative Questionnaires at Month 3 and 8	Month 3- The infusion center managing my pain or soreness from CABENUVA	1 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Feasibility of CABENUVA Administration by Other Quantitative Questionnaires at Month 3 and 8	Month 3- The infusion center managing the side effects from CABENUVA	1 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Feasibility of CABENUVA Administration by Other Quantitative Questionnaires at Month 3 and 8	Month 3- My doctor not knowing if I have a bad reaction	1 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Feasibility of CABENUVA Administration by Other Quantitative Questionnaires at Month 3 and 8	Month 3- Scheduling upcoming CABENUVA visits	1 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Feasibility of CABENUVA Administration by Other Quantitative Questionnaires at Month 3 and 8	Month 3- Transportation to the infusion center for the CABENUVA visits	1 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Feasibility of CABENUVA Administration by Other Quantitative Questionnaires at Month 3 and 8	Month 3- Others at the clinic may find out that I am HIV positive	1 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Feasibility of CABENUVA Administration by Other Quantitative Questionnaires at Month 3 and 8	Month 3- Other	1 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Feasibility of CABENUVA Administration by Other Quantitative Questionnaires at Month 3 and 8	Month 3- The infusion center not aware of my other medical history	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Feasibility of CABENUVA Administration by Other Quantitative Questionnaires at Month 3 and 8	Month 3- Infusion center not aware of my other medications and possible interactions	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Feasibility of CABENUVA Administration by Other Quantitative Questionnaires at Month 3 and 8	Month 3- Rescheduling missed CABENUVA visits	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Feasibility of CABENUVA Administration by Other Quantitative Questionnaires at Month 3 and 8	Month 3- Forgetting my appointments for the CABENUVA visits	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Feasibility of CABENUVA Administration by Other Quantitative Questionnaires at Month 3 and 8	Month 3- Frequency of the required visits to infusion center clinic as well as my primary HIV doctor	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Feasibility of CABENUVA Administration by Other Quantitative Questionnaires at Month 3 and 8	Month 3- Parking at the infusion center for CABENUVA visits	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Feasibility of CABENUVA Administration by Other Quantitative Questionnaires at Month 3 and 8	Month 3- The infusion center hours for CABENUVA visits	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Feasibility of CABENUVA Administration by Other Quantitative Questionnaires at Month 3 and 8	Month 3- Childcare during CABENUVA visits	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Feasibility of CABENUVA Administration by Other Quantitative Questionnaires at Month 3 and 8	Month 3- Infusion center not being an HIV-specific clinic	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Feasibility of CABENUVA Administration by Other Quantitative Questionnaires at Month 3 and 8	Month 3- Missing	5 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Feasibility of CABENUVA Administration by Other Quantitative Questionnaires at Month 3 and 8	Month 8- The infusion center managing my pain or soreness from CABENUVA	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Feasibility of CABENUVA Administration by Other Quantitative Questionnaires at Month 3 and 8	Month 8- The infusion center managing the side effects from CABENUVA	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Feasibility of CABENUVA Administration by Other Quantitative Questionnaires at Month 3 and 8	Month 8- My doctor not knowing if I have a bad reaction	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Feasibility of CABENUVA Administration by Other Quantitative Questionnaires at Month 3 and 8	Month 8- Scheduling upcoming CABENUVA visits	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Feasibility of CABENUVA Administration by Other Quantitative Questionnaires at Month 3 and 8	Month 8- Transportation to the infusion center for the CABENUVA visits	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Feasibility of CABENUVA Administration by Other Quantitative Questionnaires at Month 3 and 8	Month 8- Others at the clinic may find out that I am HIV positive	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Feasibility of CABENUVA Administration by Other Quantitative Questionnaires at Month 3 and 8	Month 8- Other	3 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Feasibility of CABENUVA Administration by Other Quantitative Questionnaires at Month 3 and 8	Month 8- The infusion center not aware of my other medical history	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Feasibility of CABENUVA Administration by Other Quantitative Questionnaires at Month 3 and 8	Month 8- Infusion center not aware of my other medications and possible interactions	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Feasibility of CABENUVA Administration by Other Quantitative Questionnaires at Month 3 and 8	Month 8- Rescheduling missed CABENUVA visits	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Feasibility of CABENUVA Administration by Other Quantitative Questionnaires at Month 3 and 8	Month 8- Forgetting my appointments for the CABENUVA visits	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Feasibility of CABENUVA Administration by Other Quantitative Questionnaires at Month 3 and 8	Month 8- Frequency of the required visits to infusion center clinic as well as my primary HIV doctor	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Feasibility of CABENUVA Administration by Other Quantitative Questionnaires at Month 3 and 8	Month 8- Parking at the infusion center for CABENUVA visits	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Feasibility of CABENUVA Administration by Other Quantitative Questionnaires at Month 3 and 8	Month 8- The infusion center hours for CABENUVA visits	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Feasibility of CABENUVA Administration by Other Quantitative Questionnaires at Month 3 and 8	Month 8- Childcare during CABENUVA visits	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Feasibility of CABENUVA Administration by Other Quantitative Questionnaires at Month 3 and 8	Month 8- Infusion center not being an HIV-specific clinic	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Feasibility of CABENUVA Administration by Other Quantitative Questionnaires at Month 3 and 8	Month 8- Missing	1 Participants

Secondary

Number of Participants Assessed for Feasibility of CABENUVA Administration by Qualitative Interviews at Month 8

Qualitative interviews were conducted at Month 8 to evaluate the opinions of participants on the feasibility of CABENUVA administration at IC/ASA.

Time frame: At Month 8

Population: Analysis was performed on the Safety set which includes any participant who completed any portion of any questionnaire at the specified timepoint.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Participants Receiving CABENUVA	Number of Participants Assessed for Feasibility of CABENUVA Administration by Qualitative Interviews at Month 8	Professional and caring staff	23 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Feasibility of CABENUVA Administration by Qualitative Interviews at Month 8	Consistency of providers	2 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Feasibility of CABENUVA Administration by Qualitative Interviews at Month 8	Protects participants' privacy	14 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Feasibility of CABENUVA Administration by Qualitative Interviews at Month 8	Scheduling flexibility	4 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Feasibility of CABENUVA Administration by Qualitative Interviews at Month 8	Appointment reminders	1 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Feasibility of CABENUVA Administration by Qualitative Interviews at Month 8	Quick and easy administration process	6 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Feasibility of CABENUVA Administration by Qualitative Interviews at Month 8	Hassle-free for participants	1 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Feasibility of CABENUVA Administration by Qualitative Interviews at Month 8	Good facilities/environment	8 Participants

Secondary

Number of Participants Assessed for Feasibility of CABENUVA Administration (Concern About Continuing to Receive CABENUVA) by Other Quantitative Questionnaires at Month 3 and 8

The tailored questionnaire for participants receiving CABENUVA was developed specifically for this study and contains items regarding the reasons for switching to CABENUVA, adherence to their previous oral HIV medication, preferences and attitudes regarding their medication regimen, and perceived advantages and disadvantages of receiving injections at the IC/ASA. In this outcome measure, participants were asked about their views on the IC/ASA administration model (any concerns about continuing to receive CABENUVA at an infusion center) at Months 3 and 8.

Time frame: At Month 3 and 8

Population: Analysis was performed on the Safety set which includes any participant who completed any portion of any questionnaire at the specified timepoint.

Arm	Measure	Group	Category	Value (COUNT_OF_PARTICIPANTS)
Participants Receiving CABENUVA	Number of Participants Assessed for Feasibility of CABENUVA Administration (Concern About Continuing to Receive CABENUVA) by Other Quantitative Questionnaires at Month 3 and 8	Month 3- Do you have any concerns about continuing to receive CABENUVA at an infusion center?	Yes	3 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Feasibility of CABENUVA Administration (Concern About Continuing to Receive CABENUVA) by Other Quantitative Questionnaires at Month 3 and 8	Month 3- Do you have any concerns about continuing to receive CABENUVA at an infusion center?	No	33 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Feasibility of CABENUVA Administration (Concern About Continuing to Receive CABENUVA) by Other Quantitative Questionnaires at Month 3 and 8	Month 3- Do you have any concerns about continuing to receive CABENUVA at an infusion center?	Missing	5 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Feasibility of CABENUVA Administration (Concern About Continuing to Receive CABENUVA) by Other Quantitative Questionnaires at Month 3 and 8	Month 8- Do you have any concerns about continuing to receive CABENUVA at an infusion center?	Yes	3 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Feasibility of CABENUVA Administration (Concern About Continuing to Receive CABENUVA) by Other Quantitative Questionnaires at Month 3 and 8	Month 8- Do you have any concerns about continuing to receive CABENUVA at an infusion center?	No	34 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Feasibility of CABENUVA Administration (Concern About Continuing to Receive CABENUVA) by Other Quantitative Questionnaires at Month 3 and 8	Month 8- Do you have any concerns about continuing to receive CABENUVA at an infusion center?	Missing	1 Participants

Secondary

Number of Participants Assessed for Overall Opinion of Receiving the Injection at an IC/ ASA by Other Quantitative Questionnaires at Months 1, 3 and 8

Time frame: At Months 1, 3 and 8

Population: Analysis was performed on the Safety set which includes any participant who completed any portion of any questionnaire at the specified timepoint.

Arm	Measure	Group	Category	Value (COUNT_OF_PARTICIPANTS)
Participants Receiving CABENUVA	Number of Participants Assessed for Overall Opinion of Receiving the Injection at an IC/ ASA by Other Quantitative Questionnaires at Months 1, 3 and 8	At month 1 - What is your overall opinion about going to an infusion center to receive CABENUVA?	Very positive	35 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Overall Opinion of Receiving the Injection at an IC/ ASA by Other Quantitative Questionnaires at Months 1, 3 and 8	At month 1 - What is your overall opinion about going to an infusion center to receive CABENUVA?	Somewhat positive	5 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Overall Opinion of Receiving the Injection at an IC/ ASA by Other Quantitative Questionnaires at Months 1, 3 and 8	At month 1 - What is your overall opinion about going to an infusion center to receive CABENUVA?	A little positive	1 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Overall Opinion of Receiving the Injection at an IC/ ASA by Other Quantitative Questionnaires at Months 1, 3 and 8	At month 1 - What is your overall opinion about going to an infusion center to receive CABENUVA?	Neutral	1 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Overall Opinion of Receiving the Injection at an IC/ ASA by Other Quantitative Questionnaires at Months 1, 3 and 8	At month 1 - What is your overall opinion about going to an infusion center to receive CABENUVA?	A little negative	1 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Overall Opinion of Receiving the Injection at an IC/ ASA by Other Quantitative Questionnaires at Months 1, 3 and 8	At month 1 - What is your overall opinion about going to an infusion center to receive CABENUVA?	Somewhat negative	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Overall Opinion of Receiving the Injection at an IC/ ASA by Other Quantitative Questionnaires at Months 1, 3 and 8	At month 1 - What is your overall opinion about going to an infusion center to receive CABENUVA?	Very negative	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Overall Opinion of Receiving the Injection at an IC/ ASA by Other Quantitative Questionnaires at Months 1, 3 and 8	At month 1 - What is your overall opinion about going to an infusion center to receive CABENUVA?	Missing	1 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Overall Opinion of Receiving the Injection at an IC/ ASA by Other Quantitative Questionnaires at Months 1, 3 and 8	At month 3 - What is your overall opinion about going to an infusion center to receive CABENUVA?	Very positive	28 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Overall Opinion of Receiving the Injection at an IC/ ASA by Other Quantitative Questionnaires at Months 1, 3 and 8	At month 3 - What is your overall opinion about going to an infusion center to receive CABENUVA?	Somewhat positive	7 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Overall Opinion of Receiving the Injection at an IC/ ASA by Other Quantitative Questionnaires at Months 1, 3 and 8	At month 3 - What is your overall opinion about going to an infusion center to receive CABENUVA?	A little positive	1 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Overall Opinion of Receiving the Injection at an IC/ ASA by Other Quantitative Questionnaires at Months 1, 3 and 8	At month 3 - What is your overall opinion about going to an infusion center to receive CABENUVA?	Neutral	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Overall Opinion of Receiving the Injection at an IC/ ASA by Other Quantitative Questionnaires at Months 1, 3 and 8	At month 3 - What is your overall opinion about going to an infusion center to receive CABENUVA?	A little negative	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Overall Opinion of Receiving the Injection at an IC/ ASA by Other Quantitative Questionnaires at Months 1, 3 and 8	At month 3 - What is your overall opinion about going to an infusion center to receive CABENUVA?	Somewhat negative	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Overall Opinion of Receiving the Injection at an IC/ ASA by Other Quantitative Questionnaires at Months 1, 3 and 8	At month 3 - What is your overall opinion about going to an infusion center to receive CABENUVA?	Very negative	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Overall Opinion of Receiving the Injection at an IC/ ASA by Other Quantitative Questionnaires at Months 1, 3 and 8	At month 3 - What is your overall opinion about going to an infusion center to receive CABENUVA?	Missing	5 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Overall Opinion of Receiving the Injection at an IC/ ASA by Other Quantitative Questionnaires at Months 1, 3 and 8	At month 8 - What is your overall opinion about going to an infusion center to receive CABENUVA?	Very positive	27 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Overall Opinion of Receiving the Injection at an IC/ ASA by Other Quantitative Questionnaires at Months 1, 3 and 8	At month 8 - What is your overall opinion about going to an infusion center to receive CABENUVA?	Somewhat positive	9 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Overall Opinion of Receiving the Injection at an IC/ ASA by Other Quantitative Questionnaires at Months 1, 3 and 8	At month 8 - What is your overall opinion about going to an infusion center to receive CABENUVA?	A little positive	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Overall Opinion of Receiving the Injection at an IC/ ASA by Other Quantitative Questionnaires at Months 1, 3 and 8	At month 8 - What is your overall opinion about going to an infusion center to receive CABENUVA?	Neutral	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Overall Opinion of Receiving the Injection at an IC/ ASA by Other Quantitative Questionnaires at Months 1, 3 and 8	At month 8 - What is your overall opinion about going to an infusion center to receive CABENUVA?	A little negative	1 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Overall Opinion of Receiving the Injection at an IC/ ASA by Other Quantitative Questionnaires at Months 1, 3 and 8	At month 8 - What is your overall opinion about going to an infusion center to receive CABENUVA?	Somewhat negative	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Overall Opinion of Receiving the Injection at an IC/ ASA by Other Quantitative Questionnaires at Months 1, 3 and 8	At month 8 - What is your overall opinion about going to an infusion center to receive CABENUVA?	Very negative	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Overall Opinion of Receiving the Injection at an IC/ ASA by Other Quantitative Questionnaires at Months 1, 3 and 8	At month 8 - What is your overall opinion about going to an infusion center to receive CABENUVA?	Missing	1 Participants

Secondary

Number of Participants Assessed for Overall Opinion of Receiving the Injection at an IC/ ASA by Qualitative Interview at Month 8

Participants were asked about their overall favorable and non-favorable opinion of receiving CABENUVA at the IC/ASA.

Time frame: At Month 8

Population: Analysis was performed on the Safety set which includes any participant who completed any portion of any questionnaire at the specified timepoint.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Participants Receiving CABENUVA	Number of Participants Assessed for Overall Opinion of Receiving the Injection at an IC/ ASA by Qualitative Interview at Month 8	Effectiveness of treatment	5 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Overall Opinion of Receiving the Injection at an IC/ ASA by Qualitative Interview at Month 8	Convenience of treatment	11 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Overall Opinion of Receiving the Injection at an IC/ ASA by Qualitative Interview at Month 8	No daily reminder of diagnosis	5 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Overall Opinion of Receiving the Injection at an IC/ ASA by Qualitative Interview at Month 8	Treatment cadence	13 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Overall Opinion of Receiving the Injection at an IC/ ASA by Qualitative Interview at Month 8	Not needing to worry about forgetting to take the pill	5 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Overall Opinion of Receiving the Injection at an IC/ ASA by Qualitative Interview at Month 8	Reduced worry about unwanted disclosure of HIV	4 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Overall Opinion of Receiving the Injection at an IC/ ASA by Qualitative Interview at Month 8	Reduces pill burden	6 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Overall Opinion of Receiving the Injection at an IC/ ASA by Qualitative Interview at Month 8	No more pill side effects	2 Participants

Secondary

Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires at Month 1

Time frame: At Month 1

Population: Analysis was performed on the Safety set which includes any participant who completed any portion of any questionnaire at the specified timepoint.

Arm	Measure	Group	Category	Value (COUNT_OF_PARTICIPANTS)
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires at Month 1	Concern about unwanted disclosure of HIV status when attending appointments at HIV providers office	Very concerned	12 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires at Month 1	Concern about unwanted disclosure of HIV status when attending appointments at HIV providers office	Moderately concerned	7 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires at Month 1	Concern about unwanted disclosure of HIV status when attending appointments at HIV providers office	Somewhat concerned	4 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires at Month 1	Concern about unwanted disclosure of HIV status when attending appointments at HIV providers office	A little concerned	3 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires at Month 1	Concern about unwanted disclosure of HIV status when attending appointments at HIV providers office	Not at all concerned	17 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires at Month 1	Concern about unwanted disclosure of HIV status when attending appointments at HIV providers office	Missing	1 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires at Month 1	Concern about unwanted disclosure of HIV status when attending appointments at IC	Very concerned	10 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires at Month 1	Concern about unwanted disclosure of HIV status when attending appointments at IC	Moderately concerned	5 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires at Month 1	Concern about unwanted disclosure of HIV status when attending appointments at IC	Somewhat concerned	5 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires at Month 1	Concern about unwanted disclosure of HIV status when attending appointments at IC	A little concerned	5 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires at Month 1	Concern about unwanted disclosure of HIV status when attending appointments at IC	Not at all concerned	18 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires at Month 1	Concern about unwanted disclosure of HIV status when attending appointments at IC	Missing	1 Participants

Secondary

Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 10) at Months 3 and 8

Participants were asked their opinion on who did they reach out to obtain answers to their questions.

Time frame: At Months 3 and 8

Population: Analysis was performed on the Safety set which includes any participant who completed any portion of any questionnaire at the specified timepoint.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 10) at Months 3 and 8	Month 3- My regular HIV provider	18 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 10) at Months 3 and 8	Month 3- Staff at infusion center	15 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 10) at Months 3 and 8	Month 3- No questions to date	9 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 10) at Months 3 and 8	Month 3- Other staff at my regular HIV provider's office	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 10) at Months 3 and 8	Month 3- Other people with HIV	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 10) at Months 3 and 8	Month 3- Social media	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 10) at Months 3 and 8	Month 3- Missing	5 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 10) at Months 3 and 8	Month 8- My regular HIV provider	20 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 10) at Months 3 and 8	Month 8- Staff at the infusion center	18 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 10) at Months 3 and 8	Month 8- No questions to date	11 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 10) at Months 3 and 8	Month 8- Other staff at my regular HIV provider's office	2 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 10) at Months 3 and 8	Month 8- Other people with HIV	1 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 10) at Months 3 and 8	Month 8- Social media	1 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 10) at Months 3 and 8	Month 8- Missing	1 Participants

Secondary

Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 11) at Months 3 and 8

Time frame: At Months 3 and 8

Population: Analysis was performed on the Safety set which includes any participant who completed any portion of any questionnaire at the specified timepoint.

Arm	Measure	Group	Category	Value (COUNT_OF_PARTICIPANTS)
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 11) at Months 3 and 8	Month 3- Concern about unwanted disclosure of HIV status when attending appointments at the IC?	Very concerned	2 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 11) at Months 3 and 8	Month 3- Concern about unwanted disclosure of HIV status when attending appointments at the IC?	Moderately concerned	5 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 11) at Months 3 and 8	Month 3- Concern about unwanted disclosure of HIV status when attending appointments at the IC?	Somewhat concerned	6 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 11) at Months 3 and 8	Month 3- Concern about unwanted disclosure of HIV status when attending appointments at the IC?	A little concerned	1 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 11) at Months 3 and 8	Month 3- Concern about unwanted disclosure of HIV status when attending appointments at the IC?	Missing	5 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 11) at Months 3 and 8	Month 8- Concern about unwanted disclosure of HIV status when attending appointments at the IC?	Very concerned	5 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 11) at Months 3 and 8	Month 8- Concern about unwanted disclosure of HIV status when attending appointments at the IC?	Moderately concerned	1 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 11) at Months 3 and 8	Month 8- Concern about unwanted disclosure of HIV status when attending appointments at the IC?	Somewhat concerned	4 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 11) at Months 3 and 8	Month 8- Concern about unwanted disclosure of HIV status when attending appointments at the IC?	A little concerned	5 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 11) at Months 3 and 8	Month 8- Concern about unwanted disclosure of HIV status when attending appointments at the IC?	Not at all concerned	22 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 11) at Months 3 and 8	Month 8- Concern about unwanted disclosure of HIV status when attending appointments at the IC?	Missing	1 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 11) at Months 3 and 8	Month 3- Concern about unwanted disclosure of HIV status when attending appointments at the IC?	Not at all concerned	22 Participants

Secondary

Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 1) at Month 3 and 8

Time frame: At Month 3 and 8

Population: Analysis was performed on the Safety set which includes any participant who completed any portion of any questionnaire at the specified timepoint.

Arm	Measure	Group	Category	Value (COUNT_OF_PARTICIPANTS)
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 1) at Month 3 and 8	Month 3- Have you been treated differently, or experienced stigma or discrimination at the IC?	Yes	1 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 1) at Month 3 and 8	Month 3- Have you been treated differently, or experienced stigma or discrimination at the IC?	No	34 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 1) at Month 3 and 8	Month 3- Have you been treated differently, or experienced stigma or discrimination at the IC?	Prefer not to answer	1 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 1) at Month 3 and 8	Month 3- Have you been treated differently, or experienced stigma or discrimination at the IC?	Missing	5 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 1) at Month 3 and 8	Month 8- Have you been treated differently, or experienced stigma or discrimination at the IC?	Yes	1 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 1) at Month 3 and 8	Month 8- Have you been treated differently, or experienced stigma or discrimination at the IC?	No	34 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 1) at Month 3 and 8	Month 8- Have you been treated differently, or experienced stigma or discrimination at the IC?	Prefer not to answer	2 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 1) at Month 3 and 8	Month 8- Have you been treated differently, or experienced stigma or discrimination at the IC?	Missing	1 Participants

Secondary

Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 2) at Months 3 and 8

Time frame: At Months 3 and 8

Population: Analysis was performed on the Safety set which includes any participant who completed any portion of any questionnaire at the specified timepoint.

Arm	Measure	Group	Category	Value (COUNT_OF_PARTICIPANTS)
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 2) at Months 3 and 8	Month 3- Your experience at IC compared to your experience at your HIV provider's office/clinic?	A lot worse	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 2) at Months 3 and 8	Month 3- Your experience at IC compared to your experience at your HIV provider's office/clinic?	Somewhat worse	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 2) at Months 3 and 8	Month 3- Your experience at IC compared to your experience at your HIV provider's office/clinic?	A little worse	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 2) at Months 3 and 8	Month 3- Your experience at IC compared to your experience at your HIV provider's office/clinic?	About the same	1 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 2) at Months 3 and 8	Month 3- Your experience at IC compared to your experience at your HIV provider's office/clinic?	A little better	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 2) at Months 3 and 8	Month 3- Your experience at IC compared to your experience at your HIV provider's office/clinic?	Somewhat better	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 2) at Months 3 and 8	Month 3- Your experience at IC compared to your experience at your HIV provider's office/clinic?	A lot better	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 2) at Months 3 and 8	Month 8- Your experience at IC compared to your experience at your HIV provider's office/clinic?	A lot worse	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 2) at Months 3 and 8	Month 8- Your experience at IC compared to your experience at your HIV provider's office/clinic?	Somewhat worse	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 2) at Months 3 and 8	Month 8- Your experience at IC compared to your experience at your HIV provider's office/clinic?	A little worse	1 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 2) at Months 3 and 8	Month 8- Your experience at IC compared to your experience at your HIV provider's office/clinic?	About the same	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 2) at Months 3 and 8	Month 8- Your experience at IC compared to your experience at your HIV provider's office/clinic?	A little better	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 2) at Months 3 and 8	Month 8- Your experience at IC compared to your experience at your HIV provider's office/clinic?	Somewhat better	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 2) at Months 3 and 8	Month 8- Your experience at IC compared to your experience at your HIV provider's office/clinic?	A lot better	0 Participants

Secondary

Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 3) at Months 3 and 8

Time frame: At Months 3 and 8

Population: Analysis was performed on the Safety set which includes any participant who completed any portion of any questionnaire at the specified timepoint.

Arm	Measure	Group	Category	Value (COUNT_OF_PARTICIPANTS)
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 3) at Months 3 and 8	Month 3- Do you believe you have been treated differently based on any of the following factors.	Age	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 3) at Months 3 and 8	Month 3- Do you believe you have been treated differently based on any of the following factors.	Race/ethnicity	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 3) at Months 3 and 8	Month 3- Do you believe you have been treated differently based on any of the following factors.	Sex	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 3) at Months 3 and 8	Month 3- Do you believe you have been treated differently based on any of the following factors.	Gender identity	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 3) at Months 3 and 8	Month 3- Do you believe you have been treated differently based on any of the following factors.	Sexual preference	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 3) at Months 3 and 8	Month 3- Do you believe you have been treated differently based on any of the following factors.	HIV status	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 3) at Months 3 and 8	Month 3- Do you believe you have been treated differently based on any of the following factors.	Religion	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 3) at Months 3 and 8	Month 3- Do you believe you have been treated differently based on any of the following factors.	Physical appearance	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 3) at Months 3 and 8	Month 3- Do you believe you have been treated differently based on any of the following factors.	Housing status	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 3) at Months 3 and 8	Month 3- Do you believe you have been treated differently based on any of the following factors.	Due to pregnancy/being pregnant	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 3) at Months 3 and 8	Month 3- Do you believe you have been treated differently based on any of the following factors.	Other	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 3) at Months 3 and 8	Month 3- Do you believe you have been treated differently based on any of the following factors.	None of the above	1 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 3) at Months 3 and 8	Month 8- Do you believe you have been treated differently based on any of the following factors.	Age	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 3) at Months 3 and 8	Month 8- Do you believe you have been treated differently based on any of the following factors.	Race/ethnicity	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 3) at Months 3 and 8	Month 8- Do you believe you have been treated differently based on any of the following factors.	Sex	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 3) at Months 3 and 8	Month 8- Do you believe you have been treated differently based on any of the following factors.	Gender identity	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 3) at Months 3 and 8	Month 8- Do you believe you have been treated differently based on any of the following factors.	Sexual preference	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 3) at Months 3 and 8	Month 8- Do you believe you have been treated differently based on any of the following factors.	HIV status	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 3) at Months 3 and 8	Month 8- Do you believe you have been treated differently based on any of the following factors.	Religion	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 3) at Months 3 and 8	Month 8- Do you believe you have been treated differently based on any of the following factors.	Physical appearance	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 3) at Months 3 and 8	Month 8- Do you believe you have been treated differently based on any of the following factors.	Housing status	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 3) at Months 3 and 8	Month 8- Do you believe you have been treated differently based on any of the following factors.	Due to pregnancy/being pregnant	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 3) at Months 3 and 8	Month 8- Do you believe you have been treated differently based on any of the following factors.	Other	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 3) at Months 3 and 8	Month 8- Do you believe you have been treated differently based on any of the following factors.	None of the above	1 Participants

Secondary

Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 4) at Months 3 and 8

Time frame: At Months 3 and 8

Population: Analysis was performed on the Safety set which includes any participant who completed any portion of any questionnaire at the specified timepoint.

Arm	Measure	Group	Category	Value (COUNT_OF_PARTICIPANTS)
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 4) at Months 3 and 8	Month 3- How comfortable are you with the infusion center managing your CABENUVA injections?	Extremely comfortable	28 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 4) at Months 3 and 8	Month 3- How comfortable are you with the infusion center managing your CABENUVA injections?	Very comfortable	6 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 4) at Months 3 and 8	Month 3- How comfortable are you with the infusion center managing your CABENUVA injections?	Somewhat comfortable	2 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 4) at Months 3 and 8	Month 3- How comfortable are you with the infusion center managing your CABENUVA injections?	Neutral	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 4) at Months 3 and 8	Month 3- How comfortable are you with the infusion center managing your CABENUVA injections?	Somewhat uncomfortable	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 4) at Months 3 and 8	Month 3- How comfortable are you with the infusion center managing your CABENUVA injections?	Very uncomfortable	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 4) at Months 3 and 8	Month 3- How comfortable are you with the infusion center managing your CABENUVA injections?	Extremely uncomfortable	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 4) at Months 3 and 8	Month 3- How comfortable are you with the infusion center managing your CABENUVA injections?	Missing	5 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 4) at Months 3 and 8	Month 8- How comfortable are you with the infusion center managing your CABENUVA injections?	Extremely comfortable	24 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 4) at Months 3 and 8	Month 8- How comfortable are you with the infusion center managing your CABENUVA injections?	Very comfortable	10 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 4) at Months 3 and 8	Month 8- How comfortable are you with the infusion center managing your CABENUVA injections?	Somewhat comfortable	1 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 4) at Months 3 and 8	Month 8- How comfortable are you with the infusion center managing your CABENUVA injections?	Neutral	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 4) at Months 3 and 8	Month 8- How comfortable are you with the infusion center managing your CABENUVA injections?	Somewhat uncomfortable	1 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 4) at Months 3 and 8	Month 8- How comfortable are you with the infusion center managing your CABENUVA injections?	Very uncomfortable	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 4) at Months 3 and 8	Month 8- How comfortable are you with the infusion center managing your CABENUVA injections?	Extremely uncomfortable	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 4) at Months 3 and 8	Month 8- How comfortable are you with the infusion center managing your CABENUVA injections?	Missing	2 Participants

Secondary

Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 5) at Months 3 and 8

Time frame: At Months 3 and 8

Population: Analysis was performed on the Safety set which includes any participant who completed any portion of any questionnaire at the specified timepoint.

Arm	Measure	Group	Category	Value (COUNT_OF_PARTICIPANTS)
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 5) at Months 3 and 8	Month 3- How welcome do you feel at the infusion center?	Neutral	1 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 5) at Months 3 and 8	Month 3- How welcome do you feel at the infusion center?	Extremely welcome	25 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 5) at Months 3 and 8	Month 3- How welcome do you feel at the infusion center?	Very welcome	10 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 5) at Months 3 and 8	Month 3- How welcome do you feel at the infusion center?	Somewhat welcome	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 5) at Months 3 and 8	Month 3- How welcome do you feel at the infusion center?	Somewhat unwelcome	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 5) at Months 3 and 8	Month 3- How welcome do you feel at the infusion center?	Very unwelcome	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 5) at Months 3 and 8	Month 3- How welcome do you feel at the infusion center?	Extremely unwelcome	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 5) at Months 3 and 8	Month 3- How welcome do you feel at the infusion center?	Missing	5 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 5) at Months 3 and 8	Month 8- How welcome do you feel at the infusion center?	Extremely welcome	29 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 5) at Months 3 and 8	Month 8- How welcome do you feel at the infusion center?	Very welcome	7 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 5) at Months 3 and 8	Month 8- How welcome do you feel at the infusion center?	Somewhat welcome	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 5) at Months 3 and 8	Month 8- How welcome do you feel at the infusion center?	Neutral	1 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 5) at Months 3 and 8	Month 8- How welcome do you feel at the infusion center?	Somewhat unwelcome	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 5) at Months 3 and 8	Month 8- How welcome do you feel at the infusion center?	Very unwelcome	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 5) at Months 3 and 8	Month 8- How welcome do you feel at the infusion center?	Extremely unwelcome	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 5) at Months 3 and 8	Month 8- How welcome do you feel at the infusion center?	Missing	1 Participants

Secondary

Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 6) at Months 3 and 8

Time frame: At Months 3 and 8

Population: Analysis was performed on the Safety set which includes any participant who completed any portion of any questionnaire at the specified timepoint.

Arm	Measure	Group	Category	Value (COUNT_OF_PARTICIPANTS)
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 6) at Months 3 and 8	Month 3- How respectful are the infusion center staff when you are there for your injections?	Extremely respectful	30 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 6) at Months 3 and 8	Month 3- How respectful are the infusion center staff when you are there for your injections?	Very respectful	6 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 6) at Months 3 and 8	Month 3- How respectful are the infusion center staff when you are there for your injections?	Somewhat respectful	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 6) at Months 3 and 8	Month 3- How respectful are the infusion center staff when you are there for your injections?	Neutral	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 6) at Months 3 and 8	Month 3- How respectful are the infusion center staff when you are there for your injections?	Somewhat unrespectful	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 6) at Months 3 and 8	Month 3- How respectful are the infusion center staff when you are there for your injections?	Very unrespectful	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 6) at Months 3 and 8	Month 3- How respectful are the infusion center staff when you are there for your injections?	Extremely unrespectful	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 6) at Months 3 and 8	Month 3- How respectful are the infusion center staff when you are there for your injections?	Missing	5 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 6) at Months 3 and 8	Month 8- How respectful are the infusion center staff when you are there for your injections?	Extremely respectful	31 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 6) at Months 3 and 8	Month 8- How respectful are the infusion center staff when you are there for your injections?	Very respectful	6 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 6) at Months 3 and 8	Month 8- How respectful are the infusion center staff when you are there for your injections?	Somewhat respectful	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 6) at Months 3 and 8	Month 8- How respectful are the infusion center staff when you are there for your injections?	Neutral	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 6) at Months 3 and 8	Month 8- How respectful are the infusion center staff when you are there for your injections?	Somewhat unrespectful	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 6) at Months 3 and 8	Month 8- How respectful are the infusion center staff when you are there for your injections?	Very unrespectful	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 6) at Months 3 and 8	Month 8- How respectful are the infusion center staff when you are there for your injections?	Extremely unrespectful	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 6) at Months 3 and 8	Month 8- How respectful are the infusion center staff when you are there for your injections?	Missing	1 Participants

Secondary

Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 7) at Months 3 and 8

Time frame: At Months 3 and 8

Population: Analysis was performed on the Safety set which includes any participant who completed any portion of any questionnaire at the specified timepoint.

Arm	Measure	Group	Category	Value (COUNT_OF_PARTICIPANTS)
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 7) at Months 3 and 8	Month 3- Satisfaction level of privacy at the IC for receiving your injections?	Extremely satisfied	25 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 7) at Months 3 and 8	Month 3- Satisfaction level of privacy at the IC for receiving your injections?	Very satisfied	9 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 7) at Months 3 and 8	Month 3- Satisfaction level of privacy at the IC for receiving your injections?	Somewhat satisfied	1 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 7) at Months 3 and 8	Month 3- Satisfaction level of privacy at the IC for receiving your injections?	Neutral	1 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 7) at Months 3 and 8	Month 3- Satisfaction level of privacy at the IC for receiving your injections?	Somewhat dissatisfied	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 7) at Months 3 and 8	Month 3- Satisfaction level of privacy at the IC for receiving your injections?	Very dissatisfied	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 7) at Months 3 and 8	Month 3- Satisfaction level of privacy at the IC for receiving your injections?	Extremely dissatisfied	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 7) at Months 3 and 8	Month 3- Satisfaction level of privacy at the IC for receiving your injections?	Missing	5 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 7) at Months 3 and 8	Month 8- Satisfaction level of privacy at the IC for receiving your injections?	Extremely satisfied	27 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 7) at Months 3 and 8	Month 8- Satisfaction level of privacy at the IC for receiving your injections?	Very satisfied	6 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 7) at Months 3 and 8	Month 8- Satisfaction level of privacy at the IC for receiving your injections?	Somewhat satisfied	1 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 7) at Months 3 and 8	Month 8- Satisfaction level of privacy at the IC for receiving your injections?	Neutral	1 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 7) at Months 3 and 8	Month 8- Satisfaction level of privacy at the IC for receiving your injections?	Somewhat dissatisfied	1 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 7) at Months 3 and 8	Month 8- Satisfaction level of privacy at the IC for receiving your injections?	Very dissatisfied	1 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 7) at Months 3 and 8	Month 8- Satisfaction level of privacy at the IC for receiving your injections?	Extremely dissatisfied	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 7) at Months 3 and 8	Month 8- Satisfaction level of privacy at the IC for receiving your injections?	Missing	1 Participants

Secondary

Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 8) at Months 3 and 8

Time frame: At Months 3 and 8

Population: Analysis was performed on the Safety set which includes any participant who completed any portion of any questionnaire at the specified timepoint.

Arm	Measure	Group	Category	Value (COUNT_OF_PARTICIPANTS)
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 8) at Months 3 and 8	Month 3- How convenient is it for you to get to the infusion center for your CABENUVA visits?	Very convenient	20 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 8) at Months 3 and 8	Month 3- How convenient is it for you to get to the infusion center for your CABENUVA visits?	Somewhat convenient	7 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 8) at Months 3 and 8	Month 3- How convenient is it for you to get to the infusion center for your CABENUVA visits?	A little convenient	3 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 8) at Months 3 and 8	Month 3- How convenient is it for you to get to the infusion center for your CABENUVA visits?	Neutral	1 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 8) at Months 3 and 8	Month 3- How convenient is it for you to get to the infusion center for your CABENUVA visits?	A little inconvenient	2 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 8) at Months 3 and 8	Month 3- How convenient is it for you to get to the infusion center for your CABENUVA visits?	Somewhat inconvenient	3 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 8) at Months 3 and 8	Month 3- How convenient is it for you to get to the infusion center for your CABENUVA visits?	Very inconvenient	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 8) at Months 3 and 8	Month 3- How convenient is it for you to get to the infusion center for your CABENUVA visits?	Missing	5 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 8) at Months 3 and 8	Month 8- How convenient is it for you to get to the infusion center for your CABENUVA visits?	Very convenient	23 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 8) at Months 3 and 8	Month 8- How convenient is it for you to get to the infusion center for your CABENUVA visits?	Somewhat convenient	4 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 8) at Months 3 and 8	Month 8- How convenient is it for you to get to the infusion center for your CABENUVA visits?	A little convenient	3 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 8) at Months 3 and 8	Month 8- How convenient is it for you to get to the infusion center for your CABENUVA visits?	Neutral	3 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 8) at Months 3 and 8	Month 8- How convenient is it for you to get to the infusion center for your CABENUVA visits?	A little inconvenient	2 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 8) at Months 3 and 8	Month 8- How convenient is it for you to get to the infusion center for your CABENUVA visits?	Somewhat inconvenient	1 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 8) at Months 3 and 8	Month 8- How convenient is it for you to get to the infusion center for your CABENUVA visits?	Very inconvenient	1 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 8) at Months 3 and 8	Month 8- How convenient is it for you to get to the infusion center for your CABENUVA visits?	Missing	1 Participants

Secondary

Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 9) at Months 3 and 8

Time frame: At Months 3 and 8

Population: Analysis was performed on the Safety set which includes any participant who completed any portion of any questionnaire at the specified timepoint.

Arm	Measure	Group	Category	Value (COUNT_OF_PARTICIPANTS)
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 9) at Months 3 and 8	Month 3- How long does it typically take you to get to the infusion center?	16-30 minutes	12 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 9) at Months 3 and 8	Month 3- How long does it typically take you to get to the infusion center?	1-15 minutes	9 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 9) at Months 3 and 8	Month 3- How long does it typically take you to get to the infusion center?	31-45 minutes	9 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 9) at Months 3 and 8	Month 3- How long does it typically take you to get to the infusion center?	46-60 minutes	5 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 9) at Months 3 and 8	Month 3- How long does it typically take you to get to the infusion center?	More than 60 minutes	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 9) at Months 3 and 8	Month 3- How long does it typically take you to get to the infusion center?	Missing	6 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 9) at Months 3 and 8	Month 8- How long does it typically take you to get to the infusion center?	1-15 minutes	8 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 9) at Months 3 and 8	Month 8- How long does it typically take you to get to the infusion center?	16-30 minutes	15 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 9) at Months 3 and 8	Month 8- How long does it typically take you to get to the infusion center?	31-45 minutes	11 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 9) at Months 3 and 8	Month 8- How long does it typically take you to get to the infusion center?	46-60 minutes	1 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 9) at Months 3 and 8	Month 8- How long does it typically take you to get to the infusion center?	More than 60 minutes	2 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 9) at Months 3 and 8	Month 8- How long does it typically take you to get to the infusion center?	Missing	1 Participants

Secondary

Number of Participants Assessed for Preference on the Location to Receive CABENUVA by Qualitative Interviews at Month 8

Time frame: At Month 8

Population: Analysis was performed on the Safety set which includes any participant who completed any portion of any questionnaire at the specified timepoint.

Arm	Measure	Category	Value (COUNT_OF_PARTICIPANTS)
Participants Receiving CABENUVA	Number of Participants Assessed for Preference on the Location to Receive CABENUVA by Qualitative Interviews at Month 8	Comfortable with care at IC/ASA	20 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Preference on the Location to Receive CABENUVA by Qualitative Interviews at Month 8	Home	5 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Preference on the Location to Receive CABENUVA by Qualitative Interviews at Month 8	Closer proximity to participants	8 Participants

Secondary

Number of Participants Assessed for Preference on the Location to Receive CABENUVA With Other Quantitative Questionnaires at Months 1, 3 and 8

Time frame: At Month 1, 3 and 8

Population: Analysis was performed on the Safety set which includes any participant who completed any portion of any questionnaire at the specified timepoint.

Arm	Measure	Group	Category	Value (COUNT_OF_PARTICIPANTS)
Participants Receiving CABENUVA	Number of Participants Assessed for Preference on the Location to Receive CABENUVA With Other Quantitative Questionnaires at Months 1, 3 and 8	Month 8- Where would you prefer to receive CABENUVA?	At a pharmacy	1 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Preference on the Location to Receive CABENUVA With Other Quantitative Questionnaires at Months 1, 3 and 8	Month 8- Where would you prefer to receive CABENUVA?	Other	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Preference on the Location to Receive CABENUVA With Other Quantitative Questionnaires at Months 1, 3 and 8	Month 8- Where would you prefer to receive CABENUVA?	Missing	3 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Preference on the Location to Receive CABENUVA With Other Quantitative Questionnaires at Months 1, 3 and 8	Month 1- Where would you prefer to receive CABENUVA?	At an infusion center	28 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Preference on the Location to Receive CABENUVA With Other Quantitative Questionnaires at Months 1, 3 and 8	Month 1- Where would you prefer to receive CABENUVA?	At home	8 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Preference on the Location to Receive CABENUVA With Other Quantitative Questionnaires at Months 1, 3 and 8	Month 1- Where would you prefer to receive CABENUVA?	At my HIV doctor's clinic	5 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Preference on the Location to Receive CABENUVA With Other Quantitative Questionnaires at Months 1, 3 and 8	Month 1- Where would you prefer to receive CABENUVA?	At a pharmacy	2 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Preference on the Location to Receive CABENUVA With Other Quantitative Questionnaires at Months 1, 3 and 8	Month 1- Where would you prefer to receive CABENUVA?	Other	0 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Preference on the Location to Receive CABENUVA With Other Quantitative Questionnaires at Months 1, 3 and 8	Month 1- Where would you prefer to receive CABENUVA?	Missing	1 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Preference on the Location to Receive CABENUVA With Other Quantitative Questionnaires at Months 1, 3 and 8	Month 3- Where would you prefer to receive CABENUVA?	At an infusion center	18 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Preference on the Location to Receive CABENUVA With Other Quantitative Questionnaires at Months 1, 3 and 8	Month 3- Where would you prefer to receive CABENUVA?	At home	9 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Preference on the Location to Receive CABENUVA With Other Quantitative Questionnaires at Months 1, 3 and 8	Month 3- Where would you prefer to receive CABENUVA?	At my HIV doctor's clinic	6 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Preference on the Location to Receive CABENUVA With Other Quantitative Questionnaires at Months 1, 3 and 8	Month 3- Where would you prefer to receive CABENUVA?	At a pharmacy	1 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Preference on the Location to Receive CABENUVA With Other Quantitative Questionnaires at Months 1, 3 and 8	Month 3- Where would you prefer to receive CABENUVA?	Other	1 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Preference on the Location to Receive CABENUVA With Other Quantitative Questionnaires at Months 1, 3 and 8	Month 3- Where would you prefer to receive CABENUVA?	Missing	6 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Preference on the Location to Receive CABENUVA With Other Quantitative Questionnaires at Months 1, 3 and 8	Month 8- Where would you prefer to receive CABENUVA?	At an infusion center	21 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Preference on the Location to Receive CABENUVA With Other Quantitative Questionnaires at Months 1, 3 and 8	Month 8- Where would you prefer to receive CABENUVA?	At home	10 Participants
Participants Receiving CABENUVA	Number of Participants Assessed for Preference on the Location to Receive CABENUVA With Other Quantitative Questionnaires at Months 1, 3 and 8	Month 8- Where would you prefer to receive CABENUVA?	At my HIV doctor's clinic	3 Participants

Secondary

Number of Participants Who Agree or Completely Agree (a Score of 4 or Higher) Across All Items on the AIM

Time frame: Month 1 (Baseline), 3 and 8

Population: Analysis was performed on the Safety set which includes any participant who completed any portion of any questionnaire at the specified timepoint.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Participants Receiving CABENUVA	Number of Participants Who Agree or Completely Agree (a Score of 4 or Higher) Across All Items on the AIM	At Month 1 (baseline)	35 Participants
Participants Receiving CABENUVA	Number of Participants Who Agree or Completely Agree (a Score of 4 or Higher) Across All Items on the AIM	At month 3	32 Participants
Participants Receiving CABENUVA	Number of Participants Who Agree or Completely Agree (a Score of 4 or Higher) Across All Items on the AIM	At month 8	33 Participants

Secondary

Number of Participants Who Agree or Completely Agree (a Score of 4 or Higher) Across All Items on the FIM at Month 1 and 3

Time frame: At Months 1 and 3

Population: Analysis was performed on the Safety set which includes any participant who completed any portion of any questionnaire at the specified timepoint.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Participants Receiving CABENUVA	Number of Participants Who Agree or Completely Agree (a Score of 4 or Higher) Across All Items on the FIM at Month 1 and 3	Month 3	31 Participants
Participants Receiving CABENUVA	Number of Participants Who Agree or Completely Agree (a Score of 4 or Higher) Across All Items on the FIM at Month 1 and 3	Month 1	37 Participants

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026

Study Using CABENUVA™ for the Treatment of Human Immunodeficiency Virus (HIV)-1, Administered in Infusion Centers (IC) or Alternate Sites of Administration (ASA) in the United States (U.S.)

Conditions

Keywords

Brief summary

Related papers

Interventions

Sponsors

Study design

Eligibility

Inclusion criteria

Exclusion criteria

Design outcomes

Primary

Secondary

Countries

Participant flow

Recruitment details

Participants by arm

Withdrawals & dropouts

Baseline characteristics

Adverse events

Outcome results

Number of Participants Who Agree or Completely Agree (a Score of 4 or Higher) Across All Items on the Feasibility of Intervention Measure (FIM)

Change in AIM Score of Expert Panel Over Time Through Month 6

Change in AIM Score Over Time in HIV Care Providers at Month 4 and 8

Change in AIM Score Over Time in IC/ ASA Staff at Month 3 and 8

Change in AIM Score Over Time in Participants at Month 3 and 8

Change in Composite Score and Each Item of Composite Score Over Time

Change in FIM Score of Expert Panel Over Time Through Month 6

Change in FIM Score Over Time in HIV Care Providers at Month 4 and 8

Change in FIM Score Over Time in IC/ ASA Staff at Month 3 and 8

Change in FIM Score Over Time in Participants at Month 3 and 8

Composite Score of Feasibility Process Indications

Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of CABENUVA Administration in Participants by Qualitative Interviews at Month 6

Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of CABENUVA Administration in Participants by Qualitative Interviews Prior to Month 1

Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of CABENUVA Administration (Interval of Time) in Participants by Quantitative Questionnaires Prior to Month 1

Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Communication for CABENUVA Administration in Participants by Quantitative Questionnaires Prior to Month 1

Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Insurance and Communication for CABENUVA Administration in Participants by Quantitative Questionnaires at Month 3

Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Insurance and Communication for CABENUVA Administration in Participants by Quantitative Questionnaires at Month 6

Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Insurance Coverage for CABENUVA Administration in Participants by Quantitative Questionnaires Prior to Month 1

Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Referring Participants for CABENUVA Administration by Quantitative Questionnaires Prior to Month 1

Number of Expert Panel That Agree or Completely Agree (a Score of 4 or Higher) Across All Items on the AIM Scale

Number of Expert Panel That Agree or Completely Agree (a Score of 4 or Higher) Across All Items on the FIM Scale

Number of HIV Care Providers Assessed for Acceptability of CABENUVA Administration in Participants at IC/ ASA by Other Quantitative Questionnaire at Months 1, 4 and 8

Number of HIV Care Providers Assessed for Acceptability of CABENUVA Administration in Participants at IC/ASA by Qualitative Interviews at Month 8

Number of HIV Care Providers Assessed for Acceptability of the Process of Participants Receiving Injections at ICs/ ASAs by Qualitative Interviews at Month 8

Number of HIV Care Providers Assessed for Acceptability of the Process of Referring Participants to the IC/ ASA for CABENUVA by Other Quantitative Questionnaires at Months 1, 4 and 8

Number of HIV Care Providers Assessed for Advantages of Participants Receiving CABENUVA at IC/ ASA by Qualitative Interviews at Month 8

Number of HIV Care Providers Assessed for Advantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Month 1, 4 and 8

Number of HIV Care Providers Assessed for Disadvantages for Participants Receiving CABENUVA at IC/ ASA by Qualitative Interviews at Month 8

Number of HIV Care Providers Assessed for Disadvantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Month 1

Number of HIV Care Providers Assessed for Disadvantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Months 4 and 8

Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 1

Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 4

Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8

Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Qualitative Interviews at Month 8

Number of HIV Care Providers Assessed for Overall Opinion of Continuing to Refer Participants to an IC/ ASA by Other Quantitative Questionnaires at Month 8

Number of HIV Care Providers Assessed for Overall Opinion of Referring Patients to an IC/ ASA by Qualitative Interview at Month 8

Number of HIV Care Providers Assessed for Overall Opinion of Referring the Participant to an IC/ ASA by Other Quantitative Questionnaires at Month 1

Number of HIV Care Providers Assessed for Overall Opinion of Referring the Participant to an IC/ ASA by Other Quantitative Questionnaires at Month 4

Number of HIV Care Providers Assessed for Overall Opinion of Referring the Participant to an IC/ ASA by Other Quantitative Questionnaires at Month 8

Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants by Qualitative Interviews at Month 8

Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 1

Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 4

Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 8

Number of HIV Care Providers Assessed for Usefulness of Plan of Treatment (POT) by Other Quantitative Questionnaires at Months 4 and 8

Number of HIV Care Providers Assessed for Usefulness of the Blueprint Intervention and POT by Qualitative Interviews at Month 8

Number of HIV Care Providers Who Agree or Completely Agree (a Score of 4 or Higher) Across All Items on the Acceptability of Intervention Measure (AIM)

Number of HIV Care Providers Who Agree or Completely Agree (a Score of 4 or Higher) Across All Items on the FIM at Month 1, 4 and 8

Number of IC/ ASA Staff Assessed for Acceptability of CABENUVA Administration in Participants at IC/ ASA by Other Quantitative Questionnaire at Months 3 and 8

Number of IC/ ASA Staff Assessed for Acceptability of CABENUVA Administration in Participants at IC/ ASA by Other Quantitative Questionnaire Prior to Month 1

Number of IC/ASA Staff Assessed for Acceptability of CABENUVA Administration in Participants at IC/ASA by Qualitative Interviews at Month 8

Number of IC/ASA Staff Assessed for Barriers/Concerns of CABENUVA Administration in Participants by Qualitative Interviews at Month 8

Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3

Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8

Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1

Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Qualitative Interviews at Month 8

Number of IC/ASA Staff Assessed for Overall Opinion of Administering the Injection at an IC/ ASA by Other Quantitative Questionnaires Prior to Month 1 and at Months 3 and 8

Number of IC/ASA Staff Assessed for Overall Opinion of Administering the Injection at an IC/ ASA by Qualitative Interview at Month 8

Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires at Month 3